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ABSTRACT 
 
Two new alkaloids of the mersinine type, mersiphyllines A (37) and B (38), 
were isolated from the polar fraction of the alkaloid extract of K. singapurensis 
following repeated fractionation via gel-permeation chromatography. The structures of 
these alkaloids were elucidated based on NMR spectroscopy, formation of an alkaloid-
borane complex 40, as well as X-ray diffraction analysis.  
Concise partial syntheses of several new indole alkaloids isolated from 
Tabernaemontana, Alstonia, and Leuconotis species were carried out. These include, 
lirofoline A (44) from ibogaine (46), alstolucine A (91) from alstolucine B (94), and 
()-eburnamaline (96) from (+)-eburnamonine (98). 
Some transformations of the ring-opened Aspidosperma alkaloid, leuconolam 
(54) were investigated, inter alia, its reactions with base leading to enolate-mediated 
ring closure to yield the epimeric pentacylic meloscine-like compounds (74 and 76), its 
reaction with acids leading to transannular closure to the pentacyclic, doubly 
spirocyclic, 6,7-dehydroleuconoxine (63), or to the tetracyclic amino lactam-lactone 
(78). Bromination (Br2/CHCl3) of leuconolam (54) was shown to proceed via a two-step 
sequence involving the intermediacy of 6,7-dehydroleuconoxine (63). Other reactions 
investigated include enolate-mediated -oxygenation, hydroboration, and reaction with 
trifluoroacetic acid. These studies led to concise semisynthesis of leuconoxine (56), and 
the new leuconoxine alkaloids, leuconodines A (67) and F (72). The results from these 
reactions also led to the realization that the original assignment of epi-leuconolam as 55 
was incorrect. This was confirmed upon carrying out an X-ray diffraction analysis, 
which showed that ‘epi-leuconolam (55)’ is in actual fact 6,7-dehydroleuconoxine (63).      
The original stereochemical/configurational assignments of the alkaloids 
scholaricine (114a) and alstoumerine (118a) were reinvestigated (NMR, derivatization, 
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X-ray diffraction analysis) and the structures revised accordingly (to 114b and 118b, 
respectively). The revised structure of alstoumerine (118b) was necessary for the 
structure elucidation of the new bisindole, lumutinine C (116).  
X-ray diffraction analyses were carried out for the macroline-macroline 
bisindole alkaloids, perhentinine (104) (via formation of the dimethyl diiodide salt of 
the ring E-cyclized hemiketal form, 104b) and macralstonine (105), and the results were 
then applied to support the configurational assignment of C-20 in the new Alstonia 
bisindoles, perhentidines AC (101103).      
Andransinine (119) (in all probability an artifact derived from the alkaloid 
andranginine (120) during isolation of alkaloids from A. angustiloba and K. pauciflora), 
was found to exhibit polymorphism in the solid state, forming crystals with different 
crystal systems and space groups in different solvent systems. In addition, it undergoes 
spontaneous resolution when crystallized in ethyl acetate, forming racemic 
conglomerate crystals. 
X-ray diffraction analyses of a number of new indole and bisindole alkaloids 
isolated from various plants of the genus Alstonia, Kopsia, Leuconotis, and 
Tabernaemontana were carried out. These include: the bisindole alkaloids, leuconoline 
(124) from L. griffithii, and lumusidines A (125) and B (126) (via its dimethyl diiodide 
salts, 125a and 126a) from A. macrophylla, the novel indole alkaloids voatinggine (128) 
and tabertinggine (129) from T. corymbosa, grandilodines A (135) and B (136) from K. 
grandifolia, and leuconodines B (68) and E (71) from L. griffithii.  
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ABSTRAK  
(BAHASA MALAYSIA VERSION) 
 
Dua alkaloid baru jenis mersinine, mersiphylline A (37) dan B (38), telah 
diasingkan daripada fraksi kutub ekstrak alkaloid K. singapurensis, berikutan fraksi 
berulangan menggunakan kromatografi gel penjerapan. Struktur alkaloid yang 
dinyatakan dikenalpasti menggunakan teknik spekstroskopi NMR, pembentukan 
kompleks alkaloid-borane 40, serta analisis pembelauan sinar-X.  
Sintesis separa untuk beberapa alkaloid indola yang diasing daripada spesis 
Tabernaemontana, Alstonia, and Leuconotis telah dijalankan. Ini termasuk lirofoline A 
(44) daripada ibogaine (46), alstolucine A (91) daripada alstolucine B (94), dan ()-
eburnamaline (96) daripada (+)-eburnamonine (98). 
Beberapa transformasi alkaloid Aspidosperma, leuconolam (54) telah disiasat. 
Ini termasuk, tindak balas dengan alkali secara perantaraan enolat, yang membawa 
kepada penutupan  gelang kepada sebatian jenis meloscine (74 and 76), tindak balas 
dengan asid menghasilkan sebatian gandaan dua spirosiklik, 6,7-dehydroleuconoxine 
(63) secara penutupan ‘transannular’, atau kepada sebatian tetrasiklik amino laktam-
lakton (78). Pembrominan (Br2/CHCl3) leuconolam (54) menunjukkan bahawa 
tindakbalas ini berlaku dalam dua langkah, yang melibatkan 6,7-dehydroleuconoxine 
(63) sebagai perantaraan. Tindak balas yang lain termasuk pengoksigenan- dengan 
perantaraan enolat, penghidroboranan, dan tindak balas dengan TFA. Tindakbalas yang 
dinyatakan telah membawa kepada sintesis separa leuconoxine (56), dan alkaloid 
leuconoxin yang baru, leuconodine A (67) and F (72). Keputusan daripada penyelidikan 
ini juga membawa kepada kesedaran bahawa penentuan asal untuk struktur epi-
leuconolam sebagai 55 adalah salah. Keputusan ini disahkan dengan menjalankan 
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analisis pembelauan sinar-X, yang menunjukkan bahawa ‘epi-leuconolam (55)’ 
sebenarnya adalah 6,7-dehydroleuconoxine (63).      
Stereokimia/konfigurasi asal untuk alkaloid scholaricine (114a) dan 
alstoumerine (118a) telah disiasat semula (NMR, penyediaan terbitan, analisis 
pembelauan sinar-X) dan struktur yang dinyatakan telah dikemaskini dengan 
sewajarnya (kepada 114b dan 118b). Struktur alstoumerine (118b) yang telah 
dikemaskini adalah amat penting dalam penentuan struktur alkaloid bisindola yang 
baru, lumutinine C (116). 
Analisis pembelauan sinar-X telah dijalankan untuk alkaloid macroline-
macroline, perhentinine (104) (melalui pembentukan garam dimetil diiodida gelang E-
tertutup bentuk hemiketal, 104b) dan macralstonine (105). Keputusan yang diperolehi 
daripada analisis yang dinyatakan telah digunakan untuk membantu dalam penentuan 
konfigurasi C-20 untuk alkaloid bisindola yang baru daripada Alstonia, perhentidine 
AC (101103).      
Andransinine (119) (kebarangkalian merupakan artifak yang berasal daripada 
alkaloid andranginine (119) semasa proses pengasingan alkaloid daripada A. 
angustiloba dan L. griffithii), didapati mempamerkan sifat ‘polymorphism’ dalam 
keadaan pepejal, membentuk hablur dengan sistem hablur serta kumpulan ruangan yang 
berbeza dalam pelarut yang berlainan. Tambahan pula, ia akan menjalani resolusi secara 
spontan semasa penghabluran di dalam etil asetat, menghasilkan hablur racemic 
konglomerat.  
Analisis pembelauan sinar-X untuk beberapa alkaloid indola dan bisindola baru 
yang diasingkan daripada pelbagai tumbuhan dengan genus Alstonia, Kopsia, 
Leuconotis, dan Tabernaemontana telah dilakukan. Ini termasuk: alkaloid bisindola, 
leuconoline (124) daripada L. griffithii, dan lumusidine A (126) dan B (126) (melalui 
pembentukan garam dimetil diiodida, 125a dan 126a) daripada A. macrophylla, alkaloid 
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indola istimewa, voatinggine (128) dan tabertinggine (129) daripada T. corymbosa, 
grandilodine A (135) and B (136) daripada K. grandifolia, dan leuconodine B (68) dan 
E (71) daripada L. griffithii. 
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CHAPTER ONE 
General Introduction to the Alkaloids 
 
Alkaloids have a wide distribution in the plant kingdom. More than 20% of all 
plant species produce alkaloids.
1 
Among the plant kingdom which produce alkaloids 
includes angiosperma, aspidosperma, gymnosperms, club mosses (Lycopodium), 
horsetails (Equisetum), mosses, and algae.
27
 Alkaloids also occur in microorganisms 
(bacteria, fungi), many marine animals (sponges, slugs, worms, bryozoa), arthropods, 
amphibians (toads, frogs, salamanders), and also in a few birds, and mammals.
29
 As of 
2001, a total of 26,900 alkaloids have been isolated from various sources.
10
 Among 
notable alkaloids include reserpine, an antihypertensive alkaloid from Rauwolfia 
serpentina, vinblastine, an antitumor alkaloid from Catharanthus roseus, morphine 
from Papaver somniferum, which exhibits nacrotic effects, atropine from Atropa 
belladonna, which acts as muscle relaxant, cocaine from the leaves of cocoa plant, 
which is a local anesthetic and a potent central nervous system stimulant, and strychnine, 
a nerve stimulant from Strychnos nux-vomica.
11
 
 
 
 
 
 
2 
 
1.1 Definition of Alkaloid 
 
In 1819, a German pharmacist Carl F. W. Meissner introduces the term alkaloid. 
This term is usually applied to basic, nitrogen-containing compounds of plant origin. 
The first modern definition of alkaloid is by Winterstein and Trier who described these 
compounds as basic nitrogen containing compounds of either plant or animal origin.
12 
Alkaloids were defined as compounds meeting additional four qualifications as follows: 
i. Nitrogen is present as part of the heterocyclic ring system 
ii. The compound occurrence is restricted to plant kingdom 
iii. The compound has complex molecular structure 
iv. The compound  manifests significant physiological activity 
Several nitrogenous compounds from plants or from other living organisms 
which do not confer to the above mentioned criteria are termed ‘pseudoalkaloids’. This 
type of classifications which separates nitrogeneous compounds into true alkaloid and 
pseudoalkaloid based on biogenesis is very arbitrary. 
  In 1983, Pelletier suggested a simple general definition of an alkaloid: “An 
alkaloid is a cyclic compound containing nitrogen in a negative oxidation state which is 
of limited distribution in living organisms.”13 This definition encompasses compounds 
with nitrogen as part of a heterocyclic system as well as those with extracyclic bond 
nitrogen such as colchicines or capsaicin. However, compounds such as amino acids, 
amino sugars, peptides, nucleic acids, porphyrind, and vitamins or simple widely 
wimple widely distributed plant bases such as methyl amine, trimethylamine, -
phenylethyl amine derivatives, and other straight chain alkyl amines such as hordenine 
and ephedrine are not considered alkaloids because their nitrogen is not involved in the 
heterocyclic ring.
1
 More recently, Hesse has defined alkaloids as nitrogen containing 
organic substances of natural origin with a greater or lesser degree of basic character.
14
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1.3 Classification of Alkaloids  
 
Five distinct alkaloid classes were put forward according to the position of the 
N-atom in the main structural element:
14
  
i. Heterocyclic alkaloids 
ii. Alkaloids with exocyclic N-atoms and aliphatic amines  (e.g., cassaine, 
capsaicine) 
iii. Putrescine, spermidine, and spermine alkaloids (e.g., paucine, inandenin-12-
one, chaenorhin) 
iv. Peptide alkaloids (e.g., integerrine, mucronine A) 
v. Terpene and steroid alkaloids (e.g., aconitine, conessine) 
 
 Among the five classes, the heterocyclic alkaloids constitute the largest group. 
These can be further divided into 15 subclasses based on the carbon-nitrogen skeleton 
as shown below:
14 
 
a. Pyrrolidine  i.  Pyridine 
b. Indole  j.  Pyrrolizidine 
c. Piperidine k.  Indolizidine 
d. Tropane l.  Quinolizidine 
e. Imidazole m.  Pyrazine 
f. Isoquinoline n.  Pteridine 
g. Quinoline o.  Purine bases 
h. Quinazoline  
4 
 
 
5 
 
 
 
6 
 
1.4 Indole Alkaloids 
 
Indole alkaloids constitute an important class of natural products, and include a 
large number of pharmacologically important substances, such as the antitumour 
alkaloids, vinblastine and vincristine, the antihypertensive alkaloid, reserpine, the 
hallucinatory alkaloid, lysergic acid, and the cardio-arrhythmic alkaloid, ajmalicine.
15 
They are defined as natural products containing an indole nucleus or an oxidized, 
reduced, or substituted equivalent of it. The number of indole alkaloids of known 
structure amounts to approximately 5191 (2001).
10
 This figure includes both those 
compounds that incorporate the actual indole chromophore and those containing its 
derivatives, namely, dihydroindole, indolenine, -methyleneindoline, pseudoindoxyl, 
and oxindole. Also members of this group are alkaloids in which the nucleus 
incorporates an additional benzene or pyridine ring, for instance, carbazole or - and -
carbolines and their derivatives.  
 
1.5 Structural Classes of the Monoterpenoid Indole Alkaloids 
 
To further subclass the indole alkaloids, criteria such as structural and biogenetic 
pathways are applied. They can be divided into two main categories. First category 
comprises the simple indole alkaloids which do not present a structural uniformity, 
possessing only the indole nucleus or a direct derivative of it as a common feature (e.g., 
harmane, 1). 
 
 
7 
 
 
 
The indole bases of the second category contain two structural units, viz., 
tryptamine (2) (or tryptophan, 3) with the indole nucleus, and a C9 or C10 monoterpene 
moiety derived from secologanin (4). 
 
 
 
 The majority of the indole alkaloids from plants of the Apocynaceae belong to 
this category and can be classified into nine main types depending on the structural 
characteristic of their skeletons (Scheme 1.1).
1618
 
8 
 
 
Scheme 1.1. The three major skeletal classes from loganin 
 
Following Hesse,
1618
 eight main types have been defined: vincosan, 
vallesiachotaman, corynanthean, strychnan, aspidospermatan (all belonging to the class 
I skeleton with an intact secologanin), plumeran, eburnan (belonging to the class II 
skeleton, corresponding to a rearranged secologanin), and ibogan (belonging to the class 
III skeleton, corresponding to a further rearranged monoterpene). A ninth type, tacaman 
(with class III skeleton) was added by Verpoorte and Van Beek to account for the 
isolation of a few tacamines.
1920
 The nine main skeletal types are given in Table 1.1. 
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Table 1.1. Classification of indole alkaloids 
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Table 1.1, continued. Classification of indole alkaloids 
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1.6 Biogenesis of the Monoterpenoid Indole Alkaloids 
 
The biogenesis of indole alkaloids is shown in Scheme 1.2. Although there are 
more than 1000 known structural types of indole alkaloids, they are nevertheless all 
derived from a common intermediate, namely, strictosidine (8). Wenkert, Scott, and 
others
21,22 
suggested that 8 is transformed to geissoschizine (9), ajmalicine (10) and 
preakuammicine (11), and eventually to stemmadenine (13), whose isomerization and 
collapse via enamine 14 provides didehydrosecodine (15), from which the 
Aspidosperma, Iboga, and Vinca/Eburnea alkaloids are in turn derived. 
12 
 
 
Scheme 1.2. Biogenesis of indole alkaloids. 
13 
 
1.7 Objectives 
 
The objectives of the present research include the following: 
i) Structure elucidation of selected alkaloids with difficult stereochemical 
issues (e.g., the mersiphyllines from Kopsia singapurensis)  
ii) Investigations of reactions of selected alkaloids (e.g., leuconolam from 
Leuconotis species) 
iii) Implementation of viable partial syntheses of selected alkaloids (e.g., 
lirofoline A from Tabernaemontana corymbosa) 
iv) Structure elucidation of several indole alkaloids via partial synthesis (e.g., 
alstolucine A from Alstonia spatulata and ()-eburnamaline from Leuconotis 
griffithii) 
v) Reinvestigation of the stereochemical assignment of several indole alkaloids 
(e.g., scholaricine and alstoumerine from Alstonia species) 
vi) Determination of absolute configuration of several bisindole alkaloids via 
chemical transformations and X-ray diffraction analyses (e.g., perhentinine, 
macralstonine, and perhentidines A – C from Alstonia species) 
vii) X-ray diffraction analyses of a number of new indole and bisindole alkaloids 
(from Alstonia, Kopsia, Leuconotis, and Tabernaemontana species).  
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CHAPTER TWO 
Mersiphyllines A and B, Two New Pentacyclic Alkaloids of the 
Mersinine Group. Determination of Relative Configuration at a 
Quaternary Center via Formation of an AlkaloidBorane Complex 
 
2.1  Introduction 
 
The alkaloids of the mersinine group represent a novel subclass of the 
monoterpenoid indole alkaloids.
2326
 To date these alkaloids have been found 
exclusively and for the first time in only one species, a variant of the Malayan Kopsia 
singapurensis.
25 
These alkaloids are characterized by a novel pentacyclic skeleton 
incorporating a quinolinic chromophore, and from a biogenetic viewpoint can be 
considered to have arisen from an aspidofractinine precursor 19 via formation of an 
aziridinium intermediate 20, followed in succession by aziridinium ring opening and 
reduction as shown in Scheme 2.1.
23
  
 
 
Scheme 2.1 
 15 
 
There are a total of 16 mersinine-type alkaloids, representing variations in 
aromatic substitution, functional groups, and stereochemistry.
25
 The mersinine alkaloids 
can be divided into two broad stereochemical groups, viz., those with cis-D/E ring 
junction stereochemistry and a C-20CO2Me group (e.g., mersinines A (21) and B 
(22)), and those with trans-D/E ring junction stereochemistry and a C-20CO2Me 
group (e.g., mersinine C (23)).
25
 The relative configurations at C-2, C-7, and C-21 are 
all R, based on extensive NOE experiments,
23,24
 as well as an X-ray diffraction study of 
mersinine A (21).
27 
 
 
 16 
 
 
 
2.2 Results and Discussion 
 
Two additional alkaloids, mersiphyllines A (37) and B (38), were obtained from 
the leaf extract of K. singapurensis.
28
 These polar alkaloids proved difficult to purify as 
they resisted resolution by conventional chromatography, as well as HPLC. Eventually, 
mersiphyllines A and B were successfully separated by repeated passage through 
Sephadex G-75, with MeOH as the eluent (gel permeation chromatography). The 
separation process was very time consuming and laborious and yielded only 0.5 mg of 
37 and 0.2 mg of 38 in each separation. Many repeated separations were performed in 
order to obtain sufficient amounts for further spectroscopic analysis and chemical 
transformations. 
Mersiphylline A (37) was initially obtained as a light yellowish oil, and 
subsequently, as colorless block crystals from EtOH, mp 184186 oC, []25D –59 (c 
 17 
 
0.43, CHCl3). The UV spectrum (219, 245, and 287 nm) was similar to those of the 
other mersinine alkaloids,
24
 while the IR spectrum showed bands at 3463, 1746, and 
1717 cm
–1
, due to OH, ester/acid and carbamate functionalities, respectively. The EIMS 
showed an [M]
+
 at m/z 486, which analyzed for C24H26N2O9, differing from mersinines 
AC (2123) by 14 mass units. The 13C NMR data (Table 2.1) accounted for all 24 
carbon resonances, and confirmed the presence of a carbamate (C 154.4) and two 
carboxyl functions (C 170.8 and 175.4, attributable to ester and/or acid groups), in 
addition to a low-field quaternary resonance (C 87.3) due to C-16, which is  to both a 
nitrogen and an oxygen atom. The 
1
H NMR data (Table 2.1) showed signals due to two 
adjacent aromatic hydrogens (AB doublets at H 6.65, 6.74), two olefinic hydrogens (H 
5.86), a methylenedioxy function (H 6.01, 6.02), two singlets due to carbamate and 
ester methoxy groups (H 3.77, 3.81), and two broad OH singlets, H 5.25 and 16.35, 
which undergo exchange with D2O. The COSY and HMQC data showed the presence 
of NCH2CH2, NCH2CH=CH, CHCH2CH2 partial structures, as well as an isolated 
aminomethine corresponding to H-21. These, and the HMBC data (three-bond 
correlations from H-2 to C-8, C-6, C-16; H-5 to C-7; H-9 to C-7; H-15 to C-17; H-19 to 
C-2, C-17; H-21 to C-3, C-15, C-17, C-19) (Figure 2.1) indicated that 37 has the same 
carbon skeleton as the mersinines (e.g., mersinines AC, 2123).2325  
 
 
Figure 2.1. Selected HMBCs of 37. 
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However, instead of the presence of the two characteristic methyl ester groups, 
one at C-16 and the other at C-20, as is the case in the other mersinine alkaloids,
24 
the 
1
H NMR data showed the presence of only one ester function, and two OH signals (one 
strongly deshielded), although two carboxyl functionalities associated with ester and/or 
acid functions were present (C 170.8 and 175.4). One of the two carbonyl resonances 
must therefore be due to an acid group. In the HMBC spectrum, the ester methyl 
hydrogens at H 3.77 showed a clear three-bond correlation to the carbonyl resonance at 
C 170.8, indicating that this carbonyl (C-22) is associated with the methyl ester 
function. On the other hand, clear three-bond correlations were observed from H-21 and 
H-19 to the carbonyl carbon at C 175.4 (C-17) indicating that this carbonyl is 
associated with the acid group attached to C-20. In both mersiphylline A (37) and 
mersiphylline B (38) (which differs from mersiphylline A (37) only in the aromatic 
substitution, i.e., 12-OMe instead of 11,12-methylenedioxy, Table 2.1), the EIMS 
showed, in addition to the [M]
+
 peaks, strong fragment peaks due to MCO2 and 
MCOOH (m/z 442 and 441, respectively, in the case of 37, and m/z 428 and 427, 
respectively, in the case of 38), while the acid functionality in 37 can be readily 
esterified with TMSCHN2 in MeOH/PhCH3 (replacement of low field acid signal at C 
16.35 by a methyl ester signal at H 3.71 in the methyl ester product), providing 
additional proof for the presence of the carboxylic acid function in 37. The 
1
H NMR 
spectra of mersiphyllines A (37) and B (38) are shown in Figures 2.2 and 2.3, 
respectively. 
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Table 2.1. 
1
H (400 MHz) and 
13
C (100 MHz) NMR data () of compounds 37, 38, and 
40 
Position 37
a
 38
a
 40
b
 
C H C H C H 
2 48.0 2.60 m 48.5 2.66 m 46.7 2.66 dd (12.6, 6.6) 
3 52.7 3.89 m 52.9 4.14 br d (16) 66.1 4.24 ddd (16, 4, 1) 
  3.51 br d (16)  3.59 br d (16)  3.75 m 
5 50.2 3.37 m 51.1 3.80 m 59.7 3.46 dd (10, 6) 
5  2.60 m  2.72 m  2.85 ddd (13, 10, 5) 
6 39.0 2.08 dd (13, 4.5) 38.8 2.14 dd (13, 4.5) 37.3 1.99 dd (13, 5) 
6  2.78 td (13, 6)  2.84 td (13, 6)  3.29 td (13, 6) 
7 44.7  44.5  43.6 
8 129.0  136.3  129.1  
9 117.2 6.74 d (8.2) 116.2 6.90 d (8) 115.7 6.44 d (8.6) 
10 103.9 6.65 d (8.2) 125.0 7.17 t (8) 104.0 6.66 d (8.6) 
11 147.8  111.7 6.94 d (8) 148.2  
12 139.8  152.6  140.4  
13 119.3  125.7  119.5  
14 127.1 5.86 m 126.9 5.89 m 127.1 5.99 m 
15 133.4 5.86 m 133.3 5.89 m 132.1 5.89 ddd (9.5, 2.4, 1) 
16 87.3  87.4  87.4 
17 175.4  175.9  169.4  
18 20.4 0.84 m 20.4 0.75 s 20.6 0.79 m 
18  1.45 m  1.44 m  1.43 m 
19 23.9 0.84 m 24.2 0.82 m 24.8 0.79 m 
19  2.84 m  2.74 m  2.46 m 
20 44.1  44.7  43.2  
21 70.7 3.35 s 70.4 3.49 s 73.4 3.85 m 
22 170.8  170.6   170.5  
12-OMe   56.6 3.88 s   
22-OMe 53.0 3.77 s 53.1 3.75 s 53.1 3.74 s 
NCO2Me 53.3 3.81 s 53.1 3.75 s 53.2 3.79 s 
NCO2Me 154.4  155.9  154.5  
OCH2O 101.6 6.01 d (1.3) 
6.02 d (1.3) 
  102.1 6.02 d (1.2) 
6.03 d (1.2) 
16-OH  5.25 br s  5.32 br s  5.36 br s 
17-OH  16.35 s  15.27 br s   
aCDCl3; 
bCD2Cl2; assignments based on COSY, HMQC, and HMBC. 
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Figure 2.2. 
1
H NMR spectrum (CDCl3, 400 MHz) of mersiphylline A (37). 
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Figure 2.3. 
1
H NMR spectrum (CDCl3, 400 MHz) of mersiphylline B (38). 
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The reciprocal NOEs observed for H-9/H-21 and H-19/H-21 (Figure 2.4), 
permitted assignment of the relative configurations at C-7 and C-21, which were similar 
to those in mersinines A (21) and B (22).
23,24
 The configuration at the quaternary C-16 
was deduced to be similar to that in 22, i.e., S, from the characteristic C-16OH shift of 
H 5.25 and the C-2 shift of C 48.0.
23 
The presence of Wenkert-Bohlmann bands
29
 in 
the IR has been previously invoked to signify the presence of a trans-D/E ring junction, 
with a -oriented N-4 lone pair, in mersinine C (23), mersifoline C (29), mersidasine F 
(35) and mersidasine G (36).
24,25 
This conclusion was also supported by the NOE 
enhancement observed for H-3, H-5, and H-9 on irradiation of H-21. In the case of 
37 and 38, although Wenkert-Bohlmann bands were not detected (possibly due to 
intramolecular H-bonding involving the N-4 lone pair, vide infra), these NOEs were 
also observed, suggesting the presence of a trans-C/D junction. Irradiation of H-2 
resulted in enhancement of H-6, H-18, and 16-OH, while irradiation of H-18 
resulted in enhancement of H-2 (Figure 2.4). These observations indicated a -
orientation for H-2 (2S), and represents a significant departure from the previous 
mersinine alkaloids, where the orientation of H-2 is  (2R) as indicated by the observed 
H-2/H-21 or H-6/H-18 NOEs. This may also be reflected to some extent by the 
noticeable departure in the 
1
H (H-6, H-18, H-19) and 13C (C-6) NMR data 
compared to those of the mersinines (vide supra). 
The remaining issue concerns the relative configuration at the carboxyl bearing 
quaternary center, C-20. In this instance the observed NOEs were insufficient to 
unambiguously assign the configuration.  
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Figure 2.4. Selected NOEs of 37. 
 
An early indication that the orientation of the acid group is  was from the 
observation of the deshielded, low-field, acid-H signal at C 16.35, suggesting 
intramolecular H-bonding to N-4 (with its -oriented lone pair in view of the trans-D/E 
fusion mentioned earlier). 
In the event, a second line of evidence was obtained which provided cogent 
proof of 20R configuration. In an attempt to reduce the acid group, alkaloid 37 was 
treated with BH3.THF.
3032
 Instead of the alcohol 39, an unexpected alkaloid-borane 
complex 40 was obtained (Scheme 2.2), as deduced from the data.  
The mass-spectral data clearly showed boron incorporation ([M]
+
, m/z 498), 
while the IR spectrum showed the characteristic BH stretching frequencies at 2431, 
2376, and 2285 cm
–1
 (Figure 2.5).
33
 The 
1
H and 
13
C NMR data (Table 2.1) of the 
complex 40 were essentially similar to those of 37, except for loss of the low field acid 
signal in 
1
H NMR data, and the distinct downfield shifts of the C-3, C-5, and C-21 
signals in the 
13
C NMR data (and the corresponding H-3, H-5, and H-21 signals in the 
1
H NMR data), an effect somewhat reminiscent of that shown by alkaloid N-oxide 
derivatives, suggesting that N-4 has been rendered electron-deficient.  
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Figure 2.5. IR spectrum (neat) of mersiphylline A-borane complex 40. 
 
 
 
 
 
BH2 stretching 
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Scheme 2.2 
 
A likely formulation for the alkaloid-borane complex 40 is one in which BH2 
has been incorporated into the molecule via formation of an O=COboron, as well as a 
dative N-4B bond, linked at the carboxyl oxygen and at N-4, respectively, as shown 
in 40. Such a structure would be compatible with the MS, IR, and NMR data (the BH 
hydrogens were not observed in the 
1
H NMR spectrum due to broadening
34,35
). 
Additional confirmation was obtained by accurate mass measurements of both the 
C24H27N2O9
11
B ([M]
+
) as well as the C24H26N2O9
10
B ([M – H]+) peaks in HREIMS, 
which were in excellent agreement with the proposed constitution of the complex.  
The formation of the alkaloid-borane complex 40 is presumably via the 
proposed pathway shown in Scheme 2.3. Reaction of the alkaloid with BH3.THF gives 
in the first instance, the acid-borane complex 41, which on loss of H2, followed by 
intramolecular interception by N-4 of the resulting organoborane intermediate 42, 
furnishes the alkaloid-borane complex 40 (This unexpected diversion accounts for the 
exclusive formation of 40 at the expense of the alcohol 39,
 
normally formed via the 
 26 
 
intermediacy of trialkoxyboroxine 43 and its subsequent hydrolysis to 39
31,36,37
) 
(Scheme 2.3). 
The formation of the alkaloid-borane complex 40 is only possible if the C-20 
carboxylic acid function has a -orientation (20R) (C-20COOH and N-4 lone pair syn). 
The alkaloid-borane complex 40 also showed a better resolved 
1
H NMR spectrum with 
less overlap compared to that of mersiphylline A (37) allowing for better NOE data to 
be obtained (Table 2.1). The 
1
H NMR spectrum of 40 is shown in Figure 2.6. Attempts 
to obtain a 
11
B NMR on the alkaloid-borane complex 40 was unsuccessful due to 
insufficient amount of material available (the formation of the alkaloid-borane complex 
is also reversible, if left in solution in CDCl3 or EtOH over a prolonged period).  
 
Scheme 2.3
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Figure 2.6. 
1
H NMR spectrum (CD2Cl2, 400 MHz) of mersiphylline A-borane complex 40.
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Finally, to obtain support for the above deduction, as well as to secure 
unambiguous proof of the structure, X-ray diffraction analysis was carried out for 37 
(Figure 2.7) which provided confirmation of the structure and relative configuration 
deduced from all the above observations. 
Suitable crystals of 37 were obtained by slow evaporation in EtOH. The 
structure and relative configuration of 37 is shown in Figure 2.7. From the X-ray crystal 
structure, it can be seen that 37 exists as a zwitterion [(N-4H)C-17OO)] in the 
solid state. It can also be seen that 37 co-crystallizes with the solvent used during 
crystallization. Hydrogen bonding between the EtOH molecule with C-17OO can also 
be seen from the crystal structure.  
                                                                        
 
                                                   Figure 2.7. X-ray crystal structure of 37.  
 
With the structure of mersiphylline A (37) thus established, the structure of 
mersiphylline B (38) follows readily from the spectroscopic data. 
 
 
 29 
 
 
 
2.3 Conclusion 
 
Mersiphyllines A (37) and B (38) represent yet another addition to the mersinine 
group of alkaloids, constituting a new and distinct stereochemical group, with a trans 
D/E ring junction stereochemistry, a -oriented carboxylic acid functionality linked to 
the quaternary C-20 (20R), and a -oriented hydrogen at C-2 (2S). Although several 
examples of related organoborane complexes exist in the literature, such as the 
condylocarpine-BH3 adduct,
38 
various simple cyclic borane derivatives of amino acids,
33
 
and the chiral oxazaborolidines (or CBS reagent),
34
 the present example nevertheless 
represents the first instance where the formation of an alkaloid-borane complex has 
been invoked to underpin a difficult stereochemical assignment at a quaternary 
stereogenic center in an alkaloid. 
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CHAPTER THREE 
A Biomimetic Partial Synthesis of Lirofoline A 
 
3.1 Introduction 
 
Lirofolines A (44) and B (45) were new alkaloids recently isolated from two 
Tabernaemontana species.
39
 Both 44 and 45 were isolated from the stem-bark extract of 
T. corymbosa, while 45 was also isolated from the stem-bark extract of T. divaricata 
(single flower variety) (isolation and structure by K. H. Lim and H. S. Pang). 
 
 
 
The lirofolines are characterized by a novel pentacyclic skeleton, previously 
unencountered as a natural product. After the structures were solved by the application 
of spectroscopic methods, a search in the literature indicated that the basic ring system 
has been encountered previously as unwanted minor side products in reactions in the 
ibogaine and catharanthine series (chemical transformations of ibogaine (46) to 
voacangine (47)
40 
 (Scheme 3.1) and coupling of catharanthine (48) and its derivatives 
with vindoline
41 
(Scheme 3.2)).
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Scheme 3.1 
 
 
Scheme 3.2 
 
The 
1
H and 
13
C NMR data of lirofolines A (44) and B (45) are summarized in 
Table 3.1, while the 
1
H NMR spectra of 44 and 45 are shown in Figures 3.1 and 3.2, 
respectively. 
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Table 3.1. 
1
H and 
13
C NMR data () of lirofolines A (44) and B (45)a 
Position 44 45 
C H C H 
2 153.7  152.6 
3 53.5 2.72 dt (10, 3) 53.5 2.67 dt (10, 2.5) 
  3.27 dt (10, 3)  3.27 dt (10, 2.5) 
5 67.1 4.88 d (12) 67.2 4.92 d (12) 
5  4.94 d (12)  4.98 d (12) 
6 182.9 10.1 (s) 192.5 
7 111.8  108.0 
8 127.0  126.8 
9 103.1 7.74 br d (2.4) 103.9 7.36 d (2) 
10 156.8  156.6 
11 112.8 6.88 dd (8.8, 2.4) 111.6 6.90 dd (8.5, 2) 
12 109.8 7.12 d (8.8) 110.0 7.17 d (8.5) 
13 129.9  129.8  
14 25.5 1.81 m 25.4 1.81 m 
15 31.1 1.90 dddd (12.5, 10, 4, 2) 31.2 1.91 dddd (13, 10, 4, 2.5)  
15  1.20 ddt (12.5, 6.8, 2)  1.18 ddt (13, 7.5, 2) 
16 29.7 3.55 br dt (12, 2) 31.8 3.67 dt (12, 2) 
17 33.4 1.70 m 32.4 1.58 m 
17  2.20 br t (12)  2.29 tdd (12, 2.5, 2) 
18 11.7 0.96 t (7.3) 11.7 0.96 t (7.5) 
19 27.4 1.59 m 27.3 1.60 m 
  1.59 m  1.60 m 
20 37.8 1.72 m 37.7 1.73 dq (10, 7.5) 
21 51.8 2.85 br s 51.9 2.82 br s 
22   67.0 4.73 dd (17, 4) 
    4.78 dd (17, 4) 
10-OMe 55.8 3.89 s 55.9 3.90 s 
22-OH    4.15 br s 
 aCDCl3, 400 and 100 MHz, respectively; assignments based on COSY, HMQC, and HMBC. 
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Figure 3.1. 
1
H NMR spectrum (CDCl3, 400 MHz) of natural lirofoline A (44).
42 
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Figure 3.2. 
1
H NMR spectrum (CDCl3, 400 MHz) of lirofoline B (45).
43 
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3.2 Results and Discussion 
 
Based on the previous observations (vide supra), it follows that the ring system 
of the lirofolines in all probability arises from similar precursors and in like fashion, 
viz., via scission of the C-5C-6 bond of an oxidized derivative to the iminium ion 
intermediate 49, followed by intramolecular bond formation between C-5 and N-1 
(Scheme 3.3).  
 
 
Scheme 3.3 
 
Based on this supposition, and with limited, but sufficient amounts of the 
requisite precursor (ibogaine (46), ca. 50 mg) available from our ongoing work in 
alkaloid chemistry, we decided to carry out such a biomimetic conversion of ibogaine 
(46) to lirofoline A (44) under Polonovski conditions.  
The 
1
H and 
13
C NMR data of ibogaine (46) are summarized in Table 3.2, while 
the 
1
H NMR spectrum of 46 is shown in Figure 3.3. 
The first step in the Polonovski approach to this biomimetic transformation 
involved oxidation of ibogaine (46) to its N-oxide 50, using m-chloroperbenzoic acid 
(m-CPBA) in CH2Cl2 at 30
 o
C to give 74% of 50 (Scheme 3.4).  
36 
 
Ibogaine N-oxide (50) was obtained as a colorless oil, with [D +71 (c 0.16, 
CHCl3). The UV spectrum (210, 224, 280, 297, and 307 nm) showed absorption 
maxima characteristic of an indole chromophore, while the IR spectrum showed the 
presence of an NH (3149 cm
–1
) function. The HRESIMS of 50 showed an [M  H] at 
m/z 327.2080, which is consistent with the molecular formula C20H26N2O2  H (16 mass 
units higher than that of 46). The 
1
H NMR data showed characteristic downfield shifts 
for H-3, H-5, and H-21, while the same downfield shifts were observed for C-3, C-5, 
and C-21 in 
13
C NMR data, when compared with those of ibogaine (46). The 
1
H and 
13
C 
NMR data of 50 are summarized in Table 3.2, while the 
1
H NMR spectrum of 50 is 
shown in Figure 3.4. 
With ibogaine N-oxide (50) to hand, a Polonovski transformation was carried 
out. Ibogaine N-oxide (50) on treatment with acetic anhydride (10 equiv in 50 ml 
CH2Cl2, added dropwise at 10 

C for 30 min), followed by hydrolysis (NaOH) gave a 
single major product 51 in 70% yield. High dilution used in this reaction was necessary 
to obtain optimum yields for this reaction based on our previous work on related 
Polonovski transformations.
44  
In the presence of acetic anhydride, cleavage of the C-5C-6 bond takes place, 
leading to the iminium ion 52. The iminium ion 52 then undergoes a concerted 
conjugate addition by acetate anion, followed by intramolecular bond formation 
between C-5 and N-1 to give 53. Basic hydrolysis with 10% NaOH during work up 
leads to the alcohol 51.   Attempted purification and characterization of the alcohol 51 
was not successful due to its facile decomposition during chromatography, upon 
exposure to air, and in CDCl3.  
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Table 3.2. 
1
H and 
13
C NMR data () of ibogaine (46) and ibogaine N-oxide (50)a 
Position 46 50 
C H C H 
2 142.9  139.8  
3 49.9 2.97 dt (9, 3) 70.3 3.54 br d (12) 
  3.07 dt (9, 2)  3.79 br d (12) 
5 54.2 3.14 m 76.9 3.71 br d (11.5) 
  3.37 m  3.93 m 
6 20.7 2.61 m 21.1 3.08 m  
  3.32 m  2.94 m 
7 109.1  107.2  
8 129.7  128.1  
9 100.3 6.93 d (2) 100.0 6.82 d (2) 
10 153.9  153.9  
11 110.8 6.77 dd (8.5, 2) 111.8 6.78 dd (8.7, 2.3) 
12 110.6 7.13 d (8.5) 111.5 7.19 d (8.7) 
13 130.1  130.3  
14 26.5 1.84 m 26.1 2.17 m 
15 32.1 1.20 ddt (13, 5, 2.5) 31.6 1.49 m 
  1.79 m  2.26 m 
16 41.5 2.88 ddd (11, 4, 1.5) 37.0 3.24 m 
17 34.2 1.64 ddd (13, 6.5, 4) 30.4 1.82 m  
  2.03 ddt (13, 11, 2.5)  1.97 m 
18 11.9 0.89 t (7) 13.0 0.93 t (7.8) 
19 27.8 1.47 m 31.2 2.10 m 
  1.54 m   
20 41.9 1.54 m 43.1 1.69 m 
21 57.5 2.84 br s 72.4 3.49 br s 
NH  7.54 br s  9.71 br s 
10-OMe 56.0 3.85 s 56.1 3.83 s 
aCDCl3, 400 and 100 MHz, respectively; assignments based on COSY, HMQC, and HMBC. 
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Figure 3.3. 
1
H NMR spectrum (CDCl3, 400 MHz) of ibogaine (46).  
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Figure 3.4. 
1
H NMR spectrum (CDCl3, 400 MHz) of ibogaine N-oxide (50).
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To reduce decomposition, the crude product mixture was quickly filtered 
through a short pad of silica gel followed immediately by the oxidation step. Only a 
1
H 
NMR spectrum was obtained due to the tendency of alcohol 51 to decompose in CDCl3. 
In the 
1
H NMR spectrum (Figure 3.5), the characteristic pair of AB doublets due to H-5, 
which are observed downfield at  4.88 and 4.78 (J = 11.4 Hz), provided firm evidence 
for the formation of the lirofoline skeleton. Recovery of alcohol 51 after the NMR 
experiment was not successful due to its rapid decomposition. 
The next step involves oxidation of the alcohol 51 to an aldehyde. The first 
choice oxidation reagent Dess-Martin periodinane,
45
 however, did not give any 
significant product. Alcohol 51 was successfully oxidized with tetra-n-
propylammonium perruthenate (TPAP, 5 mol %) in the presence of excess N-
methylmorpholine N-oxide (NMO, 20 equiv) and 4 Å molecular sieves (Ley 
oxidation)
46
 to give lirofoline A (44) in 30% yield (Scheme 3.4).  
The spectroscopic data (
1
H and 
13
C NMR, IR, UV) and other properties ([D 
and Rf of TLC in different solvent systems) of semisynthetic 44 were indistinguishable 
from those of the natural 44. The 
1
H NMR spectrum of semisynthetic 44 is shown in 
Figure 3.6.  
Further attempts to further transform lirofoline A (44) to lirofoline B (45) could 
not be carried out due to the limited amount of 44 available.  
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Figure 3.5. 
1
H NMR spectrum (CDCl3, 400 MHz) of alcohol 51. 
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Figure 3.6. 
1
H NMR spectrum (CDCl3, 400 MHz) of semisynthetic lirofoline A (44).
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Scheme 3.4 
 
3.3 Conclusion 
 
A biomimetic partial synthesis of lirofoline A (44) has been achieved from 
ibogaine (46) under Polonovski conditions. Despite the above transformation, the 
possibility that the lirofolines isolated from the natural sources could be artifacts was 
rendered unlikely by the observation that repeated extractions of fresh material of T. 
divaricata consistently provided 45, while 44 was isolated from an entirely different 
Tabernaemontana species (T. corymbosa). Furthermore, subjecting the putative 
precursor of the lirofolines, ibogaine (46) or its N-oxide 50, to reaction under the 
conditions of the extraction, resulted only in recovery of the intact starting materials, 
with no evidence of any transformation into either 44 or 45.
39 
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CHAPTER FOUR 
Transformations of Leuconolam and Partial Synthesis of  
Some Leuconoxine-type Alkaloids 
 
4.1 Introduction 
 
The ring-opened Aspidosperma alkaloid, leuconolam (54) and its C-21 epimer, 
epi-leuconolam (55) were first isolated from the bark extract of Leuconotis 
griffithii.
4749
 Subsequently the related diazaspiro pentacyclic alkaloid leuconoxine (56) 
was reported from the Indonesian L. eugenefolia.
50
 Since then, closely related alkaloids 
were also found in other genus such as Kopsia.
25
 These alkaloids include rhazinilam 
(57),
51 
rhazinal (58),
52 
 rhazinicine (59),
53
 and arboloscine (60).
54
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Another new indole alkaloid recently reported from Kopsia (K. singapurensis) 
was mersicarpine (61), which is characterized by a novel tetracyclic carbon skeleton, 
containing a seven-membered imine ring.
55
 The structure of 61 represents a departure 
from the rhazinilam-leuconolam group of alkaloids which coexists with 54 in the stem-
bark extract of the plant. From a biogenetic viewpoint, it appears to have lost the two-
carbon tryptamine bridge corresponding to C-5 and C-6, normally present in the other 
monoterpenoid indole alkaloids. In addition, the presence of the lactam-containing ring 
D suggested an affinity to leuconoxine (56), although a further rearrangement appears to 
have occurred leading to loss of the two-carbon chain and formation of the seven-
membered imine-containing ring C. Since the initial report of the isolation and structure 
elucidation of 61, several total syntheses have also been subsequently reported which 
have provided confirmation of the proposed structure.
56
 A possible biogenetic pathway 
from a leuconolam precursor was also presented in the initial report, in which the key 
step was the formation of a benzylic carbocation 62 from a dehydroleuconoxine 
precursor, 63, followed by a 1,2-alkyl shift leading to the iminium ion intermediate 64 
(Scheme 4.1).
55
 It was noted that the halogenated marine alkaloids, chartellamides A 
and B (65 and 66) from the marine bryozoan Chartelle papyraceae,
57
 possess a structure 
displaying a remarkable resemblance to the 6-5-7 ring system of 61 and in addition 
incorporate a -lactam unit corresponding to that present in the proposed intermediate 
64, providing additional support for the proposed pathway.  
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Scheme 4.1 
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Recently, six new leuconoxine-type alkaloids, leuconodines AF (6772), and a 
nor-rhazinilam derivative, nor-rhazinicine (73), were isolated from the stem-bark 
extract of L. griffithii,
58
 representing the latest additions to this group of Aspidosperma 
alkaloids. 
The availability of leuconolam (54) (one of the major alkaloids in L. griffithii), 
presented the opportunity to explore its chemistry, in particular to attempt various 
transformations aimed at transannular cyclization to leuconoxine (56) and its congeners.  
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4.2 Results and Discussion 
 
4.2.1 Base-induced transformations 
 
In an earlier report,
49
 treatment of leuconolam (54) with KOH in EtOH/MeOH 
gave the cyclized product 74 (the optical antipode of the 21-hydroxy derivative of ()-
meloscine 75)
59
 as the sole product in high yield.
 
 At the time of this report, no evidence 
was presented to support the stereochemical assignments. We decided to reinvestigate 
this transformation. 
When the reaction was repeated by the use of stronger bases, such as 
NaOMe/MeOH or NaHMDS/THF, the reaction did not proceed, and led only to the 
recovery of starting material. When the reaction was repeated using the original 
conditions employed in the earlier report (KOH in EtOH/MeOH for 6 h), two products 
74 and 76 were formed, with the former obtained as the major product (12 and 3%, 
respectively). The reaction was also accompanied by recovery of unreacted 54 (20%) 
(The original report claimed formation of a single product, 74, with a yield of 80%.
49 
We were not able to reproduce the reported yield.).  
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The major product 74 was obtained as a colorless oil, and subsequently as 
colorless block crystals (mp 266268 C) from CCl4/MeOH, with []
25
D = 198 (c 0.06, 
CHCl3). The UV spectrum showed absorption maxima at 210, 253, and 287 nm, 
indicating the presence of a dihydroquinolone chromophore,
59 
while the IR spectrum 
showed the presence of OH (3226 cm
1
) and lactam carbonyl functions (1667 cm
1
). 
The ESIMS of 74 showed an [M H] at m/z 327, and HRESIMS measurements gave 
the molecular formula as C19H22N2O3  H. The 
1
H and 
13
C NMR data of 74 are similar 
to those reported earlier.
49
 The attachment of C-16 to C-7 was supported by the 
observed three-bond correlation from H-16 to C-6 in the HMBC spectrum. The 
orientation of H-16 was assigned as  from the observed NOE enhancement between H-
6 and H-16 (Figure 4.1). The 1H and 13C NMR data of 74 are summarized in Table 
4.1, while the 
1
H NMR spectrum of 74 is shown in Figure 4.2. 
 
 
Figure 4.1. Selected NOEs of 75. 
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Table 4.1. 
1
H and 
13
C NMR data () of compounds 74 and 76a  
Position 74
 
76
 
C H C H 
2 170.5  170.7 
3 37.2 2.94 m 36.6 3.08 m 
  4.23 dt (13, 7.5)  4.03 dt (13, 7.5) 
5 171.0  171.1 
6 50.0 2.69 d (17.7) 41.5 2.35 d (18) 
6  3.03 d (17.7)  2.75 d (18) 
7 50.6  50.0 
8 122.0  133.0 
9 129.1 7.39 dd (8, 1.5) 123.9 6.85 br d (7.8) 
10 123.8 7.23 td (8, 1.5) 123.6 7.19 td (7.8, 1.5) 
11 129.0 7.10 td (8, 1.5) 127.9 7.01 td (7.8, 1.5) 
12 116.1 6.76 dd (8, 1.5) 117.0 7.69 d (7.8) 
13 136.0  137.2 
14 19.6 1.59 m 17.7 1.66 m 
  1.59 m  1.66 m 
15 28.0 1.44 m 30.0 1.20 td (14.5, 6.8)  
  1.81 dt (14.5, 4.5)  1.82 dt (14.5, 4.5) 
16 51.9 2.91 m 46.3 3.07 dd (13.7, 5.5) 
17 32.2 2.20 ddd (14, 10.5, 2)  30.4 1.56 m 
  2.32 dd (14, 2.5)  2.17 dd (13.7, 5)  
18 7.4 0.67 t (7.6) 8.8 0.89 t (7.3) 
19 26.3 0.96 dq (14, 7.6) 24.0 1.41 m 
  1.08 dq (14, 7.6)  1.59 m 
20 46.7  50.3 
21 100.8  99.2 
NH  8.41 br s  7.65 br s 
21-OH  2.38 br s  2.90 br s 
aCDCl3, 400 and 100 MHz, respectively; assignments based on COSY, HMQC, and HMBC. 
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Figure 4.2. 
1
H NMR spectrum (CDCl3, 400 MHz) of compound 74. 
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The minor product 76 was obtained as a colorless oil, and subsequently as 
colorless block crystals (mp 250252 oC) from CH2Cl2/hexanes, with []
25
D = 150 (c 
0.01, CHCl3). The UV (210, 251, 306 nm) and IR data (3322, 1712, 1667 cm
1
) were 
similar to those of 74 indicating the presence of similar chromophores and 
functionalities. The ESIMS of 76 showed an [M H] at m/z 327, and HRESIMS 
measurements gave the molecular formula as C19H22N2O3  H. As in the case of 74, a 
three-bond correlation from H-16 to C-6 was also observed. A major difference in the 
NMR data of 76 compared with the previous compound 74, was the notable absence of 
NOE between H-6 and H-16, which suggested that in 76, the orientation of H-16 is . 
The 
1
H and 
13
C NMR data of 76 are summarized in Table 4.1, while the 
1
H NMR 
spectrum of 76 is shown in Figure 4.3. 
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Figure 4.3. 
1
H NMR spectrum (CDCl3, 400 MHz) of compound 76. 
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Since suitable crystals of both 74 and 76 were obtained, X-ray diffraction 
analyses were carried out which confirmed the structures and relative configurations 
assigned based on the NMR data (Figure 4.4). 
 
                                                                   
      
Figure 4.4. Left: X-ray crystal structure of 74. Right: X-ray crystal structure of 76. 
 
The formation of 74 and 76 can be rationalized based on an intramolecular 
Michael addition from the presumably more stable E-enolate which approaches from 
the -face to form the major product 74, while the minor product 76 resulted from 
attack by the presumably less stable Z-enolate (Scheme 4.2).  
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Scheme 4.2 
 
4.2.2 Acid-induced transformations 
 
It was initially envisaged that treatment of leuconolam (54) with acid should 
result in a facile transannular closure to give a dehydroleuconoxine derivative 63 which 
could serve as a possible starting compound for further elaboration to leuconoxine (56) 
and its recently discovered congeners (leuconodines) or to mersicarpine (61) (Scheme 
4.3). 
 
 
Scheme 4.3 
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Treatment of leuconolam (54) with aqueous HCl (5%) did not result in any 
reaction, leading only to recovery of starting material. When the same reaction was 
carried in a two-phase medium in the presence of a phase-transfer catalyst 
(tetraethylammonium chloride, TEACl), both epi-leuconolam (55) (45%) and 
leuconolam (54) (35%) were obtained. Careful examination of the product mixture 
revealed the formation of a minor product (compound A), with a yield of 1.5%. 
Repeating the two-phase experiment (5% HCl/CH2Cl2, TEACl) with epi-leuconolam 
(55), resulted in the isolation of leuconolam (54) (15%) and epi-leuconolam (55) (84%). 
When leuconolam (54) was treated with 10-camphorsulfonic acid (CSA) in 
anhydrous CH2Cl2, epi-leuconolam (55) was obtained in yield of 62%, accompanied by    
2% of the previously noted minor product (compound A). Similar treatment of 54 with 
CSA in anhydrous MeOH resulted in the formation of O-methylleuconolam (77)
49
 in 94% 
yield, accompanied by 2% of compound A. Treatment of 54 with conc. HCl (few drops) 
in anhydrous MeOH gave only 77 with a reduced yield of 63%. Treatment of 54 with p-
toluenesulfonic acid (PTSA) in anhydrous MeOH also yielded the O-methyl derivative 
77 as the major product (94%) with compound A detected as the minor product (1%). 
When leuconolam (54) was treated with PTSA in anhydrous CH2Cl2, an 
inversion in the product distribution was noted, with compound A obtained as the major 
product (42%), and epi-leuconolam (55) as the minor product (5%). These results are 
summarized in Table 4.2. The 
1
H and 
13
C NMR data of O-methylleuconolam (77) are 
summarized in Table 4.3, while the 
1
H NMR spectrum of 77 is shown in Figure 4.5. 
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Table 4.2. Summary of reactions of leuconolam (54) with acids 
Entry 
Starting 
material 
Reaction conditions 
Products 
54 55 Compound A 77 
1 54 5% HCl, rt, 8 h No reaction 
2 54 
5% HCl/CH2Cl2  
TEACl, rt, 14 ha 
35% 47% 1.5%  
3 54 HCl/MeOH, rt, 12 h 4%    63% 
4 54 
CSA/CH2Cl2, rt,  
14 ha 
10%  62% 2%  
5 54 
CSA/CH2Cl2, rt, 11 h  
(4 equiv MeOH 
added) 
 19%  54% 
6 54 CSA/MeOH, rt, 14 h 4%   2% 94% 
7 54 
PTSA/MeOH, rt,  
14 h 
4%   0.8% 94% 
8 54 
PTSA/CH2Cl2, rt,  
14 h 
3%  5% 42%  
9 55 
5% HCl/CH2Cl2  
TEACl, rt, 12 ha 
15% 84%   
10 55 CSA/CH2Cl2, rt, 15 h No reaction
b 
11 55 
PTSA/CH2Cl2, rt,  
10 h 
 1% 70%  
12 77 
PTSA/CH2Cl2, rt,  
10 h 
No reactionc 
aProlonged reaction time leads to reduced overall yields; btraces of 54 and compound A detected from TLC; ctraces of 54 and 55 
detected from TLC. 
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Table 4.3. 
1
H and 
13
C NMR data () of O-methylleuconolam (77)a 
Position C H 
2 178.6  
3 35.9 2.61 td (12.5, 4) 
  4.18 td (12.5, 4) 
5 166.8  
6 131.9 6.33 
7 151.0  
8 133.1  
9 126.7 7.26 ddd ( 7.5, 1, 0.5) 
10 127.0 7.34 m 
11 129.9 7.41 m 
12 128.6 7.42 m  
13 135.7  
14 19.6 1.49 m 
   
15 32.5 1.50 m 
  2.05 ddd (15, 5, 2) 
16 28.0 2.17 td (15, 6) 
  1.50 m 
17 26.2 1.75 m  
  1.50 m 
18 7.3 0.55 t (7.5) 
19 24.1 1.28 dq (13.6, 7.5) 
  1.54 m 
20 45.5  
21 97.4  
NH  8.25 br s 
21-OMe 49.9 3.15 s 
aCDCl3, 400 and 100 MHz, respectively; assignments based on COSY, HMQC, and comparison with literature. 
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Figure 4.5. 
1
H NMR spectrum (CDCl3, 400 MHz) of O-methylleuconolam (77). 
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The results of the reaction of leuconolam (54) with acid, as summarized in Table 
4.2 presented some puzzling features. The formation of epi-leuconolam (54) and 
leuconolam (54) when leuconolam (54) or epi-leuconolam (55) was treated with 
aqueous acid under two-phase conditions (entries 2 and 9, Table 4.2) suggested the 
possibility that the products obtained derived from reversible formation of the N-4C-
21 iminium ion, followed by nucleophilic capture by water to give a mixture of 55 and 
54, with 55 (epi-leuconolam) predominating in both instances. This would appear to 
suggest that 55 is the thermodynamically more stable product under such conditions. 
When the acid-induced reaction was carried out in MeOH (entries 3, 6, and 7, Table 4.2) 
in the presence of either HCl, CSA, or PTSA, virtually quantitative conversion to O-
methylleuconolam (77, 21-OMe) was observed, suggesting efficient trapping of the 
iminium ion from the -face by MeOH. The exclusive formation of the C-21 -oriented 
methyl ether product is puzzling, especially since the -OH epimer (epi-leuconolam, 55) 
appeared to be the thermodynamically preferred product. Another discrepancy was 
noted when comparing entries 4 and 10, Table 4.2. The reaction of leuconolam (54) 
with CSA in CH2Cl2 gave epi-leuconolam (55) as the major product, but when epi-
leuconolam (55) was exposed to the same conditions, no reaction occurred (cf. entries 2 
and 9, Table 4.2). Other inconsistencies were subsequently noted for the hydrogenation 
and bromination reactions of leuconolam (54) and epi-leuconolam (55). For instance, 
while epi-leuconolam (55) was smoothly hydrogenated, leuconolam (55) was by 
comparison unreactive, whereas in the case of the bromination reaction, both 54 and 55 
apparently reacted to give the same bromine addition product. Furthermore 
debromination (Zn/AcOH) of the bromine addition product apparently yielded epi-
leuconolam (55). These puzzling and apparently inconsistent results led us to reevaluate 
the earlier structure elucidation for leuconolam (54) and epi-leuconolam (55). 
61 
 
Leuconolam (54) was first reported from the Malayan Leuconotis species, L. 
griffithii and L. eugenefolia.
47,49
 The structure was confirmed by an X-ray diffraction 
analysis which showed that the N-1C-2 lactam, as well as the C-6C-7 double bond, 
were out of plane with benzene ring, therefore minimizing conjugation.
47
 The hydroxyl 
group attached to C-21 was shown to be -oriented, while the ethyl side chain attached 
to C-20 was syn to the C-21 hydroxyl group.   
Epi-leuconolam was first isolated as a minor alkaloid from L. griffithii and L. 
eugenefolia.
47,49
 It has subsequently been detected as a minor alkaloid in Kopsia 
griffithii.
60
 The structure was assigned as the C-21 epimer of leuconolam (i.e., 55) based 
on EIMS and NMR data. In the initial report, the EIMS (measured on a Kratos MS 3074 
Mass Spectrometer) apparently showed an [M]

 at m/z 326, which was also the base 
peak, and which analyzed for C19H22N2O3 by HREIMS, indicating an isomeric 
relationship with leuconolam (54).
47,49
 This was confirmed by a subsequent independent 
EIMS measurement (on a VG ProSpec Mass Spectrometer) which also showed the [M]

 
as a base peak at m/z 326, and which also analyzed for C19H22N2O3.
60
 In both instances, 
a strong [M – H2O]

 peak at m/z 308 was also detected. The 
1
H NMR spectrum showed 
features, which in many ways indicated the alkaloid’s isomeric relationship with 
leuconolam (54). A sharp singlet at H 6.02 ppm showed the presence of an isolated 
olefinic proton corresponding to H-6, while the triplet centered at H 0.76 ppm indicated 
the presence of an ethyl side chain. A notable difference observed in the 
1
H NMR 
spectrum of epi-leuconolam when compared with that of 54 however, was the absence 
of the characteristic indolic NH and C-21OH signals (Table 4.4). The 13C NMR 
spectrum of epi-leuconolam accounted for all the 19 carbons and showed a close 
similarity to the spectrum of leuconolam (54), except for small differences in the 
chemical shifts (Table 4.5).
47,49
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It was also demonstrated by the original investigators that epi-leuconolam (55) 
was likely an artifact due to the presence of acid, as extraction carried out under neutral 
or basic conditions did not result in the isolation of this compound, whereas extraction 
under acidic conditions resulted in its isolation.
47,49
 In our hands, although leuconolam 
(54) was obtained as the major compound, epi-leuconolam was invariably also detected, 
albeit as a minor alkaloid, since brief exposure to traces of acid could not be avoided 
under the conditions used for the isolation and purification. 
Since the structure of 54 rested firmly on an X-ray diffraction analysis (which 
we have repeated, Figure 4.6), we decided to reinvestigate the structure of epi-
leuconolam using a natural sample from our concurrent work in alkaloid chemistry 
(natural sample courtesy of C. Y. Gan
58
).  
                                             
                                            Figure 4.6. X-ray crystal structure of 54. 
 
LC-ESIMS analysis of epi-leuconolam gave an [M  H] peak at m/z 309, which 
indicated a molecular ion (m/z 308), 18 mass units less than that obtained previously by 
EIMS. HRESIMS gave the formula C19H20N2O2  H. The measurement was repeated by 
GC-EIMS, which also gave the molecular ion at m/z 308 (instead of the previously 
observed m/z 326 peak detected by direct probe EIMS). Banwell and co-workers have 
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also reported syntheses of rhazinal (58),
61
 rhazinilam (57), leuconolam (54), and epi-
leuconolam.
62
 The latter two compounds were obtained by oxidation of rhazinilam (57) 
(excess PCC, 18 
o
C, 4 Å molecular sieves), followed by aqueous workup 
(EtOAc/MeOH/H2O) of the reaction product mixture.
62
 The EIMS of the synthetic epi-
leuconolam showed a base peak at m/z 308, with the m/z 326 ion detected as a very 
weak peak (< 1%).  
In the original report, it was noted that the IR spectrum of epi-leuconolam 
showed a strong broad absorption at 3400 cm
1
 attributed to NH and OH.
47,49
 We have 
recorded the IR spectrum of epi-leuconolam and leuconolam (54) (Figure 4.7). It can be 
seen that while the IR spectrum of leuconolam (54) showed a broad absorption at ca. 
3260 cm
1
, epi-leuconolam did not show any significant absorption in the 3400 cm
1
 
region (the same result was obtained by Banwell and co-workers
62
). In addition, the UV 
spectra of leuconolam (54) (207, 220, 287 nm) and epi-leuconolam (203, 252, 350 nm) 
were markedly different indicating the presence of different chromophores (Figure 4.8).    
The 
1
H and 
13
C NMR data for epi-leuconolam have been reported on a number 
of occasions and were each time in agreement with those of the original report.
47,49,60,62
 
We have also carried out additional 2-D NMR experiments (COSY, HMQC, HMBC) 
for epi-leuconolam, which indicated the presence of similar correlations as those in 
leuconolam (54). 
64 
 
 
 
 
Figure 4.7. Top: IR spectrum of leuconolam (54). Bottom: IR spectrum of ‘epi-
leuconolam’. 
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Figure 4.8. Top: UV spectrum of leuconolam (54). Bottom: UV spectrum of ‘epi-
leuconolam’. 
 
 
 
66 
 
In view of the above results, we decided to undertake X-ray diffraction analysis 
of the alkaloid which has to date been assigned as epi-leuconolam (55) (natural sample, 
suitable crystals were obtained from CH2Cl2/hexanes solution). The X-ray diffraction 
analysis revealed that the alkaloid previously assigned as ‘epi-leuconolam (55)’ is in 
actual fact 6,7-dehydroleuconoxine (63) (Figure 4.9).  
 
       
   
  
Figure 4.9. X-ray crystal structure of 63. 
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The previously observed molecular ion at m/z 326 in EIMS was in all probability 
an artifact due to facile cleavage of the initially formed molecular ion followed by 
equally facile capture by water present as a contaminant in the sample, as shown in 
Scheme 4.4.  The presence of water also accounts for the observation of the broad 
absorption at 3400 cm
1
 in the IR spectrum which was attributed to the presence of 
NH/OH groups, while the revised structure, 6,7-dehydroleuconoxine (63), is now 
compatible with the UV spectrum. 
 
 
Scheme 4.4 
 
The revised structure also accounted for Banwell’s transformation of rhazinilam 
(57) to leuconolam (54) and ‘epi-leuconolam’ (or 6,7-dehydroleuconoxine (63)),62 since 
the use of excess PCC, followed by the aqueous workup, resulted in an acidic medium 
which triggered the transannular closure of leuconolam (54) to 6,7-dehydroleuconoxine 
(63). 
The 
1
H and 
13
C NMR data of leuconolam (54), ‘epi-leuconolam’ reported by 
Goh et al.,
49
 Banwell et al.,
62
 and from the present study (natural), and of semisynthetic 
6,7-dehydroleuconoxine (63) from the current study, are summarized in Tables 4.4 and 
4.5, respectively. The 
1
H NMR spectra of leuconolam (54), ‘epi-leuconolam’ (natural, 
present study), and semisynthetic 6,7-dehydroleuconoxine (63) (present study), are 
shown in Figures 4.10, 4.11, and 4.12, respectively. 
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           Table 4.4. Comparison of 
1
H NMR data () of leuconolam (54), ‘epi-leuconolam’, and 6,7-dhydroleuconoxine (63) in CDCl3 
 
Position 
leuconolam (54)
 ‘epi-leuconolam’ 
6,7-dehydroleuconoxine 
(63)
Goh 
et al.
a,49
 
Present 
study
b
 
Goh 
et al.
 a,49
 
Banwell 
et al.
c,62
 
Present 
study
 
(natural)
d,58 
Present study 
(semisynthetic)
b
 
3 2.96 dt (12, 4) 2.94 td (12.5, 4.5) 3.07 dt (10, 4.4) 3.27 – 3.00 m 3.22 ddd (15, 9.6, 6) 3.22 ddd (15, 9.5, 6) 
 3.98 dd (12, 4) 3.98 dd (12.5, 4.5) 4.44 dt (10, 4.4) 4.50 m 4.46 ddd (15, 12, 4) 4.46 ddd (15, 12, 4) 
6 5.79 s 5.77 s 6.20 s 6.21 s 6.22 s 6.22 s 
9 7.20 dd (6, 2) 7.18 dd (7.5, 1.5) 7.45 br d (8.5) 7.45 d (7.8) 7.46 ddd (7.5, 1, 0.6) 7.46 dd (7.5, 1) 
10 7.33 m 7.36 td (7.5, 1.5) 7.12 t (8.5) 7.11 t (7.8) 7.12 td (7.5, 1) 7.12 td (7.5, 1) 
11 7.33 m 7.33 td (7.5, 1.5) 7.33 t (8.5) 7.33 t (7.8) 7.33 td (7.5, 1) 7.33 td (7.5, 1) 
12 7.92 dd (6, 2) 7.91 dd (7.5, 1.5) 8.16 br d (8.5) 8.16 d (7.8) 8.16 ddd (7.5, 1, 0.6) 8.15 dd (7.5, 1) 
14 1.65 – 1.37 m 1.48 m 1.30 – 1.79 m 1.85 – 0.75 m 1.79 m 1.80 m 
 1.65 – 1.37 m 1.48 m 1.30 – 1.79 m 1.85 – 0.75 m 2.04 m 2.05 m 
15 1.65 – 1.37 m 1.57 m  1.30 – 1.79 m 1.85 – 0.75 m 1.10 td (14, 7) 1.10 td (14, 7) 
 1.79 dt (12.5, 5) 1.79 td (13.5, 4.5) 1.30 – 1.79 m 1.85 – 0.75 m 1.66 ddd (14, 6, 1.5) 1.66 ddd (14, 6, 1.5) 
16 2.00 t (12.5) 1.99 td (14, 1.7) 2.66 dd (5.5, 2.5) 2.62 m 2.62 ddd (15, 5, 2) 2.63 ddd (15, 5, 2) 
 2.14 dd (12.5, 6) 2.12 dd (14, 7.3) 3.16 dd (5.5, 2.5) 3.27–3.00 m 3.09 td (15, 6) 3.09 dd (15, 6) 
17 1.65 – 1.37 m 1.40 br t (14.5) 2.03 – 2.13 dd (5.5, 2.5) 2.05 m 1.71 td (15, 5) 1.71 td (15, 5) 
 1.65 – 1.37 m 1.60 td (14.5, 7.3) 2.03 – 2.13 dd (5.5, 2.5) 2.05 m 2.09 ddd (15, 6, 2) 2.11 dd (15, 6, 2) 
18 0.55 t (8) 0.55 t (7.5) 0.73 t (7) 0.75 t (7.2) 0.76 t (7.4) 0.76 t (7.4) 
19 1.65 – 1.37 m 1.23 dq (13.6, 7.5) 1.30 – 1.79 m 1.85–0.75 m 1.35 dq (13.6, 7.4) 1.35 dq (13.6, 7.4) 
 1.65 – 1.37 m 1.60 m 1.30 – 1.79 m 1.85–0.75 m 1.45 dq (13.6, 7.4) 1.46 dq (13.6, 7.4) 
NH 7.89 br s 7.71 br s Not observed Not observed Not observed Not observed 
21-OH 5.13 br s
 4.99 br s Not observed Not observed Not observed Not observed 
                            a270 MHz; b600 MHz; c300 MHz; d400 MHz; b,dassignments based on COSY, HMQC, and HMBC. 
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Table 4.5. Comparison of 
13
C NMR data () of leuconolam (54), ‘epi-leuconolam’, and 
6,7-dehydroleuconoxine (63) in CDCl3 
Position 
leuconolam (54)
 
‘epi-leuconolam’ 

6,7-dehydroleuconoxine 
(63)
Goh 
et al.
a,49
 
Present 
study
b
 
Goh 
et al.
a,49
 
Banwell 
et al.
c,62
 
Present 
study
 
(natural)
 d,58
 
Present study 
(semisynthetic)
b
 
2 178.3 177.8 176.1 175.8 176.1 176.3 
3 35.6 35.3 37.0 37.0 37.0 37.2 
5 166.8 166.5 173.5 173.2 173.5 173.8 
6 128.3 128.1 118.2 118.1 118.2 118.4 
7 156.1 155.6 164.2 164.1 164.2 164.5 
8 133.5 133.1 123.5 123.4 123.5 123.7 
9 126.5 129.3
 
121.6 124.2 121.6 121.8 
10 126.9 126.3 124.3 121.4 124.3 124.6 
11 129.7 129.4 131.6 131.4 131.6 131.8 
12 129.6 126.6 115.9 115.8 115.9 116.2 
13 135.3 135.0 148.6 148.6 148.6 148.9 
14 20.0 19.7 16.8 16.8 16.8 17.0 
15 32.4 24.5 26.0 26.1 26.0 26.3 
16 28.0 32.1 33.1 34.1 33.1 34.4 
17 25.7 25.4 30.4 30.4 30.4 30.7 
18 7.3 6.9 8.3 8.2 8.3 8.5 
19 24.4 27.3 34.1 33.0 34.1 33.4 
20 45.2 44.9 44.6 44.5 44.6 44.8 
21 93.8 93.6 93.7 93.6 93.7 93.9 
a68 MHz; b150 MHz; c75 MHz; d100 MHz; b,dassignments based on COSY, HMQC, and HMBC. 
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Figure 4.10. 
1
H NMR spectrum (CDCl3, 600 MHz) of leuconolam (54). 
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Figure 4.11. 
1
H NMR spectrum (CDCl3, 400 MHz) of ‘epi-leuconolam’ (natural, present study).
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Figure 4.12. 
1
H NMR spectrum (CDCl3, 600 MHz) of semisynthetic 6,7-dehydroleuconoxine (63). 
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With the problem regarding the misassigned structure of ‘epi-leuconolam’ 
resolved, the next issue to be addressed is the structure of compound A, obtained in the 
acid-induced transformations of leuconolam (54).   
Compound A was obtained as a yellowish oil and subsequently as yellowish 
block crystals from CH2Cl2/hexanes (mp 179182 
o
C) with []25D = 116 (c 0.52, 
CHCl3). The UV spectrum showed absorption maxima at 212, 240, and 340 nm, while 
the IR spectrum showed the presence of NH2 (3483 and 3397 cm
1
) and carbonyl 
functions (1743 and 1709 cm
1
). The EIMS of compound A showed an [M]

 at m/z 326, 
while HREIMS measurements gave the molecular formula C19H22N2O3 (DBE 10).  
The 
13
C NMR data (Table 4.6) accounted for all 19 carbon resonances, and 
confirmed the presence two carbonyl functions at C 166.8 (lactam carbonyl) and 170.6 
(lactone carbonyl), in addition to a low-field quaternary resonance (C 102.1) due to C-
21, which is  to both a nitrogen and an oxygen atom.  
The 
1
H NMR data (Table 4.6) showed signals due to four adjacent aromatic 
hydrogens (H 6.65, 6.66, 6.96, and 7.09) corresponding to an ortho-disubstituted 
aromatic moiety, one olefinic proton (H 6.14), and a broad two-H singlet due to an 
amino group NH2 (H 3.94, exchangeable with D2O). The COSY and HMQC data 
showed the presence of NCH2CH2CH2, C=OCH2CH2, and CH2CH3 partial structures, as 
well as an isolated vinylic hydrogen, corresponding to H-6 (Figure 4.13).  
Comparison of the NMR data of compound A (Table 4.6) with those of the 
starting leuconolam (54) (Tables 4.4 and 4.5) indicated that the N-4C-5C-6, N-4C-
3C-14C-15, C-16C-17C=O partial structures, as well as the C-20 ethyl side chain 
have remained intact. The attachment of C-5 and C-3 to N-4 was supported by the 
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observed correlations from H-6 and H-3 to C-21 (low-field quaternary resonance at C 
102.1) indicated the connection of C-21 to N-4. The observed three-bond correlations 
from H-15 to C-17, C-19, and C-21, indicated attachment of C-15, C-17, and C-19 to 
the quaternary C-20, as well as the attachment of C-20 to C-21. It remains to complete 
the assembly of the molecule by cleavage of the N-1 amide function to a free primary 
amine and attachment of the carboxyl oxygen to C-21, to reveal the amino lactam-
lactone as shown in 78.  
 
 
Figure 4.13. Selected HMBCs and NOE of 78. 
 
The 
1
H and 
13
C NMR data of compound 78 are summarized in Table 4.6, while 
the 
1
H NMR spectrum of compound 78 is shown in Figure 4.14. 
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Table 4.6. 
1
H and 
13
C NMR data () of compound 78a 
Position C H 
2 170.6 
3 35.9 2.82 ddd (13, 4, 2)  
  4.09 ddd (13, 11, 4) 
5 166.8 
6 121.9 6.14 s 
7 155.7 
8 118.0 
9 128.9 6.96 dd (8, 1.5) 
10 118.4 6.65 td (8, 1.5)  
11 130.8 7.09 td (8, 1.5) 
12 116.6 6.65 dd (8, 1.5) 
13 144.1 
14 19.8 1.58 m 
15 25.5 1.53 m  
  1.43 m 
16 26.3 2.20 ddd ( 19, 10, 1.2) 
  2.44 ddd (19, 6, 1.5) 
17 25.6 1.28 m 
  1.45 m 
18 7.1 0.68 t (7.6) 
19 25.0 1.26 m  
  1.51 m 
20 37.9 
21 102.1 
NH2  3.94 br s 
aCD2Cl2, 400 and 100 MHz, respectively; assignments based on COSY, HMQC, and HMBC. 
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Figure 4.14. 
1
H NMR spectrum (CD2Cl2, 400 MHz) of amino lactam-lactone 78. 
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                                                            Figure 4.15. X-ray crystal structure of 78 
                                                             [Flack parameter,
63
 x = 0.06(0.06);  
                                                                Hooft parameter,
64
 y = 0.02(0.03)]. 
 
In order to provide firm proof of the proposed structure, X-ray diffraction 
analysis was carried out which confirmed the structure proposed and yielded the 
absolute configuration, as shown in Figure 4.15 (since compound 78 co-crystallized 
with the solvent (CH2Cl2) used during crystallization, the presence of heavy atoms in 
the crystal lattice facilitated the determination of the absolute configuration of 78 
despite the use of Mo K radiation).  
The crystal structure showed that the NH2 group is oriented away from the 
lactone moiety and proximate to the vinylic H-6 (Figure 4.15), which is also supported 
by the observed reciprocal NOE observed between NH2 and H-6 (Figure 4.14). 
With the structure of 6,7-dehydroleuconoxine (63) (previously misassigned as 
epi-leuconolam, 55) and that of compound A (78) firmly established, the results of the 
reaction of leuconolam (54) (and 6,7-dehydroleuconoxine (63)) with acid (Table 4.7) 
become intelligible.   
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Table 4.7. Summary of reactions of leuconolam (54) with acids (updated) 
Entry 
Starting 
material 
Reaction conditions 
Products 
54 63 78 77 
1 54 5% HCl, rt, 8 h No reaction 
2 54 
5% HCl/CH2Cl2  
TEACl, rt, 14 ha 
35% 45% 1.5%  
3 54 HCl/MeOH, rt, 12 h 4%    63% 
4 54 CSA/CH2Cl2, rt, 14 h
a 10%  62% 2%  
5 54 
CSA/CH2Cl2, rt, 11 h  
(4 equiv MeOH added) 
 19%  54% 
6 54 CSA/MeOH, rt, 14 h 4%   2% 94% 
7 54 PTSA/MeOH, rt, 14 h 4%   0.8% 94% 
8 54 
PTSA/CH2Cl2, rt,  
14 h 
3%  5% 42%  
9 63 
5% HCl/CH2Cl2  
TEACl, rt, 12 ha 
15% 84%   
10 63 CSA/CH2Cl2, rt, 15 h No reaction
b 
11 63 
PTSA/CH2Cl2, rt,  
10 h 
 1% 70%  
12 77 
PTSA/CH2Cl2, rt,  
10 h 
No reactionc 
aProlonged reaction time leads to reduced overall yields; btraces of 54 and 78 detected from TLC;  ctraces of 54 and 63 detected from 
TLC. 
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The formation of 6,7-dehydroleuconoxine (63) with recovered leuconolam (54), 
when leuconolam (54) was treated with aqueous acid under two-phase conditions (entry 
2, Table 4.7) in all probability derives from reversible formation of the N-4C-21 
iminium ion 79, followed by transannular cyclization to the doubly spirocyclic 
dehydroleuconoxine (63) (Scheme 4.5). The reversible nature of this reaction is 
indicated by the formation of 54 with recovered 63, when 63 was subjected to the same 
reaction conditions (entry 9, Table 4.7). When the acid-induced reaction was carried out 
in the polar, protic, nucleophilic MeOH (entries 3, 6, and 7, Table 4.7) in the presence 
of either HCl, CSA, or PTSA, virtually quantitative conversion to O-methylleuconolam 
(77) was observed, suggesting efficient trapping of the iminium ion from the -face by 
the larger and more nucleophilic MeOH. With the larger and more nucleophilic MeOH, 
approach from the less hindered convex -face is overwhelmingly favored (Figure 4.16), 
and the nucleophilic addition step is virtually irreversible, the O-methylleuconolam (77) 
once formed is stable under the reaction conditions (77 does not react when exposed to 
acid, entry 12, Table 4.7).  
 
 
Figure 4.16. Iminium ion 79. 
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Scheme 4.5 
 
When the reaction was carried out in PTSA/CH2Cl2, a change in the product 
distribution was observed with the amino lactam-lactone 78, obtained as the major 
product (42%) and 6,7-dehydroleuconoxine (63) as the minor product (5%). TLC 
monitoring of the progress of reaction showed that the amino lactam-lactone 78 was 
formed, subsequent to the formation of 63, suggesting that 78 originated from the first-
formed 63. Further confirmation was provided by the observation that treatment of 63 
with PTSA/CH2Cl2, resulted in the formation of the lactam-lactone 78 as the major 
product in 70% yield (entry 11, Table 4.7).  
A possible pathway for the formation of 78 from 63 is shown in Scheme 4.6 
involving protonation of N-1, fragmentation to the iminium ion 79, intramolecular 
attack by the lactam carbonyl oxygen, followed by cleavage to yield 78. This pathway is 
rendered less likely on geometric grounds as examination of models showed that the 
key intermediate 80 is too strained to exist and therefore unlikely to form.  
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Scheme 4.6 
 
An alternative pathway is shown in Scheme 4.7, which involves the formation of 
a transient epi-leuconolam intermediate (55), followed in succession by protonation of 
the C-2 lactam carbonyl and nucleophilic addition of the appositely oriented C-21-OH 
on the C-2 carbonyl function, leading eventually to N-1C-2 cleavage to yield 
compound 78. 
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Scheme 4.7 
 
A third possible pathway is shown in Scheme 4.8, involving acidic hydrolysis of 
the N-1 lactam, followed in succession by fragmentation to the iminium ion 81, and 
finally, facile intramolecular capture of the iminium ion 81 by the carboxylic acid group, 
leading eventually to the amino lactam-lactone product 78. The fact that the starting 
dehydroleuconoxine 63 is comparatively more strained than the product 78 (as shown 
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by examination of models) constitutes additional support for the proposed amide 
hydrolysis under relatively mild conditions. 
 
 
Scheme 4.8 
 
In view of the facile acid-induced transannular cyclization of leuconolam (54) to 
6,7-dehydroleuconoxine (63), a two-step sequence involving cyclization followed by 
hydrogenation yielded leuconoxine (56) in ca. 55% overall yield from leuconolam (54). 
This transformation represents a partial synthesis of leuconoxine (56) from leuconolam 
(54) (Scheme 4.9) (leuconoxine (56) was previously obtained by bioconversion of 
rhazinilam (57) with Beauveria bassiana LMA (ATCC 7159), but with very low yield 
(0.6%)
65
). The 
1
H and 
13
C NMR data of 56 are summarized in Table 4.8. The 
1
H NMR 
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spectrum of natural 56 and semisynthetic 56 are shown in Figures 4.17 and 4.18, 
respectively.  
 
  
Scheme 4.9 
 
During the course of the present study, an alkaloid corresponding to 6,7-
dehydroleuconoxine (63) (NMR data identical to ‘epi-leuconolam’ or 6,7-
dehydroleuconoxine) was reported as a minor alkaloid from the stem-bark extract of 
Melodinus henryi.
66
 In view of the above, the possibility that this alkaloid is an artifact 
due to the action of traces of acid on leuconolam (54) which may have been present 
cannot be discounted. 
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Table 4.8. 
1
H and 
13
C NMR data () of leuconoxine (56)a 
Position C H 
2 172.9  
3 36.8 2.80 m 
  3.95 ddt (13, 4.4, 2.3) 
5 170.8  
6 37.6 2.68 d (17) 
  2.87 dd (17, 7.3) 
7 41.9 3.82 d (7.3) 
8 135.4  
9 123.8 7.17 dd (7.6, 1) 
10 125.5 7.14 td (7.6, 1) 
11 128.0 7.25 td (7.6, 1) 
12 120.1 7.77 dd (7.6, 1) 
13 142.1  
14 20.1 1.60 m 
  1.60 m 
15 26.2 1.60 m 
  1.97 ddd (14, 12, 5) 
16 29.4 2.49 ddd (19, 6, 1.4) 
  2.78 ddd (19, 14, 6.5) 
17 26.6 1.60 m 
  1.86 ddd (14, 6.5, 1.4) 
18 7.3 0.93 t (7.4) 
19 26.9 1.37 dq (13.4, 7.4) 
  1.78 dq (13.4, 7.4) 
20 38.1  
21 92.5  
aCDCl3, 400 and 100 MHz, respectively; assignments based on COSY, HMQC, and comparison with literature. 
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Figure 4.17. 
1
H NMR spectrum (CDCl3, 400 MHz) of natural leuconoxine (56).
58 
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Figure 4.18. 
1
H NMR spectrum (CDCl3, 400 MHz) of semisynthetic leuconoxine (56).
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4.2.3 Bromination of leuconolam  
 
Treatment of leuconolam (54) with Br2 in CHCl3 gave the dibromoleuconoxine 
derivative, 6,7-dibromoleuconoxine (82) as the sole product in about 90% yield.49  
6,7-Dibromoleuconoxine (82) was obtained as a white amorphous solid (mp 
98102 oC), with []25D = 38 (c 0.62, CHCl3). The UV spectrum showed absorption 
maxima at 208, 227, and 292 nm, while the IR spectrum showed the presence of two 
lactam carbonyls at 1691 and 1709 cm
1
. The ESIMS of 82 showed an [M  H] peak at 
m/z 467, and HRESIMS measurements gave the molecular formula C19H21N2O2
79
Br2  
H. The 
1
H and 
13
C NMR data of 82 were similar to those of 82 previously reported by 
Goh et al.
49
 The configuration of the 6,7-dibromoleuconoxine was assigned as 6,7-
dibromoleuconoxine (82) by analogy to leuconoxine and its congeners, where H or OH 
substituents attached to C-7 in the diazaspiro leuconoxine skeleton has to be -oriented 
(7-substituted analogs are highly strained and none are known). In addition, the 
observed NOE between H-6 and H-9 is only possible if H-6 has the -configuration. 
The 
1
H and 
13
C NMR data of 82 are summarized in Table 4.9, while the 
1
H NMR 
spectrum of 82 is shown in Figure 4.19. 
 
 
 
 
 
 
 
 
 
89 
 
Table 4.9. 
1
H and 
13
C NMR data () of 6,7-dibromoleuconoxine (82)a 
Position C H 
2 172.4 
3 38.7 2.73 m 
  4.08 ddd (13.5, 4, 2) 
5 164.3  
6 50.6 5.17 s 
7 63.7  
8 136.9  
9 126.5 7.33 m 
10 123.8 7.24 dt (7.2 , 1) 
11 130.4 7.36 m 
12 120.9 7.80 dd (7.2, 1) 
13 139.2 
14 19.6 1.56 m 
  1.60 m 
15 24.5 1.62 m 
  2.75 m  
16 29.4 2.64 m  
  2.82 m 
17 25.5 2.03 m 
  2.23 m 
18 7.0 0.94 t (7) 
19 28.0 1.73 m 
  1.98 m 
20 39.2  
21 100.5  
aCDCl3, 400 and 100 MHz, respectively; assignments based on COSY, HMQC, and comparison with literature. 
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Figure 4.19. 
1
H NMR spectrum (CDCl3, 400 MHz) of 6,7-dibromoleuconoxine (82). 
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Monitoring of the progress of the bromination reaction by TLC indicated that 
two products, in addition to the starting leuconolam (54), were detected at a very early 
stage of the reaction.
 
These were 6,7-dibromoleuconoxine (82) and 6,7-
dehydroleuconoxine (63). This observation suggested a two-step sequence involving 
transannular cyclization to 63, followed by bromine addition to furnish 82 (Scheme 
4.10). This was supported by the observation that treatment of 6,7-dehydroleuconoxine 
(63) with Br2/CHCl3 proceeded smoothly to yield the same dibromoleuconoxine 
product, 82. Reaction monitoring by TLC showed only the presence of 6,7-
dehydroleuconoxine (63) and the dibromoleuconoxine addition product, 82. 
Furthermore debromination of the dibromo addition product led smoothly to 6,7-
dehydroleuconoxine (63) (Scheme 4.10).  
 
 
Scheme 4.10 
 
The bromination of alkenes is a well-known reaction, which usually yields 
trans-dibromo products as a consequence of anti-addition of bromine. The generally 
accepted mechanism invokes the intermediacy of a bromonium ion intermediate 83 
(Table 4.11). In this instance however, a cis-dibromo addition product was clearly 
obtained as the sole product. Deviations from trans selectivity (usually giving rise to 
cis/trans mixtures of addition products) have nevertheless been previously observed 
(e.g., in acenaphthylene).
67 
Deviations from trans selectivity are explained by the 
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intermediacy of non-bridged cationic species such as the -bromocarbenium ion 84,68 or 
more recently by the intermediacy of the tribromide adduct 85 (Scheme 4.11).
69
  
 
 
Scheme 4.11 
 
The formation of exclusively cis-dibromo addition product in the present 
instance can be explained by acid-catalyzed epimerization of the trans addition product 
(formed either with exclusive trans selectivity via the bromonium ion 84, or, from 
cis/trans mixtures formed via intermediacy of the -bromocarbenium ion 84, or the 
tribromide adduct 85) (Scheme 4.12).  
 
 
Scheme 4.12 
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4.2.4 Reaction with BH3 
 
It was at first envisaged that a hydroboration reaction on dehydroleuconoxine (63) 
might lead to 6-hydroxyleuconoxine (or leuconodine A (67)), a new leuconoxine type 
alkaloid from L. griffithii.
58
 However, when 63 was treated with BH3.SMe2 (5 equiv) in 
THF at rt,
32,70,71
 a complex mixture of products was obtained from which two 
leuconoxine-type derivatives arising from reduction of the C-2 lactam carbonyl viz., 86 
(completely reduced product, 37%) and 87 (partially reduced product, 6%) were 
successfully isolated (Scheme 4.13).  
 
 
Scheme 4.13 
 
Compound 86 was obtained as a yellowish oil, and subsequently as yellowish 
needles from MeOH (mp 128132 oC), with []25D = 584 (c 0.35, CHCl3). The UV 
spectrum showed absorption maxima at 209, 246, and 388 nm, while the IR spectrum 
showed a conjugated lactam carbonyl at 1641 and 1682 cm
1
. The ESIMS of 86 showed 
an [M  H] at m/z 295, in agreement with the molecular formula C19H22N2O  H. A 
notable difference in the 
1
H NMR spectrum of 86 when compared with that of 6,7-
dehydroleuconoxine (63) was the presence of additional two proton signals due to a 
methylene group adjacent to a heteroatom at H 3.55, 3.81, attributable to H-2 (based on 
HMQC). Also, the characteristic C-2 lactam carbonyl signal observed in the 
13
C NMR 
spectrum of 63 was now replaced by a signal at C 40.8 attributed to C-2 in 86. These 
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observations clearly indicated deoxygenation at C-2 of 86. The 
1
H and 
13
C NMR data of 
86 are summarized in Table 4.10, while the 
1
H NMR spectrum of 86 is shown in Figure 
4.20. 
Compound 87 was obtained as a fluorescent yellowish oil, and subsequently as a 
fluorescent yellowish rods (mp 198200 oC), with []25D = 667 (c 0.33, CHCl3). The 
UV spectrum showed absorption maxima at 209, 245, and 394 nm, while the IR 
spectrum showed an OH band at 3343 cm
1
 and  a lactam carbonyl at 1666 cm
1
. The 
ESIMS of 87 showed an [M  H] at m/z 311, in agreement with the molecular formula 
C19H22N2O2  H. Notable differences in the 
1
H NMR spectrum of 87 when compared 
with that of 6,7-dehydroleuconoxine (63) were the presence of a low field proton signal 
at H 5.52 due to H-2, and a broad OH signal at H 4.02. The 
13
C NMR spectrum 
showed the absence of the characteristic C-2 lactam signal, while displaying an 
additional resonance at C 76.1, attributed to C-2. These observations indicated that the 
C-2 carbonyl in 63 has been reduced to an OH in 87. The C-2 configuration was 
assigned as S, based on the observed NOE between C-2 and C-12. of The 
1
H and 
13
C 
NMR data of 87 are summarized in Table 4.10, while the 
1
H NMR spectrum of 87 is 
shown in Figure 4.21.  
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Table 4.10. 
1
H and 
13
C NMR data () of compounds 86 and 87a 
Position 86 87 
C H C H 
2 40.8 3.55 ddd (15.4, 11, 7.8)  76.1 5.52 br s 
  3.81 dd (15.4, 7.8)   
3 39.0 3.05 ddd (13.5, 4.5, 2)  35.8 3.67 ddd (14, 4, 2)  
  4.31 ddd (13, 11, 4.5)  3.99 ddd (14, 11, 4) 
5 173.7  177.1  
6 116.9 6.16 s 117.3 5.67 s 
7 166.1  166.1  
8 122.5  120.0  
9 122.4 7.36 dd (7.5, 1) 122.7 6.99 dd (7.8, 1) 
10 119.7 6.83 td (7.5, 1) 119.3 6.68 br t (7.8) 
11 131.3 7.24 td (7.5, 1) 131.3 7.15 td (8.2, 1) 
12 109.7 6.75 dd (7.5, 1) 108.2 6.60 br d (8.2) 
13 157.0  153.7  
14 20.1 1.56 m 18.1 1.54 m 
  1.56 m  1.84 m  
15 27.4 1.69 m  24.0 0.87 m 
  2.00 m  1.73 m 
16 17.0 1.69 m  23.8 1.73 m 
  2.00 m  1.81 m 
17 25.4 1.15 m  21.5 1.31 m  
  1.53 m  2.36 td (14.5, 4) 
18 8.3 0.67 t (7.6) 8.3 0.55 t (7.4) 
19 29.6 1.14 dq (13.2, 7.6) 29.6 0.97 dq (13.1, 7.4) 
  1.38 dq (13.2, 7.6)  1.27 dq (13.1, 7.4) 
20 41.4  42.3  
21 94.5  94.7  
OH    4.02 br s 
aCDCl3, 400 and 100 MHz, respectively; assignments based on COSY, HMQC, and HMBC. 
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Figure 4.20. 
1
H NMR spectrum (CDCl3, 400 MHz) of compound 86. 
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Figure 4.21. 
1
H NMR spectrum (CDCl3, 400 MHz) of compound 87. 
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Since suitable crystals of compounds 86 and 87 were obtained, X-ray diffraction 
analyses were carried out, confirming the gross structures proposed by NMR data. The 
X-ray crystal structures of compounds 86 and 87 are shown in Figures 4.22 and 4.23, 
respectively. 
 
 
                                                                   Figure 4.22. X-ray crystal structure of 86. 
 
                                                   
                    
                                                                    Figure 4.23. X-ray crystal structure of 87. 
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A possible mechanism for the formation of compounds 86 and 87 is shown in 
Scheme 4.14. Since boranes are electron-deficient species, they behave as Lewis 
acids.
71,72
 Reduction proceeds with an electrophilic attack on the C-2 lactam carbonyl to 
form complex 88. After a hydride transfer, an alkaloid-borane complex 89 was 
generated, followed in succession by elimination and reduction to give 86. 
Alternatively, the presence of traces of water in the system will result in quenching of 
the alkaloid-borane complex 89 to give compound 87.  
 
 
Scheme 4.14 
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4.2.5 Partial syntheses of leuconodines A and B 
 
Since hydroboration of 63 did not furnish leuconodine A (67), a direct -
oxygenation of leuconoxine (56) at C-6, via enolate mediated oxidation was next 
attempted.   
It turned out however, that treatment of leuconoxine (56) with lithium 
diisopropylamide (LDA) in THF at oC, followed by oxidation of the lactam enolate 
with O2,
73
 gave compound 90 as the sole product (21%), accompanied by a significant 
amount of unreacted 56 (69%). 
The enolate mediated oxidation occurred at C-16 instead of at C-6, possibly due 
to the formation of the more stable 6-membered enolate (Scheme 4.15). 
 
 
Scheme 4.15 
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Compound 90 was obtained as a colorless oil, and subsequently as colorless 
needles from CH2Cl2/hexanes (mp 184186) with []
25
D = 29 (c 0.16, CHCl3). The 
UV spectrum showed absorption maxima at 210, 241, and 374 nm, while the IR 
spectrum showed the presence of an OH (3417 cm
1
) and carbonyl functions (1691 
cm
1
, broad). The ESIMS of 90 showed an [M  H] peak at m/z 327, in agreement with 
the molecular formula C19H22N2O3  H. Notable differences in the 
1
H NMR spectrum of 
90 when compared with that of 56 include the downfield shift of H-16 from H 2.78 and 
2.49 in 56 to H 4.45 in 90 and the presence of an OH peak at H 3.28 (exchangeable 
with D2O) in 90.  The 
13
C NMR data showed that the resonance due to C-16 had shifted 
downfield (C 64.9), when compared to that of 56. These results strongly suggested that 
oxidation had occurred at C-16. The relative configuration at C-16 was assigned as R, 
based on the observed NOE between H-16 and H-15. The 1H and 13C NMR data of 90 
are summarized in Table 4.11, while the 
1
H NMR spectrum of 90 is shown in Figure 
4.24. 
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Table 4.11. 
1
H and 
13
C NMR data () of compound 90a 
Position C H 
2 175.0 
3 36.8 2.69 ddd (13.5, 4.5, 1.5) 
  3.81 m  
5 171.0 
6 37.4 2.56 d (17) 
  2.77 dd (17, 7.8) 
7 42.4 3.83 d (7.8) 
8 135.3 
9 124.0 7.22 m 
10 126.3 7.13 m 
11 128.0 7.21 m 
12 120.9 7.60 br d (7.8) 
13 140.9 
14 20.0 1.51 m 
  1.56 m 
15 28.1 1.66 m 
  1.82 ddd (14.5, 11, 4) 
16 64.9 4.45 dd (13, 6)  
17 35.9 1.50 m  
  2.26 dd (13, 6) 
18 7.5 0.88 t (7.3) 
19 29.3 1.38 dq (14.5, 7.1) 
  1.66 m 
20 38.9 
21 93.7 
16-OH  Not observed 
aCDCl3, 400 and 100 MHz, respectively; assignments based on COSY, HMQC, and HMBC. 
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Figure 4.24. 
1
H NMR spectrum (CDCl3, 400 MHz) of compound 90. 
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Since suitable crystals of 90 were obtained from CH2Cl2/hexanes, an X-ray 
diffraction analysis was carried out, which confirmed the above observations, as well as 
yielding the relative configuration (Figure 4.25).  
 
                                                
                                            Figure 4.25. X-ray crystal structure of 90. 
 
Leuconodine A (67) was eventually obtained by treatment of leuconolam (54) 
with excess trifluoroacetic acid (TFA). Treatment of leuconolam (54) with TFA (2 
equiv) resulted in transannular cyclization to 6,7-dehydroleuconoxine (63) (Scheme 
4.16). The use of excess TFA (20 equiv) gave a mixture of two products, viz., 63 (30% 
yield) and leuconodine A (67) (25% yield) (Scheme 4.16).  
The formation of 63 and 67 in the presence of excess TFA is rationalized in 
Scheme 4.17. In the presence of excess TFA, conjugate addition by the TFA anion to 
the conjugated iminium ion 79, competes with transannular cyclization to 63, leading 
eventually to leuconodine A (67). Dess-Martin periodinane (DMP) oxidation of 
leuconodine A (67) gave another newly found leuconoxine alkaloid, leuconodine F (72) 
(76% yield) (Scheme 4.17). 
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Scheme 4.16 
 
 
Scheme 4.17 
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Leuconodine A (67) was obtained as a colorless oil, and subsequently as 
colorless block crystals from EtOH/CH2Cl2 (mp 134137 
o
C) with []25D = 19 (c 0.21, 
CHCl3). The UV spectrum showed absorption maxima at 209, 241, and 277 nm, while 
the IR spectrum showed the presence of OH (3357 cm
1
) and C=O (1676 cm
1
, lactam) 
functionalities. The EIMS of 67 showed an [M]

 at m/z 326, while HREIMS 
measurements gave the molecular formula as C19H22N2O3. The 
13
C NMR data (Table 
4.12) showed a total of 19 carbon resonances, in agreement with the molecular formula. 
The 
1
H and 
13
C NMR spectra of 67 were somewhat similar to those of the known 
alkaloid, leuconoxine (56). The 
1
H NMR spectrum of 67 showed a broad OH singlet at 
H 5.11 (exchangeable with D2O), while the 
13
C NMR spectrum of alkaloid 67 indicated 
the absence of the resonance at C 37.6, which was replaced by a lower field resonance 
at C 75.1 (an indication of oxygenation). The methine singlets at H 3.90 and 4.51 were 
assigned to H-7 and H-6, respectively, based on the observed three-bond correlations 
from H-7 to C-5 and C-9, and from H-6 to C-8 and C-21. The HMQC spectrum showed 
a H-C correlation between the methine singlet at H 4.51 and the carbon resonance at C 
75.1, suggesting that oxygenation had occurred at C-6. The relative configuration of C-7 
in 67 was deduced to be S, by analogy to leuconoxine (56) and its congeners, where any 
substituents attached to C-7 in the diazaspiro leuconoxine skeleton have to be -
oriented. The C-6 configuration was assigned as R, based on the small coupling constant 
observed between H-6 and H-7 (J ~ 0 Hz), i.e., dihedral angle ~ 90
o
, as well as from the 
observed reciprocal NOEs between H-6 and H-9. The 
1
H and 
13
C NMR data of 67 are 
summarized in Table 4.12, while the 
1
H NMR spectrum of natural 67
58
 and 
semisynthetic 67 are shown in Figures 4.26 and 4.27, respectively. 
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Table 4.12. 
1
H and 
13
C NMR data () of leuconodines A (67) and F (72)a 
Position 67 72 
C H C H 
2 173.1  172.2 
3 36.8 2.89 ddd (13, 11, 4) 37.8 3.10 ddd (13, 11, 4) 
  3.99 ddd (13, 5, 2)  4.11 ddt (13, 5, 2.3) 
5 172.0  157.5  
6 75.1 4.51 s 192.5  
7 49.6 3.90 s 53.4 4.23 s 
8 132.1  126.2  
9 124.5 7.27 dd (7.8, 1) 125.1 7.22 dd (7.6, 1) 
10 125.4 7.13 td (7.8, 1) 125.9 7.16 td (7.6, 1) 
11 128.3 7.25 td (7.8, 1) 129.9 7.37 td (7.6, 1) 
12 119.6 7.87 dd (7.8, 1) 121.0 7.82 dd (7.6, 1) 
13 141.9  142.6  
14 19.4 1.70 m 20.1 1.71 m 
  1.70 m  1.71 m 
15 27.3 1.64 m 26.3 1.71 m 
  1.92 m  2.05 m 
16 30.2 2.53 ddd (19, 6, 1.4) 29.5 2.59 ddd (19, 6, 1.4) 
  2.78 ddd (19, 14, 6.5)  2.86 ddd (19, 14, 6.5) 
17 27.5 1.60 m 26.6 1.66 td (14, 6) 
  1.94 m  1.98 ddd (14, 6.5, 1.4) 
18 7.7 0.90 t (7.3) 7.3 0.92 t (7.4) 
19 28.5 1.49 dq (13, 7.3) 27.7 1.23 dq (13, 7.4) 
  1.96 m  1.49 dq (13, 7.4) 
20 36.7  37.6  
21 93.5  88.0  
6-OH  not observed
b
   
aCDCl3, 400 and 100 MHz, respectively; 
b
6-OH was observed at H 5.11 as a broad singlet in natural 67;
58 assignments based on 
COSY, HMQC, and HMBC. 
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Figure 4.26. 
1
H NMR spectrum (CDCl3, 400 MHz) of natural leuconodine A (67).
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Figure 4.27. 
1
H NMR spectrum (CDCl3, 400 MHz) of semisynthetic leuconodine A (67). 
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Since suitable crystals of compound 67 were obtained from EtOH/CH2Cl2, an X-
ray diffraction analysis was carried out (Figure 4.28), confirming all of the above 
observations. It can be seen that 67 co-crystallized with the solvent molecule used 
during crystallization (EtOH). The EtOH molecule formed a hydrogen bond with the C-
5 lactam carbonyl. 
 
                 
   
Figure 4.28. X-ray crystal structure of 67. 
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Leuconodine F (72) was obtained as a colorless oil, and subsequently as 
colorless block crystals from MeOH (mp 246250 oC) with []25D = 94 (c 0.05, 
CHCl3). The UV spectrum displayed absorption maxima at 203, 232, 254, and 350 nm, 
while the IR spectrum showed, in addition to the lactam carbonyl functions (1689 cm
1
, 
broad), a band at 1715 cm
1
 due to a ketone. The presence of the ketone carbonyl 
function was also indicated by the carbon resonance at C 192.5 in the 
13
C NMR 
spectrum. The EIMS of 72 showed an [M H] at m/z 325, while HREIMS 
measurements gave the molecular formula as C19H20N2O3  H, differing from 
leuconoxine (56) by 14 mass units, suggesting 72 to be an oxo-derivative of 
leuconoxine (56). The 
1
H and 
13
C NMR data were generally similar to those of 
leuconoxine (56), except for the absence of the signals due to H-6. The signal due to H-
7 was now observed as a singlet at H 4.23 indicating that H-7 was unusually deshielded 
as a result of its proximity to the ketone carbonyl function. This confirmed the location 
of the ketone function at C-6. The 
1
H and 
13
C NMR data of 72 are summarized in Table 
4.12, while the 
1
H NMR spectrum of natural 72
58
 and semisynthetic 72 are shown in 
Figures 4.29 and 4.30, respectively. 
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Figure 4.29. 
1
H NMR spectrum (CDCl3, 400 MHz) of natural leuconodine F (72).
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Figure 4.30. 
1
H NMR spectrum (CDCl3, 400 MHz) of semisynthetic leuconodine F (72). 
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Since suitable crystals of compound 72 were obtained from CH2Cl2/hexanes, an 
X-ray diffraction analysis was carried out (Figure 4.31), confirming all of the above 
observations.  
 
 
 
 
 
Figure 4.31. X-ray crystal structure of 72. 
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4.3 Conclusion 
 
Several reactions of the ring-opened Aspidosperma alkaloid, leuconolam (54), 
were investigated. The based-induced reaction of leuconolam (54) resulted in enolate-
mediated transannular closure to give two epimeric pentacyclic meloscine-like products 
(74 and 76), while the acid-induced reactions (HCl in two-phase medium, CSA in 
CH2Cl2) resulted in transannular closure to give 6,7-dehydroleuconoxine (63). A two-
step sequence from leuconolam (54), comprising acid-induced closure, followed by 
catalytic hydrogenation, provided a concise semisynthesis of leuconoxine (56). When 
the acid-induced reaction of leuconolam (54) (or 6,7-dehydroleuconoxine (63)) was 
carried out with PTSA in CH2Cl2, the product was the amino lactam-lactone 78, while 
the acid-induced reactions in the presence of MeOH as solvent furnished O-
methylleuconolam (77) as the sole product in high yields. The original assignment of 
the structure of epi-leuconolam (55) was revised to 6,7-dehydroleuconoxine (63) based 
on X-ray diffraction analysis. Bromination (Br2/CHCl3) of leuconolam (54) proceeds in 
two steps via intermediacy of 6,7-dehydroleuconoxine (63) to furnish the 6,7-
dibromoleuconoxine adduct (82). Concise semisynthesis of the new leuconoxine-type 
alkaloids, leuconodines A and F (67 and 72, respectively), was achieved by treatment of 
leuconolam (54) with excess TFA (which gave leuconodine A (67) as the minor 
product), followed by oxidation of 67 to leuconodine F (72).  
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CHAPTER FIVE 
Partial Syntheses of the New Strychnan Alkaloid, Alstolucine A,  
and the New Eburnane Alkaloid, ()-Eburnamaline 
 
5.1 Alstolucine A 
 
5.1.1 Introduction 
 
Alstolucine A (91) is a new strychnan-type alkaloid obtained from the leaf 
extract of Alstonia spatulata (isolation and structure by S. J. Tan).
74
  
 
 
 
Alstolucine A (91) was obtained as a light yellowish oil, with []25D438 (c 
0.12, CHCl3). The UV spectrum showed absorption maxima at 230, 298, and 328 nm, 
characteristic of a -anilinoacrylate chromophore.75 The IR spectrum (thin film) showed 
a broadened band at 3378 cm
1 
due to the indolic NH function, another band at 1742 
cm
1 
due to a carbonate group (OCO2), and a band at 1683 cm
1 
due to an ,-
unsaturated ester function. The ESIMS of 91 showed an [M  H] peak at m/z 413, and 
HRESIMS measurements yielded the molecular formula C23H29N2O5  H (DBE 11). 
The 
13
C NMR data (Table 5.1) showed all 23 carbon resonances, comprising 
three methyl, five methylene, eight methine, and seven quaternary carbons. The 
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presence of conjugated ester and carbonate functionalities were supported by the 
observed quaternary carbon signals at δC 167.9 and 155.0, respectively, while the 
signals due to the two olefinic quaternary carbons at δC 167.9 (C-2) and 103.6 (C-16) 
were consistent with the presence of the -anilinoacrylate moiety. Two downfield 
signals at δC 76.5 and 63.8 were associated with the presence of oxymethine and 
oxymethylene moieties, respectively.  
The 
1
H NMR data (Table 5.1) showed the presence of an unsubstituted aromatic 
moiety, an indolic NH as a broad singlet at δH 8.92, an oxymethine at δH 4.76, an 
oxymethylene at δH 4.21, and three methyl groups. The highest field methyl at δH 1.33 
(t, J = 7.0 Hz) was associated with the oxymethylene at δH 4.21, constituting part of an 
ethoxy moiety, while the methyl at δH 1.34 (d, J = 6.0 Hz) was adjacent to the 
oxymethine at δH 4.76 (m) as shown by the COSY spectrum. The remaining methyl at 
δH 3.77 (s) was associated with the conjugated methyl ester function.  
The COSY, HMQC, and HMBC data revealed the structure of alstolucine A 
(91). The relative configuration at the various centers were established from the 
observed NOEs as well as analysis of the vicinal coupling constants, except for the 
carbon bearing the carbonate group at C-19, for which the NOE data proved 
inconclusive. A partial synthesis of 91 was therefore carried out, and the results 
obtained were used to establish the configuration at C-19. The 
1
H and 
13
C NMR data of 
alkaloid 91 are summarized in Table 5.1, while 
1
H NMR spectrum of alkaloid 91 is 
shown in Figure 5.1. 
An ideal starting material that bears a close resemblance to alstolucine A (91) 
would be the known alkaloid, N(4)-demethylalstogustine (92)
76
 or its C-19 epimer 
(93).
77
 Acylation of either 92 or 93 should lead to 91 (Scheme 5.1), which would then 
allow confirmation of the C-19 configuration of 91. However, since both 92 and 93 
were not available, another choice of starting material was indicated.  
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Scheme 5.1 
 
An alternative starting material for the partial synthesis of alstolucine A (91) is 
alstolucine B (94),
74
 a new alkaloid isolated from the same study. An advantage of using 
94 as starting compound is that the structure and relative configuration of 94 can be 
established by NMR and X-ray diffraction analysis. The 
1
H and 
13
C NMR data of 
alkaloid 94 are summarized in Table 5.1, while the 
1
H NMR spectrum of alkaloid 94 is 
shown in Figure 5.2. The X-ray crystal structure of 94 is shown in Figure 5.3.  
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Table 5.1. 
1
H and 
13
C NMR data () of alstolucines A (91) and B (94)a 
Position 91 94 
C H C H 
2 167.9  172.2 
3 58.9 4.04 m 60.6 3.87 br t (3.0) 
5 53.5 3.00 m 54.0 2.87 m 
5  3.20 ddd (11.4, 8.7, 6.6)  3.05 m 
6 45.6 2.00 m 43.4 1.83 m 
6  2.29 ddd (12.0, 8.0, 6.5)  3.04 m 
7 58.1  56.7 
8 135.3  135.4 
9 120.8 7.20 br d (7.5) 119.6 7.15 br d (8.0) 
10 120.9 6.90 br t (7.5) 121.1 6.90 td (8.0, 1.0) 
11 127.8 7.14 td (7.5, 1) 127.6 7.11 td (8.0, 1.0) 
12 109.6 6.82 br d (7.5) 109.7 6.80 br d (8.0) 
13 144.1  144.2  
14R 27.4 1.18 dt (13.6, 2.6) 31.7 1.47 dt (13.0, 3.0) 
14S  2.24 dt (13.6, 3.5)  2.12 dt (13.0, 3.0) 
15 27.0 3.09 m 30.8 3.47 m 
16 103.6  96.5  
18 17.2 1.34 d (6.0) 29.2 2.30 s 
19 76.5 4.76 m 208.5  
20 41.2 2.11 m 50.0 2.87 m 
21 47.6 2.67 dd (14.0, 6.0) 45.6 2.64 t (12.0) 
21  3.03 dd (14.0, 11.8)  2.83 dd (12.0, 4.0) 
22 155.0    
23 63.8 4.21 m   
  4.21 m   
24 14.3 1.33 t (7.0)  3.68 s 
CO2Me 51.0 3.77 s 50.9 8.93 br s 
CO2Me 167.9   167.2 3.90 s 
NH  8.92 br s  4.15 br s 
aCDCl3, 400 and 100 MHz, respectively; assignments based on COSY, HMQC, and HMBC. 
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Figure 5.1. 
1
H NMR spectrum (CDCl3, 400 MHz) of natural alstolucine A (91).
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Figure 5.2. 
1
H NMR spectrum (CDCl3, 400 MHz) of alstolucine B (94).
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                                                  Figure 5.3. X-ray crystal structure of 94. 
 
In the event, the C-20 configuration of alstolucine B (94) as revealed by the X-
ray diffraction analysis is 20R, which is opposite to that of alstolucine A (91, 20S). The 
first step in the transformation therefore requires epimerization of 94 to the C-20 epimer 
95, followed in succession by reduction to 92 (or 93), and acylation to 91 (Scheme 5.2). 
 
 
Scheme 5.2 
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5.1.2 Results and discussion 
 
The partial synthesis was therefore carried out as outlined in Scheme 5.2. In the 
first step, treatment of alstolucine B (94) with NaOMe/MeOH (0 
o
C, 3 h) gave a 2:1 
mixture of 94 and its C-20 epimer, 95 (Scheme 5.3).  
Compound 95 was obtained as a light yellowish oil, with []25D 371 (c 0.35, 
CHCl3). The UV spectrum showed absorption maxima at 229, 297, and 328 nm, while 
the IR spectrum (thin film) showed bands at 3378 (NH), 1704 (C=O), and 1678 (,-
unsaturated ester) cm
1
. The ESIMS of 95 showed an [M H] at m/z 339, and 
HRESIMS measurements yielded the molecular formula C20H22N2O3. The 
1
H and 
13
C 
NMR data of 95 were identical to those of alstolucine B (94), except for differences in 
the chemical shift of H-20 in the 
1
H NMR spectrum, and differences in the shifts of C-
19, C-20, and C-21 in the 
13
C NMR spectrum. Compound 95 is therefore the C-20 
epimer of alstolucine B (94). The
 1
H and 
13
C NMR data of 95 are summarized in Table 
5.2, while the 
1
H NMR spectrum of 95 is shown in Figure 5.4. 
Reduction of 95 with NaBH4 in MeOH (0 
o
C, 1 h) gave two products: the major 
product (85%) was identical to N(4)-demethylalstogustine (92),
76
 while the minor 
product (10%) was the corresponding C-19 epimer 93 (Scheme 5.3).
77
  
The []D, UV, IR, MS, 
1
H and 
13  
C NMR data of N(4)-demethylalstogustine (92) 
and its C-19 epimer 93 are identical to those reported in the literature.
76,77
 The 
1
H and 
13
C NMR data of 92 and 93 are summarized in Table 5.2, while the 
1
H NMR spectra of 
92 and 93 are shown in Figures 5.5 and 5.6, respectively. 
Subsequent treatment of N(4)-demethylalstogustine (92) with ethyl 
chloroformate and triethylamine in CH2Cl2 (5 equiv in 5 ml CH2Cl2, rt, 30 min) gave, 
after silica gel chromatography, an acylated derivative which was identical ([]D, 
1
H 
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and 
13
C NMR, MS) with alstolucine A (91) (Scheme 5.3). The 
1
H NMR spectrum of 
semisynthetic 91 is shown in Figure 5.7. 
 
Table 5.2. 
1
H and 
13
C NMR data () of compounds 92, 93, and 95a 
Position 92 93 95 
C H C H C H 
2 167.6  168.1  168.7  
3 59.1 4.07 m 59.2 4.04 m 58.6 4.05 m 
5 53.9 3.05 ddd (11, 6, 
4.5) 
53.8 2.99 ddd (11, 6.7, 
4) 
53.1 2.96 ddd  
(11.0, 6.4, 5.5) 
5  3.24 ddd (11, 9, 
6) 
 3.18 ddd (11, 9, 
6.7) 
 3.16 dt (11.0, 7.0) 
6 46.7 2.02 ddd (12.4, 6, 
5) 
45.9 1.98 ddd (12.8, 6, 
4) 
45.2 2.01 ddd  
(12.5, 6.5, 5.5) 
6  2.32 m  2.39 ddd (12, 9, 7)  2.34 ddd  
(12.5, 7.5, 6.7) 
7 58.6  58.2  58.3  
8 135.7  135.6  135.0  
9 120.9 7.20 br d (7.5) 120.8 7.20 br d (7.5) 120.8 7.19 br d (7.7) 
10 121.2 6.91 br t (7.5) 121.1 6.91 br t (7.5) 121.2 6.91 td (7.7, 1.0) 
11 128.0 7.16 br t (7.5) 127.9 7.15 br t (7.5) 128.0 7.15 td (7.7) 
12 109.7 6.85 br d (7.5) 109.7 6.83 br d (7.5) 109.8 6.84 br d (7.7) 
13 143.8  144.1  144.2  
14R 27.4 1.22 dt (13.7, 2.3) 27.6 1.19 dt (13.6, 2.7) 26.6 1.19 dt (13.7, 2.4) 
14S  2.29 m  2.23 dt (13.6, 3.4)  2.18 dt (13.7, 3.3) 
15 29.3 3.00 m 27.8 2.95 m 27.4 3.38 m 
16 102.9  103.4  102.6  
18 20.3 1.16 d (6.2) 20.2 1.26 d (6.2) 29.4 2.26 s 
19 71.1 3.62 m 69.9 3.80 m 210.0  
20 45.5 1.83 m 43.4 2.03 m 49.5 3.02 ddd  
(10.0, 6.0, 2.8) 
21 48.4 2.66 dd (14, 6) 47.4 2.71dd (14, 6) 47.0 2.81 dd (14.0, 6.0) 
21  2.94 t (14)  3.09 dd (14, 11)  3.28 dd  
(14.0, 10.0) 
CO2Me 51.5 3.82 s 51.3 3.80 s 51.2 3.77 s 
CO2Me 167.9  168.1  168.0  
NH  8.52 br s  8.65 br s  8.82 br s 
aCDCl3, 400 and 100 MHz, respectively; assignments based on COSY, HMQC, and HMBC. 
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Figure 5.4. 
1
H NMR spectrum (CDCl3, 400 MHz) of compound 95.  
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Figure 5.5. 
1
H NMR spectrum (CDCl3, 400 MHz) of N(4)-demethylalstogustine (92). 
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Figure 5.6. 
1
H NMR spectrum (CDCl3, 400 MHz) of 19-epi-N(4)-demethylalstogustine (93). 
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Figure 5.7. 
1
H NMR spectrum (CDCl3, 400 MHz) of semisynthetic alstolucine A (91). 
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5.1.3 Conclusion 
 
  A partial synthesis of alstolucine A (91) was successfully carried out. The C-19 
configuration of 91 was found to be 19R, based on chemical correlation with N(4)-
demethylalstogustine (92),
76,77
 whose configuration was established by X-ray 
diffraction.
79
  
 
 
Scheme 5.3 
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5.2 ()-Eburnamaline 
 
5.2.1 Introduction 
 
The alkaloid ()-eburnamaline (96) was obtained as a minor alkaloid from 
Leuconotis griffithii (isolation and structure by C. Y. Gan).
80
 It bears some similarity to 
the known alkaloid, ()-eburnamine (97),49,81,82 but with an additional -OH group on 
C-17.  
 
 
 
()-Eburnamaline (96) was obtained as a light yellowish oil, with []25D  (c 
0.21, CHCl3). The UV spectrum (230 and 280 nm) showed the presence of an indole 
chromophore, while the IR spectrum indicated the presence of hydroxyl groups at 3370 
cm
1
. The EIMS of 96 showed an [M]

 at m/z 312, with a prominent fragment peak due 
to loss of H2O at m/z 294, while the HREIMS showed an [M]

 at 312.1827, which 
analyzed for C19H24N2O2 (DBE 9, 16 mass units higher than ()-eburnamine (97)). The 
NMR data of 96 (Table 5.3) showed a close resemblance to those of 97,
49,81,82
 except for 
some notable differences associated with changes involving ring E. First, compared 
with 97, a doublet was observed at  3.90 (C 71.7) which indicated the presence of an 
oxymethine. This doublet coupled to the other oxymethine hydrogen (H-16) which 
required it to be vicinal to C-16. Alkaloid 96 is therefore the 17-hydroxy congener of 
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97. This conclusion is consistent with the loss of the H-17 signals seen in 97, and the 
presence of a CHCH fragment in 96, in place of the CHCH2 fragment seen in the COSY 
spectrum of 97.  
The configuration at C-16 in the 16-hydroxysubstituted eburnan alkaloids can be 
deduced from the presence or absence of paramagnetic deshielding exerted by the 
oxygen of the C-16OH substituent.8386 The relative configuration at the hydroxy-
substituted C-17 was deduced to be R (OH) based on the following evidence. First, 
the reciprocal NOEs observed for H-16/H-17, H-17/H-15, and H-17/H-18 are only 
consistent with a -oriented C-17OH (H-17). Second, the observed J16-17 of 3 Hz is 
in agreement with an equatorially-disposed H-17 (an axial or -oriented H-17 would 
result in H-17 and H-16 being trans-diaxial). Third, the resonances for H-21 and H-19 
were shifted downfield ( 4.02; 1.79, 2.30) when compared to those of ()-eburnamine 
(97) ( 3.48; 1.27, 1.89), as a result of paramagnetic deshielding exerted by the 
proximate oxygen of the -oriented C-17OH (Figure 5.8). The 1H and 13C NMR data 
for alkaloid 96 are summarized in Table 5.3, while 
1
H NMR spectrum of alkaloid 96 is 
shown in Figure 5.9. 
 
 
 
Figure 5.8. Paramagnetic deshielding exerted by C-17OH. 
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The cis-diol configuration at C-16 and C-17 for alkaloid 96 is a rather 
uncommon structural feature and as such, further proof is required to further 
substantiate the cis-diol configuration assigned. To this end a partial synthesis of 96 was 
carried out in order to obtain additional support for this uncommon structural feature. In 
addition, with more of 96 available from partial synthesis, suitable crystals can be 
obtained for X-ray diffraction analysis.  
A concise route to 96 is one based on ()-eburnamonine (98)87 as the starting 
compound (
1
H and 
13
C NMR data of alkaloid 98 are summarized in Table 5.3, while the 
1
H NMR spectrum of alkaloid 98 is shown in Figure 5.10). As shown in Scheme 5.4, 
oxidation of 98 to 17-hydroxyeburnamonine (99), followed by reduction of the lactam 
should furnish alkaloid 96.  
 
 
 
Scheme 5.4 
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Table 5.3. 
1
H and 
13
C NMR data () of ()-eburnamaline (96) and ()-eburnamonine 
(98)
a
 
Position 96 98 
C H C H 
2 131.5  132.0  
3 44.8 2.35 m 44.2 2.41 m 
  2.53 br d (13)  2.53 m 
5 50.9 3.14 ddd (14, 12, 6) 50.5 3.20 ddd (14, 11, 6) 
  3.22 dd (14, 6)  3.32 dd (14, 6) 
6 16.7 2.42 ddd (16, 6, 2) 16.4 2.41 m 
  2.88 dddd (16, 12, 6, 2)  2.88 m 
7 105.6  112.4  
8 128.7  130.0  
9 118.0 7.45 dd (7, 1) 117.9 7.42 dd (7, 2) 
10 120.2 7.13 td (7, 1) 123.7 7.27 td (7, 2) 
11 121.3 7.17 td (7, 1) 124.2 7.31 td (7, 2) 
12 112.3 7.79 dd (7, 1) 116.1 8.37 dd (7, 2) 
13 137.2  134.0  
14 20.0 1.29 m 20.5 brd (13) 
  1.70 dt (13, 3.6)  1.74 br qt (13, 3) 
15 21.9 0.66 td (13, 3.6) 26.8 1.01 td (13.5, 3) 
  1.37 br d (13)  1.48 br d (13.5)  
16 77.0 5.54 d (3) 119.7  
17 71.7 3.90 d (3) 116.7 2.56 d (17) 
    2.65 d (17) 
18 6.9 0.89 t (7.7) 9.0 0.92 t (7) 
19 22.9 1.79 dq (14.5, 7.7) 27.5 1.63 dq (14, 7) 
  2.30 dq (14.5, 7.7)  2.03 dq (14, 7) 
20 40.8  37.3  
21 55.8 4.02 br s 55.8 3.92 s 
aCDCl3, 400 and 100 MHz, respectively; assignments based on COSY, HMQC, and HMBC. 
 
 1
3
4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9. 
1
H NMR spectrum (CDCl3, 400 MHz) of natural ()-eburnamaline (96).
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Figure 5.10. 
1
H NMR spectrum (CDCl3, 400 MHz) of ()-eburnamonine (98).
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5.2.2  Results and discussion  
 
The partial synthesis was carried out based on the proposed route outlined in 
Scheme 5.4. The first step involved an -oxygenation of 98 at the adjacent C-17 of ()-
eburnamonine (98) via enolate-mediated oxidation.  
Treatment of 98 with LDA in THF at oC, followed by oxidation of the lactam 
enolate with O2,
69
 gave the desired ()-17-hydroxyeburnamonine (99) as the sole 
product (26%), accompanied by recovery of unreacted 98 (60%). The high recovery of 
98 may be due to quenching of the lactam enolate by water present in the oxygen gas. 
Attempts to improve the yield by prior drying of the oxygen gas via passage through 
CaCl2 or activated SiO2, did not result in significant improvement of the yields. A 
significant improvement in the yield (83%) was achieved with the use of ()-
camphorsulfonyl oxaziridine in place of gaseous oxygen in the enolate oxidation.
88
 
(Scheme 5.5). 
()-17-Hydroxyeburnamonine (99) was obtained as a light yellowish oil, with 
[]25D 126 (c 0.62, CHCl3). The UV spectrum (229 and 282 nm) showed the presence 
of an indole chromophore, while the IR spectrum indicated the presence of an OH and 
carbonyl group at 3382 and 1703 cm
1
, respectively. The HRESIMS showed an [M  
H]

 at 311.1760, which analyzed for C19H22N2O2  H (16 mass units higher than 98). 
The 
1
H and 
13
C NMR data (Table 5.4) were generally similar with those of 98, except 
for the downfield shifts of H-17 and C-17 to H 4.15 and C 75.1, respectively, and the 
presence of an OH ( 4.78) in the 
1
H NMR spectrum. The assignment of the 
configuration at C-17 in 99 was based on the observed downfield shift of the H-21 and 
H-19 signals (compared to 98)
82,87
 as a result of paramagnetic deshielding by the -
oriented C-17OH, as well as from the observed H-17/H-15, H-18 NOEs. The 1H and 
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13
C NMR data of compound 99 are summarized in Table 5.4, while 
1
H NMR spectrum 
of 99 is shown in Figure 5.11. 
Treatment of 99 in the presence of LiAlH4 in THF under reflux gave two 
epimeric products, 96 (54%) and 100 (39%) (Scheme 5.5).
82
 The major product showed 
[]D, TLC Rf, ESIMS, and 
1
H and 
13
C NMR data which were identical with those of 96. 
The 
1
H NMR spectrum of semisynthetic 96 is shown in Figure 5.12. 
The minor product 100 was obtained as white amorphous solid, and 
subsequently as colorless crystals from CH2Cl2 (mp 190193 

C) with []25D 44 (c 
0.62, MeOH). The UV spectrum (229 and 281 nm) showed the presence of an indole 
chromophore, while the IR spectrum indicated the presence of OH groups at 3448 cm
1
. 
The HRESIMS of 100 gave [M  H] at 313.1915, corresponding to the formula 
C19H24N2O2  H, which was similar to that of 96. Compound 100 was assigned as the 
16-OH epimer of 99 based on the observed downfield shift of H-15 compared to those 
of 96 due to paramagnetic deshielding, as well as the virtual absence of the H-16H-17 
vicinal coupling (J16-17 ≈ 0), in agreement with the required H-16H-17 dihedral angle 
of ca. 90

 in 100. The 
1
H and 
13
C NMR data for compound 100 are summarized in 
Table 5.4, while the 
1
H NMR spectrum of compound 100 is shown in Figure 5.13.  
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Scheme 5.5 
Table 5.4. 
1
H and 
13
C NMR data () of compounds 99 and 100a 
Position 99  100
b 
C H C H 
2 131.6  130.5  
3 44.7 2.35 m 45.2 2.55 m 
  2.62 br d (11)  2.55 m 
5 50.3 3.26 m  51.5 3.23 dd (14, 6) 
  3.30 m  3.14 m 
6 16.6 2.40 dd (16, 6) 16.6 2.85 m 
  2.83 dddd (16, 14, 6, 2)  2.66 m 
7 113.0  105.5  
8 130.5  129.1  
9 118.4 7.40 dd (7, 1) 110.2 7.34 br d (7.5) 
10 124.2 7.26 m 121.4 7.20 td (7.5) 
11 124.4 7.29 m 120.3 7.16 td (7.5) 
12 116.4 8.29 dd (7, 1) 118.7  br d (7.5) 
13 134.6  135.4  
14 20.2 1.37 br d (13.5) 20.4 1.33 m 
  1.77 dt (13.5, 3.5)  1.33 m 
15 23.0 1.51 br d (13.7) 22.3 1.47 td (14, 3.5) 
  0.70 td (13.7, 3.5)   1.37 m 
16 169.0 4.78 br s  79.9 5.74 br s 
17 75.1 4.15 s 73.4 3.84 br s 
     
18 7.1 0.89 t (7.4) 7.1 0.92 t  (7.3) 
19 21.2 1.96 dq (14.6, 7.4) 23.1 2.29 dq (14.5, 7.3)  
  2.22 dq (14.6, 7.4)  1.71 dq (14.5, 7.3)  
20 41.9  39.0  
21 55.6 4.17 br s 56.4 4.04 br s 
16-OH    Not observed 
17-OH  4.78 br s  Not observed 
aCDCl3, 400 and 100 MHz, respectively; 
blow solubility in CDCl3; assignments based on COSY, HMQC, and HMBC. 
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Figure 5.11. 
1
H NMR spectrum (CDCl3, 400 MHz) of ()-17-hydroxyeburnamonine (99). 
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Figure 5.12. 
1
H NMR spectrum (CDCl3, 400 MHz) of semisynthetic ()-eburnamaline (96). 
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Figure 5.13. 
1
H NMR spectrum (CDCl3, 400 MHz) of compound 100. 
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As a sufficient amount of ()-eburnamaline (96) was made available, attempts 
were made to obtain suitable crystals for X-ray analysis, but to no avail. However, the 
16-OH epimeric compound 100 crystallized readily in CH2Cl2, and therefore an X-ray 
diffraction analysis was carried out which yielded the absolute configuration of 
compound 100 (Figure 5.14). The absolute configuration at C-16 and C-17 of 
compound 100 were found to be 16S and 17R, respectively. With the absolute 
configuration of the 16-OH epimer 100 determined, the absolute configuration of C-16 
and C-17 of ()-eburnamaline (96) could be readily deduced as 16R and 17R, 
respectively. 
Compound 100 was first obtained as white amorphous solid, and subsequently 
as colorless needles from slow evaporation from CH2Cl2 solution. The crystal structure 
obtained showed that 100 co-crystallized with the solvent. The presence of heavy atoms 
(CH2Cl2) in the unit cell enabled measurement of the Flack parameter,
63
 which in turn 
permitted the determination of the absolute configuration (Figure 5.14).  
 
                                                     
 
                                                         Figure 5.14. X-ray crystal structure of 100  
                                                           [Flack parameter: x = 0.06(0.06)]. 
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5.2.3 Conclusion 
 
The partial synthesis of ()-eburnamaline (96) was achieved via a concise two-
step oxidation-reduction sequence from ()-eburnamonine (98). The absolute 
configuration of ()-eburnamaline (96) was determined via correlation with its C-16 
epimer 100, for which crystal data was available from an X-ray diffraction analysis. 
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CHAPTER SIX 
Absolute Configuration of Perhentinine and Macralstonine  
and Determination of C-20 Configuration in the  
New Alstonia Bisindoles, Perhentidines AC 
 
6.1  Introduction 
 
Perhentidines AC (101103) are new bisindole alkaloids from the stem-bark 
extract of Alstonia macrophylla and Alstonia angustifolia (isolation and structure by S. 
H. Lim and S. J. Tan).
89 
 
 
 
Examination of the 
1
H and 
13
C NMR data of alkaloids 101103 (Tables 6.1 and 
6.2), indicated that these bisindoles are constituted from the union of macroline units, 
with the upper half corresponding to an E-seco-macroline (or alstomicine) moiety, and 
the lower half corresponding to a type B macroline (12-substituted alstophylline or 9-
substituted-10-methoxyalstonerine). The 
1
H and 
13
C NMR data of alkaloids 101103 
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are shown in Tables 6.1 and 6.2, while the 
1
H NMR spectra of alkaloids 101103 are 
shown in Figures 6.16.3. 
 
Table 6.1. 
1
H NMR data () of perhentidines AC (101103)a 
Position 101 102 103 
3 4.14 m 3.98 m 4.14 m 
5 3.48 d (7.6) 3.63 m 3.45 m 
6 2.57 d (17) 2.58 d (17) 2.56 d (17) 
6 3.29 m 3.37 dd (17, 7) 3.29 dd (17, 7) 
9 7.56 d (7.5) 7.56 d (8) 7.56 d (7.5) 
10 7.16 t (7.5) 7.14 m 7.16 t (7.5) 
11 7.26 m 7.22 m 7.24 m 
12 7.36 d (7.5) 7.32 d (8) 7.34 d (7.5) 
14  2.01 m 1.48 m 2.04 m 
14 2.46 m 2.26 m 2.50 m 
15 2.27 m 2.11 m 2.21 m 
16 1.66 m 1.88 m 1.60 m 
17a 3.88 dd (11, 2) 4.09 m 3.83 dd (11, 2) 
17b 3.91 dd (11, 2) 4.49 d (12) 3.90 m 
18 1.55 s 1.40 s 1.30 s 
20 3.26 m 3.55 m 3.42 m 
21a 2.92 dd (13, 10.5) 3.05 m 2.60 t (12) 
21b 3.26 m 3.17 m 3.23 dd (12, 4) 
N1Me 3.69 s 3.57 s 3.69 s 
N4Me 2.36
b
 s 2.36 s 2.37 s 
3' 3.80 m 3.72 m 3.77 m 
5' 3.05 d (7) 3.01 m 2.87 d (7) 
6' 2.40 m 2.34 m 2.26 d (17) 
6' 3.23 dd (17, 7) 3.20 m 3.18 dd (17, 7) 
9' 7.22 d (8.6) 7.20 d (8.6)  
10' 6.75 d (8.6) 6.76 d (8.6)  
11'   6.83 d (9) 
12'   7.07 d (9) 
14'   1.75 td (12, 4) 1.70 td (12.5, 3.5) 1.75 m 
14' 2.01 m 1.99 m 2.04 m 
15' 2.50 m 2.51 m 2.50 m 
16' 1.84 m 1.82 m 1.75 m 
17' 4.14 m 4.12 m 4.08 dd (11, 4) 
17' 4.39 t (11) 4.37 t (11) 4.32 t (11) 
18' 2.06 s 2.05 s 2.06 s 
21' 7.49 s 7.48 s 7.49 s 
N1Me' 3.58 s 3.53 s 3.53 s 
N4Me' 2.37
b
 s 2.24 s 2.24 s 
10'-OMe   3.89 s 
11'-OMe 3.83 s 3.94 s  
aCDCl3, 400MHz; 
bassignments are interchangeable; assignments based on COSY, HSQC, and HMBC. 
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Table 6.2. 
13
C NMR data () of perhentidines AC (101103)a 
Position 101 102 103 
2 132.8 132.9 133.1 
3 53.2 53.2 53.3 
5 59.5 59.6 59.3 
6 22.1 22.5 22.1 
7 106.1 106.1 106.2 
8 126.4 126.5 126.5 
9 118.4 118.2 118.3 
10 118.9 118.9 118.8 
11 121.0 121.1 120.8 
12 108.8 109.2 108.8 
13 137.1 137.4 137.1 
14 32.2 32.7 32.0 
15 31.5 32.4 31.7 
16 42.6 42.2 42.7 
17 66.8 66.1 66.7 
18 31.8 34.4 32.6 
19 212.9 214.7 213.3 
20 55.5 52.7 53.9 
21 26.0 26.3 28.8 
N1Me 29.1 29.1 28.9
c
 
N4Me 41.3
b
 41.4 41.3 
2' 133.5 133.7 133.9 
3' 53.9 53.9 53.9 
5' 54.6 54.7 54.4 
6' 22.5 22.77 25.2 
7' 105.8 105.3 105.3 
8' 122.9 123.3 126.2 
9' 116.0 115.9 118.0 
10' 104.8 104.3 151.2 
11' 153.6 153.9 106.4 
12' 110.9 110.2 107.1 
13' 136.3 136.2 133.0 
14' 32.2 32.1 32.3 
15' 22.7 22.85 22.7 
16' 38.4 38.6 38.3 
17' 67.6 67.8 67.6 
18' 24.9 25.1 25.0 
19' 195.2 195.6 195.5 
20' 121.0 121.2 121.0 
21' 157.2 157.5 157.5 
N1Me' 32.3 32.5 29.0
c
 
N4Me' 41.9
b
 41.8 41.6 
10'-OMe   56.9 
11'-OMe 56.7 56.7 
aCDCl3, 100 MHz; 
b,cassignments are interchangeable; assignments based on COSY, HSQC, and HMBC.
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Figure 6.1. 
1
H NMR spectrum (CDCl3, 400 MHz) of perhentidine A (101).  
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Figure 6.2. 
1
H NMR spectrum (CDCl3, 400 MHz) of perhentidine B (102).  
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Figure 6.3. 
1
H NMR spectrum (CDCl3, 400 MHz) of perhentidine C (103).  
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Although the gross structures could be established from the NMR data, 
including the relative configurations at the stereogenic centers, the relative 
configuration at C-20 for these alkaloids could not be determined directly (except for 
perhentidine C (103)), as the combined NMR data (including NOESY) were insufficient 
for establishing the configuration (the signals of H-20 in both perhentidines A and B 
were observed as multiplets, while the signal of one of the C-21 hydrogens in 
perhentidine A (101), and of both the C-21 hydrogens in perhentidine B (102) were also 
observed as multiplets). Since the perhentidines are regioisomers of the previously 
isolated Alstonia bisindoles, perhentinine (104)
90
 and the E-seco form (106) of 
macralstonine (105),
9195
 determination of the C-20 configuration of these bisindole 
alkaloids, 104 and 105 would be useful in facilitating the assignment of C-20 
configuration in the regioisomeric perhentidines. Establishment of the configuration at 
C-20 for both 104 and 105 was therefore carried out by X-ray diffraction analysis, and 
the results obtained were used to facilitate the assignment of the C-20 configuration of 
the perhentidines.  
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6.2 Determination of the Configuration at C-20 of Perhentinine and 
Macralstonine  
 
6.2.1 Perhentinine 
 
 The bisindole alkaloid perhentinine (104) was first isolated from the bark extract 
of A. macrophylla by Y. M. Choo in 2004.
90
 The structure was established based on 
interpretation of the spectral data (NMR, MS, UV, and IR) which indicated constitution 
from the union of an E-seco-macroline (or alstomicine) moiety and a 12-substituted 
alstophylline, the connection between the two moieties being mediated by a methylene 
bridge. The data were however insufficient to establish the configuration at C-20.  
Since NOE data were of little assistance as the H-20 and H-21 signals in 
perhentinine were observed as multiplets, the O-acetyl derivative 104a was prepared, in 
anticipation of an improved resolution of the H-10 and H-21 signals. Fortuitously, the 
H-20 and H-21 signals of the O-acetyl derivative were clearly resolved, and analysis of 
the coupling constants (J20-21a = 11.0, J20-21b = 3.5 Hz; H-20 and H-21a trans-diaxial) 
and the observed NOEs (H-21a/H-15; H-21b/H-14, H-20; 18-Me/H-17, H-20) allowed 
assignment of the configuration at C-20 as S (Figure 6.4).  
 
 
Figure 6.4. Selected NOEs of 104a. 
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The 
1
H and 
13
C NMR data of 104 and 104a are summarized in Tables 6.3 and 
6.4, respectively, while the 
1
H NMR spectra of 104 and 104a are shown in Figures 6.5 
and 6.6, respectively.
 
 
Table 6.3. 
1
H NMR data () of perhentinine (104) and O-acetylperhentinine (104a)a 
Position 104
b
 104a
c
 Position 104
b
 104a
c
 
3 4.09 dd (4, 2) 4.00 m 3' 3.79 t (3) 3.80 br s 
5 3.46 d (7) 3.26 m 5' 2.99 d (7) 3.02 d (7) 
6 2.54 m 2.44 d (17) 6' 2.28 m 2.54 m 
6 3.32 m 3.14 dd (17, 7) 6' 3.08 m 3.14 dd (16.5, 7) 
9 7.52 d (8) 7.54 br d (7.5) 9' 6.90 s 6.87 s 
10 7.13 td (8, 1) 7.13 td (7.5, 1) 12' 6.69 s 6.69 s 
11 7.22 td (8, 1) 7.22 td (7.5, 1) 14'   1.75 td (12, 3) 1.75 m 
12 7.32 d (8) 7.32 br d (7.5) 14' 2.04 m 2.06 m 
14  1.98 m 1.86 m 15' 2.54 m 2.53 dt (11.5, 6) 
14 2.41 m 1.86 m 16' 1.84 dt (11, 4) 1.88 m 
15 2.14 m 2.14 m 17' 4.13 ddd  (11, 4, 1) 4.14 dd (11, 2) 
16 1.57 m 1.88 m 17' 4.37 t (11) 4.41 t (11) 
17a 3.95 dd (11, 3)  4.28 dd (11, 3.5) 18' 2.05 s 2.07 s 
17b 4.01 dd (11, 2) 4.58 t (11) 21' 7.51 s 7.51 s 
18 1.72 s  1.71 s N1Me' 3.55 s 3.57 s 
20 3.32 m  3.08 td (11, 3.5) N4Me' 2.25 s 2.30 s 
21a 2.41 m 2.31 m 11'-OMe 3.87 s 3.88 s 
21b 3.08 m 2.97 dd (13.5, 3.5)    
N1Me 3.65 s 3.64 s    
N4Me 2.34 s 2.28 s    
OCOMe  2.06 s    
aCDCl3; 
b400 MHz; c600 MHz; assignments based on COSY, HSQC, and HMBC.  
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Table 6.4. 
13
C NMR data () of perhentinine (104) and O-acetylperhentinine (104a)a 
Position 104
b
 104a
c
 Position 104
b
 104a
c
 
2 132.9 133.8 2' 131.1 131.5 
3 53.1 53.5 3' 53.7 53.8 
5 59.2 54.2 5' 54.7 54.7 
6 22.6 21.8 6' 22.0 22.8 
7 105.9 106.8 7' 105.4 105.6 
8 126.3 126.6 8' 120.1 119.2 
9 118.2 118.3 9' 118.7 119.4 
10 119.0 118.7 10' 119.1 118.7 
11 120.9 120.7 11' 153.6 153.7 
12 108.7 108.8 12' 91.3 91.4 
13 137.0 137.0 13' 136.5 136.7 
14 32.3 30.3 14' 32.4 32.4 
15 31.5 31.3 15' 22.8 22.9 
16 43.1 43.6 16' 38.3 38.4 
17 66.5 63.5 17' 67.7 67.8 
18 31.1 31.7 18' 24.9 25.4 
19 213.2 213.1 19' 195.4 195.6 
20 54.5 54.1 20' 120.8 121.1 
21 32.0 33.2 21' 157.4 157.7 
N1Me 29.0 29.2 N1Me' 28.9 29.0 
N4Me 41.7 42.1 N4Me' 41.2 41.9 
OCOMe  21.1 11'-OMe 55.5 55.6 
OCOMe  171.4    
aCDCl3; 
b100 MHz; c150 MHz; assignments based on COSY, HSQC, and HMBC.  
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Figure 6.5. 
1
H NMR spectrum (CDCl3, 400 MHz) of perhentinine (104). 
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Figure 6.6. 
1
H NMR spectrum (CDCl3, 600 MHz) of O-acetylperhentinine (104a).
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Additional confirmation by X-ray diffraction analysis was next attempted. 
However, attempts to obtain suitable crystals of perhentinine (104) were singularly 
unsuccessful. Eventually, it was found that treatment of 104 with excess MeI provided 
suitable crystals (recrystallized from hot MeOH), which, upon X-ray diffraction 
analysis, revealed the formation of the dimethyl diiodide salt of the ring-E cyclized 
(hemiketal) form of perhentinine 104b (Figure 6.7), from which the absolute 
configuration at C-20 of the precursor E-seco-compound, perhentinine (104), could be 
established as 20S.  
 
 
 
 
 
Figure 6.7. X-ray crystal structure of 104b  
[Flack parameter:
63
 x = 0.04(0.03), Hooft parameter:
64
 y = 0.022(0.07)]. 
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6.2.2 Macralstonine  
 
 
 
Macralstonine (105) was first isolated by Sharp from the bark extract of A. 
macrophylla,
91
 and subsequently investigated in detail by Hesse and Schmid,
92
 who 
observed that macralstonine exists as an equilibrium mixture of acyclic (ketone, 106) 
and cyclized (hemiketal, 105) forms in CHCl3 solution. We have confirmed this by 
analysis of high-field NMR data (600 MHz) of macralstonine. Thus, in CDCl3 solution, 
the ratio of acyclic to cyclized form was 2.32:1, while in CD2Cl2, it was 1.14:1, and in 
THF-d8, it was detected only as the cyclized hemiketal form 105, albeit with poor 
solubility in this solvent. The two forms were readily distinguishable with the use of 2-
D NMR methods. (The 
1
H and 
13
C NMR data of 105 and 106 (in CDCl3 and THF) are 
summarized in Tables 6.5 and 6.6, respectively, while the 
1
H NMR spectra of 105 and 
106 in CDCl3, CD2Cl2, and THF are shown in Figures 6.8, 6.9, and 6.10, respectively).
 
 
The E-seco-macralstonine (106) could be trapped by conversion to its O-acetyl 
derivative 106a,
92
 in which case the NMR data of the pure O-acetyl-E-seco-
macralstonine could be determined (The 
1
H and 
13
C NMR data of 106a are summarized 
in Tables 6.5 and 6.6, respectively, while the 
1
H NMR spectrum of 106a is shown in 
Figure 6.11).  
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Table 6.5. 
1
H NMR data () of compounds 105, 106, and 106aa  
Position 105
a
 106
a
 105
b
 106a
a
 
3 3.95 m 4.00 m 3.91 m 3.90 m 
5 2.93 d (6) 3.59 m 2.84 d (7) 3.43 d (6) 
6a 2.13 m  2.56 d (17) 2.20 d (16.2) 2.49 d (17) 
6b 2.63 dd (17, 10) 3.35 dd (17, 7.5) 2.76 dd (16.2, 7) 3.33 dd (17, 7) 
9 7.33 (7.5) 7.51 d (7.5) 7.22 d (7.5) 7.53 d (7.5) 
10 7.00 m 7.12 t (7.5) 6.84 t (7.5) 7.12 td (7.5, 1) 
11 7.09 m 7.21 t (7.5) 7.01 t (7.5) 7.19 td (7.5, 1) 
12 7.09 m 7.30 d (7.5) 7.10 d (7.5) 7.29 d (7.5) 
14a 1.87 m 1.44 d (12)  1.83 m 1.28 d (12) 
14b 2.86 td (13, 3.5)  2.35 m  2.92 td (12.5, 4) 1.89 m 
15 1.77 m 2.01 m 1.62 m 2.03 m 
16 1.77 m 1.90 m 1.63 m 2.23 m 
17a 3.49 m  4.12 dd (12, 3)  3.27 td (11.5, 5) 4.59 m 
17b 4.52 t (11.5)  4.43 d (12)  4.49 t (11.5) 4.59 m 
18 1.51 s 1.68 s 1.40 s 1.59 s 
20 1.91 m 3.39 td (11, 4) 1.74 m 3.06 td (11, 4) 
21a 2.43 m 2.39 m 2.42 dd (13.5, 10.5) 2.37 m 
21b 3.06 dd (14, 3.5) 3.00 m 2.99 dd (13.5, 3.5) 3.15 m 
N1Me 3.47 s 3.56 s 3.45 s 3.55 s 
N4Me 2.28 s 2.38 s 2.21 s 2.31 s 
OCOMe    2.15 s 
3' 3.75 m 3.79 m 3.78 m 3.81 m  
5' 3.00 m 3.00 m 3.03 d (7) 3.03 m 
6'a 2.33 m 2.35 m  2.26 d (16.2) 2.39 m 
6'b 3.00 m  3.17 dd (16.5, 7) 3.09 dd (16.2, 7) 3.17 m 
9' 6.74 s 6.90 s 6.72 s 6.90 s 
12' 6.40 s 6.69 s 6.42 s 6.69 s 
14'a
 
 1.76 m  1.77 m  1.69 m 1.78 m  
14'b 2.01 m  2.01 m  1.99 m 2.07 m  
15' 2.60 m 2.60 m 2.47 m 2.59 m 
16' 1.87 m 1.87 m 1.83 m 1.89 m 
17'a 4.19 dd (11, 3)  4.14 dd (12, 3)  4.14 dd (11.5, 3) 4.14 d (11) 
17'b 4.38 m  4.38 t (12)  4.37 t (11.5) 4.39 t (11) 
18' 2.07 s 2.09 s 1.98 s 2.09 s 
21' 7.52 s 7.53 s 7.57 s 7.54 s 
N1Me' 3.50 s 3.59 s 3.51 s 3.57 s 
N4Me' 2.13 s 2.24 s 2.13 s 2.26 s 
11'-OMe 3.92 s 3.65 s 3.59 s 3.91 s 
a600MHz; bCDCl3;
 cTHF-d8; assignments based on COSY, HSQC, and HMBC.  
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Table 6.6.
 13
C NMR data () of compounds 105, 106, and 106aa 
Position 105
b
 106
b
 105
c
 106a
b
 
2 133.3 132.6 134.4 133.4 
3 54.0 53.1 54.7 53.2 
5 55.5 59.6 56.7 53.6 
6 22.7 22.4 23.3 22.1 
7 106.5 105.9 106.7 106.6 
8 126.45 126.36 127.3 126.5 
9 117.9 118.0 117.9 118.0 
10 118.4 118.9 118.6 118.7 
11 120.2 121.0 120.4 120.8 
12 108.5 109.0 109.0 109.0 
13 136.8 137.2 137.7 137.2 
14 26.9 33.0 27.4 31.5 
15 25.9 32.3 26.6 31.5 
16 44.0 42.1 45.5 41.9 
17 61.4 66.2 61.5 62.6 
18 29.5 33.9 29.1 32.7 
19 99.0 214.5 98.5 213.9 
20 45.6 53.8 46.9 53.9 
21 28.8 32.49 29.6 31.8 
N1Me 29.07 29.14 28.7 29.1 
N4Me 41.69 41.4 41.7 42.1 
OCOMe    21.3 
OCOMe    171.4 
2' 131.2 131.5 131.7 131.3 
3' 53.76 53.8 54.4 53.9 
5' 54.7 54.7 55.4 54.7 
6' 22.5 22.8 22.9 22.9 
7' 105.1 105.6 105.7 105.5 
8' 119.7 119.1 120.6 120.1 
9' 118.8 119.5 119.3 119.4 
10' 120.1 120.2 121.9 119.0 
11' 153.9 153.8 154.8 153.9 
12' 91.4 91.2 91.9 91.3 
13' 136.1 136.6 137.1 136.7 
14' 32.4 32.47 33.3 32.4 
15' 22.9 22.9 23.6 22.8 
16' 38.5 38.4 39.5 38.4 
17' 67.87 67.85 68.2 67.8 
18' 25.0 25.1 24.6 25.1 
19' 195.5 195.8 193.9 195.7 
20' 121.2 121.2 121.9 121.1 
21' 157.4 157.7 157.3 157.6 
N1Me' 28.7 29.04 28.6 29.0 
N4Me' 41.77 41.74 42.1 41.9 
11'-OMe 55.3 55.6 55.1 55.5 
a150 MHz; bCDCl3; 
cTHF-d8; assignments based on COSY, HSQC, and HMBC. 
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Figure 6.8. 
1
H NMR spectrum (CDCl3, 600 MHz) of macralstonine (105) and E-seco-macralstonine (106). 
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Figure 6.9. 
1
H NMR spectrum (CD2Cl2, 400 MHz) of macralstonine (105) and E-seco-macralstonine (106). 
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Figure 6.10. 
1
H NMR spectrum (THF-d8, 600 MHz) of macralstonine (105). 
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Figure 6.11. 
1
H NMR spectrum (CDCl3, 600 MHz) of O-acetyl-E-seco-macralstonine (106a). 
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The relative configuration at C-20 in the O-methyl congener of macralstonine, 
107, isolated from the Thai A. macrophylla was established as 20R based on its NOESY 
spectrum.
93,95
 In the case of macralstonine (105), however, NOE was not feasible due to 
the observation of H-20 and H-21 as multiplets.  
 
 
 
In the case of the O-acetyl-E-seco-macralstonine derivative 106a, H-20 was 
clearly seen as a triplet of doublets (J20-21a = 11.0, J20-21b = 4.0 Hz; H-20 and H-21a 
trans-diaxial) at H 3.06 and this, coupled with the observed NOEs (H-20/H-14, H-18; 
H-21a/H-15, H-9'; H-21b/H-16, H-17, H-9'), allowed assignment of the C-20 
configuration as R (Figure 6.12). 
 
 
Figure 6.12. Selected NOEs of 106a. 
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In the event, macralstonine crystallized as the cyclized hemiketal form (105) 
from CH2Cl2/MeOH solution.
 
X-ray analysis was therefore carried out and confirmed 
the 20R absolute configuration (Figure 6.13). 
The X-ray crystal structure of 105 also showed that it existed as the cyclized 
form in the solid state. Repeating the X-ray diffraction experiment using different 
crystals yielded the same outcome as the first experiment.  
 
 
 
 
 
Figure 6.13. X-ray crystal structure of 105  
[Flack parameter:
63
 x = 0.1(0.4); Hooft parameter:64 y = 0.30(0.14)]. 
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With the C-20 configuration of both perhentinine and macralstonine determined 
via their acetate derivatives (104a and 106a), the same approach can be used for the 
determination of the C-20 configuration in the perhentidines.  
 
6.3 Determination of the Configuration at C-20 of Perhentidines AC 
 
The gross structures of the perhentidines AC (101103) were established via 
extensive application of 2D NMR techniques, including determination of the relative 
configurations at the various stereogenic centers, with the exception of the configuration 
at C-20.
89 
Examination of the 
1
H NMR data of perhentidines A (101) and B (102) showed 
that the signals of H-20 in both alkaloids were observed as multiplets (Table 6.1). 
Furthermore, the signal of one of the C-21 hydrogens in perhentidine A (101), and of 
both the C-21 hydrogens in perhentidine B (102), were also observed as multiplets. 
Acetylation of alkaloids 101 and 102 yielded the O-acetyl derivatives 101a and 102a, in 
which the signals for H-20 and H-21 of both the compounds were clearly resolved 
(Table 6.7). The signal due to H-20 in O-acetylperhentidine A (101a) was seen as a 
triplet of doublets at H 2.99 with J = 10.7 and 3.8 Hz (i.e., J20-21a = J15-20 = 10.7 Hz, J20-
21b = 3.8 Hz). The signal of one of the hydrogens on C-21 was observed as a doublet of 
doublets at H 2.83 (J21a-21b = 14 Hz, J20-21a = 10.7 Hz). The large coupling constant of 
10.7 Hz due to the coupling between H-20 and H-21a, suggested that the conformation 
adopted about the C-20C-21 bond was one that places the two vicinal hydrogens at C-
20 and C-21 anti (trans-diaxial) to one another. The preferred anti conformation was 
likely due to the presence of three bulky groups, two on C-20, and one on C-21, which 
resulted in steric hindrance to free rotation about the C-20C-21 bond. The observation 
that H-20 is trans-diaxial to H-21a, coupled with the observed NOE interactions 
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between H-21a and H-15; H-20 and H-14, H-21b; H-21b and H-14; 18-Me and H-17, 
H-20 (Figure 6.14) allowed the configuration at C-20 in the acetate derivative 101a, and 
therefore in perhentidine A (101) as well, to be assigned as 20S. 
 
                                    
Figure 6.14. Selected NOEs of 101a.  
 
In the case of O-acetylperhentidine B (102a), the signal due to H-20 was also seen 
as a triplet of doublets at H 3.23 with J = 11 and 5 Hz. The observed H-20H-21a 
coupling of 11 Hz, indicated a trans-diaxial disposition of the two hydrogens, as in the 
case of O-acetylperhentidine A acetate (101a). In this instance however, the definitive 
NOEs, which allowed the assignment of the configuration at C-20, were different from 
those observed in 101a. Thus, in the case of O-acetylperhentidine B (102a), NOEs were 
observed between H-20 and H-14, H-21b; H-21a and H-15; H-21b and H-16, H-17; H-
18 and H-14, H-15, H-20 (Figure 6.15). These NOEs are consistent with the assignment 
of the C-20 configuration in 102a (and therefore 102) as 20R.  
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Figure 6.15. Selected NOEs of 102a 
 
The 
1
H and 
13
C NMR data of compounds 101a and 102a are summarized in 
Tables 6.7 and 6.8, respectively, while the 
1
H NMR spectra of compounds 101a and 
102a are shown in Figures 6.16 and 6.17, respectively. 
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Table 6.7. 
1
H NMR data () of compounds 101a103aa 
Position 101a
b
 102a
b
 103a
c
 
3 4.03 m 3.88 m 4.07 m 
5 3.25 m 3.44 m 3.25 m 
6 2.50 m 2.52 m 2.48 m 
6 3.25 m 3.35 dd (17, 8) 3.25 m 
9 7.57 d (8) 7.58 d (7.5) 7.58 br d (7.5) 
10 7.15 t (8) 7.14 t (7.5) 7.16 td (7.5, 1) 
11 7.23 t (8) 7.22 t (7.5) 7.23 td (7.5, 1) 
12 7.34 d (8) 7.31 d (7.5) 7.33 br d (7.5) 
14  1.94 m 1.32 m 1.94 m 
14 1.94 m 1.81 m 1.94 m 
15 2.25 m 2.14 m 2.21 m 
16 1.94 m 2.21 m 1.87 m 
17a 4.15 dd (11, 3.5) 4.63 m 4.22 dd (11, 4) 
17b 4.53 dd (11, 9) 4.63 m 4.49 dd (11, 9) 
18 1.59 s 1.30 s 1.34 s 
20 2.99 td (10.7, 3.8) 3.23 td (11, 5) 3.15 m 
21a 2.83 dd (14, 10.7) 3.04 m 2.48 m 
21b 3.17 dd (14, 3.8) 3.32 dd (14, 5) 3.15 m 
N1Me 3.66 s 3.55 s 3.67 s 
N4Me 2.35 s 2.28 s 2.37 s 
OCOMe 2.03 s 2.16 s 1.99 s 
3' 3.79 m 3.72 m 3.81 m 
5' 3.05 m 3.01 m 2.81 d (7) 
6' 2.40 d (16) 2.35 d (16) 2.26 d (16) 
6' 3.23 m 3.18 dd (16, 7) 3.11 m 
9' 7.23 d (8.5) 7.19 d (8.5) 
10' 6.76 d (8.5) 6.77 d (8.5)  
11'   6.83 d (8.7) 
12'   7.07 d (8.7) 
14'   1.74 m 1.71 td (12, 3.5) 1.75 m 
14' 1.98 m 1.99 m 2.08 m 
15' 2.48 m 2.50 m 2.48 m 
16' 1.84 m 1.82 m 1.69 m 
17' 4.13 dd (11.5, 3.5) 4.12 dd (11, 3) 4.09 m 
17' 4.39 t (11.5) 4.37 t (11) 4.31 t (11) 
18' 2.06 s 2.06 s 2.06 s 
21' 7.49 s 7.50 s 7.50 s 
N1Me' 3.48 s 3.52 s 3.53 s 
N4Me' 2.27 s 2.24 s 2.31 s 
10'-OMe   3.88 s 
11'-OMe 3.85 3.92 s  
aCDCl3, 
b600 MHz; c400 MHz; assignments based on COSY, HSQC, and HMBC. 
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Table 6.8. 
13
C NMR data () of compounds 101a103aa 
Position 101a
b
 102a
b
 103a
c
 
2 133.6 133.6 133.1 
3 53.5 53.2 53.7 
5 54.6 53.3 55.0
d
 
6 21.7 22.1 21.8 
7 107.0 106.7 107.1 
8 126.7 126.7 126.8 
9 118.4 118.0 118.5 
10 118.8 118.6 118.7 
11 120.7 120.7 120.7 
12 108.8 109.1 108.9 
13 137.0 137.2 137.2 
14 30.3 31.3 30.1 
15 30.8 31.6 31.2 
16 43.0 42.0 43.3 
17 63.7 62.6 64.0 
18 32.2 34.1 32.9 
19 212.8 214.1 213.1 
20 54.8 52.4 53.2
d
 
21 26.2 25.6 29.0 
N1Me 29.1 28.9 29.1
e
 
N4Me 41.9 41.9 41.6
f
 
OCOMe 21.2 21.3 21.2 
OCOMe 171.3 171.6 171.2 
2' 133.8 133.6 133.8 
3' 53.9 53.8 54.0 
5' 54.6 54.6 54.4 
6' 22.5 22.7 25.3 
7' 105.8 105.2 105.3 
8' 122.9 123.2 126.3 
9' 116.1 115.8 118.0 
10' 104.7 104.5 151.2 
11' 153.5 153.8 106.5 
12' 110.9 110.0 107.3 
13' 136.3 136.1 133.1 
14' 32.2 32.0 32.2 
15' 22.7 22.8 22.8 
16' 38.4 38.5 38.5 
17 67.7 67.7 67.5 
18' 25.0 25.0 25.1 
19' 195.3 195.5 195.7 
20' 121.0 121.1 120.9 
21' 157.2 157.4 157.8 
N1Me 32.2 32.4 29.2
e
 
N4Me 42.1 41.7 42.2
f
 
10'-OMe   56.9 
11'-OMe 56.6 56.6  
aCDCl3; 
b150 MHz; c100 MHz; d–fassignments are interchangeable; assignments based on COSY, HSQC, and HMBC. 
 1
7
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.16. 
1
H NMR spectrum (CDCl3, 600 MHz) of O-acetylperhentidine A (101a).  
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Figure 6.17. 
1
H NMR spectrum (CDCl3, 600 MHz) of O-acetylperhentidine B (102a).  
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In the case of perhentidine C (103), the relative configuration of C-20 in 103 can 
be deduced directly from analysis of the coupling constants and the observed NOEs of 
the parent compound. In the case of 103, and unlike 101 and 102, the H-21 resonances 
were well resolved in the 
1
H NMR spectrum, whereas the resonances of H-20 and H-21 
were multiplets in the O-acetyl derivative 103a (Table 6.7). As before, the signal due to 
one of the hydrogens on C-21 was observed as a triplet at H 2.60 (J21a-21b = J21a-20 = 12 
Hz) indicating a preferred conformation about the C-20C-21 bond which places the 
two vicinal hydrogens anti (trans-diaxial) to one another due to steric hindrance caused 
by the presence of three bulky groups. This, coupled with the observed NOE 
interactions between H-21a and H-15, H-6'; H-21b and H-14; 18-Me and H-16, H-17, 
H-20 (Figure 6.18) allowed the configuration at C-20 to be assigned as 20S.  
 
         
Figure 6.18. Selected NOEs of 103. 
 
The 
1
H and 
13
C NMR data of 103a are summarized in Tables 6.7 and 6.8, 
respectively, while the 
1
H NMR spectrum of 103a is shown in Figure 6.19. 
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Figure 6.19. 
1
H NMR spectrum (CDCl3, 400 MHz) of O-acetylperhentidine C (103a).  
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6.4 Comparison of NMR Data between Alkaloids 101104, and 106  
 
Since we now have two bisindole alkaloids, viz., perhentinine (104) (and its 
cyclized hemiketal derivative in the form of its dimethyl diiodide salt, 104b) and 
macralstonine (105) (and its ring-opened form as its acetate derivative, 106a) that 
possess opposite C-20 configuration, and for which we have obtained X-ray crystal 
structure data, these two alkaloids can therefore serve as model compounds for 
comparison of the perhentidines. 
It was observed that in the NMR spectra of the parent bisindoles (101104, 106), 
the signals of the C-17 oxymethylene hydrogens are well separated in the case of the 
20R bisindoles, 102 and 106 (17b17a ~ 0.30.4 ppm), whereas these signals 
were very close in the 20S compounds, 101, 103, and 104 (17b17a ~ 0.020.07 
ppm) (Figure 6.20). In the case of the O-acetyl derivatives (101a104a106a) however, 
this trend was reversed, and a clear distinction could be observed between the 20S and 
20R series. Thus, the signals due to the C-17 oxymethylene hydrogens in the acetate 
derivatives of the 20S series (101a, 103a, and 104a) were observed as well separated 
AX doublet of doublets (17b17a ~ 0.30.4 ppm), while those in the O-acetyl 
derivatives of the 20R series (102a and 106a) were invariably observed as overlapped 
multiplets (17b17a ~ 0 ppm) (Figure 6.20). This not only provided additional 
strong support for the assignment of the C-20 configurations in alkaloids 101105 based 
on analysis of the NMR coupling constants and NOE data (vide infra), but in addition 
could serve as a potentially general method for the determination of the configuration at 
C-20 in related bisindoles with a similar constitution and branching of the monomeric 
units.
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Figure 6.20. Partial 
1
H NMR spectrum (400 MHz) of alkaloids 101105 and 106, and acetates 101a104a and 106a.
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6.5 Conclusion 
 
In conclusion, we have established complete and firm structure assignment of the 
new macroline-macroline bisindoles perhentidines A (101), B (102), and C (103), 
including the determination of the configuration at C-20. We have also obtained X-ray 
confirmation (determination of absolute configuration) of the structures of the 
previously isolated bisindole alkaloids, perhentinine (104) and macralstonine (105), 
which has also facilitated the firm assignment of the structures of perhentidines AC 
(101103).  
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CHAPTER SEVEN 
Reinvestigation of the Stereochemical Assignment of Scholaricine and 
Alstoumerine Revision of Configurational Assignment of C-20 of 
Scholaricine and C-16 and C-19 of Alstoumerine 
 
7.1 Scholaricine 
 
 
 
In the course of the ongoing investigations of indole alkaloids (e.g., see Chapter 
5), the NMR data of many strychnan alkaloids were compared (9294, 
108114).75,96103 It emerged from such a comparison that the conﬁguration at C-20 
attributed to the alkaloid scholaricine (114) required re-examination. Specifically, the 
resonances of C-2, C-14, and C-16 in the akuammicine-type alkaloids with C-20S are 
characteristically observed at δC 172, 31, and 96, respectively, while those with C-20R 
are usually found at δC 168, 27, and 103, respectively (Table 7.1). An attempt was 
previously made to rationalize the C-14 and C-16 shifts on the basis of the -gauche 
effects.
77
 However, this analysis can only be applied in cases where the piperidine ring 
adopts a chair conformation, which is not always the case for this group of alkaloids.
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The indole alkaloid scholaricine (114) was first reported by Atta-ur-Rahman and 
co-workers from the leaf extract of Alstonia scholaris, but without any stereochemical 
assignments.
102
 The configuration at C-20 was subsequently assigned as 20R by 
Yamauchi et al.
98
 from the observation that the same ketone product 115, was obtained 
from the oxidation of scholaricine (114) and 19-epi-scholaricine (113), following the 
method used by Hesse for the assignment of the C-19 and C-20 configurations of 19-
epi-alstogustine.
79
  
Comparison of the 
13
C NMR data of scholaricine (114) showed resonances for 
C-2, C-14, and C-16 at δC 172.1, 30.8, and 96.3, respectively, which correspond to the 
C-20S series of these strychnan derivatives (Tables 7.1 and 7.2). The C-20S 
configuration was also supported by the observed H-21/H-5, H-6 and H-20/H-14S 
NOEs (axial H-20 in chair ring D). To secure unambiguous confirmation, an X-ray 
diffraction analysis was carried out (Figure 7.1) using a sample of 114 from our 
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previous study of another Alstonia species,
104
 which confirmed the configuration (C-
20S) deduced from the NMR data (
13
C NMR and NOEs).  
Scholaricine (114) was recrystallized by slow evaporation from EtOAc solution. 
From the crystal structure, an intramolecular hydrogen bond was observed between C-
19OH and the C-17 carbonyl oxygen (Figure 7.1). 
 
 
Figure 7.1. X-ray crystal structure of 114. 
 
 
 
The 
1
H and 
13
C NMR data of alkaloid 114 (obtained from the current study) are 
summarized in Table 7.2, while the 
1
H NMR spectrum of alkaloid 114 is shown in 
Figure 7.2. 
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     Table 7.1. 
13
C NMR data () of compounds 9294, and 108114 found in the literaturea 
Position 92
97
 
(20R) 
93
99,100 
(20R)
 
94
75
 
(20S) 
108
75 
(20S)
 
109
75 
(20R)
 
110
75 
(20R)
 
111
98,103 
(20S)
 
112
77 
(20R)
 
113
98
 
(20R) 
114
102
 
(20R)
b 
2 167.6 168.1 172.2 171.8 168.5 168.7 172.6 167.1 168.5 172.2
c
  
3 59.1 59.2 60.6 60.4 58.5 58.6 61.0 58.9 60.2 60.2 
5 53.9 53.8 54.0 53.6 52.7 53.1 54.2 53.5 54.4 53.9 
6 46.7 45.9 43.4 43.0 44.8 45.2 46.0 46.0 46.6 43.4 
7 58.6 58.2 56.7 57.1 58.9 58.3 57.3 59.2 59.5 58.0 
8 135.7 135.6 135.4 136.4 136.1 135.0 135.8 136.2 138.2 132.2 
9 128.0 127.9 119.6 111.3 112.4 120.8 121.4 113.3 112.3 111.3 
10 121.2 121.1 121.1 122.2 122.2 121.2 119.8 121.9 122.3 122.4 
11 120.9 120.8 127.6 115.8 116.0 128.0 127.6 110.3 115.8 115.1 
12 109.7 109.7 109.7 141.7 141.8 109.8 109.6 144.4 143.1 137.0 
13 143.8 144.1 144.2 132.2 132.2 144.2 143.8 132.4 132.9 141.8 
14 27.4 27.6 31.7 31.5 26.4 26.6 31.2 27.0 28.2 31.0 
15 29.3 27.8 30.8 30.7 27.4 27.4 28.9 29.2 27.9 28.9 
16 102.9 103.4 96.5 96.5 102.3 102.6 96.9 103.1 104.5 96.7 
18 20.3 20.2 29.2 29.3 29.4 29.4 19.8 20.2 21.3 19.7 
19 71.1 69.9 208.5 208.5 209.8 210.0 68.4 71.0 69.2 68.5 
20 45.5 43.4 50.0 49.6  49.3  49.5 43.7 45.8 44.9 46.0 
21 48.4 47.4 45.6 45.4 46.5 47.0 48.2 48.1 49.2 48.2 
CO2Me 51.5 51.3 50.9 51.0 51.3 51.2 51.8 51.5 50.7 51.8 
CO2Me 167.9 168.1 167.2 167.5 167.8 168.0 168.9 167.8 168.0 169.1
c
 
12-OMe        55.5  
        aCDCl3; bprevious configurational assignment; cthe original assignments by Atta-ur-Rahman et al. for C-2 and CO2Me were c169.1 and 172.2, respectively.102
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Table 7.2. 
1
H and 
13
C NMR data () of scholaricine (114) (current study)a 
Position C H 
2 172.1 
3 60.7 3.91 t (3) 
5 53.7 2.89 m 
5  3.07 m 
6 43.1 1.90 dd (13, 6) 
6  2.89 m 
7 57.4  
8 136.7  
9 110.9 6.69 dd (8, 1) 
10 122.3 6.81 t (8) 
11 115.6 6.76 br d (8) 
12 142.0  
13 131.9  
14R 30.8 1.45 dt (13, 3) 
14S  2.01 m 
15 28.7 3.45 br d (3) 
16 96.3  
18 19.6 1.17 d (6) 
19 68.4 3.29 dq (9, 6) 
20 45.7 1.78 m 
21 47.9 2.01 m 
21  2.89 m 
CO2Me 51.9 3.88 s 
CO2Me 169.1  
NH  8.59 br s 
aCDCl3, 400 MHz; assignments based on COSY and HMQC. 
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Figure 7.2. 
1
H NMR spectrum (CDCl3, 400 MHz) of scholaricine (114). 
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7.2 Alstoumerine 
 
Lumutinine C (116) is a new bisindole alkaloid isolated from the stem-bark 
extract of Alstonia macrophylla (isolation and structure by S. H. Lim).
105
 Lumutinine C 
(116) represents a ring A/F fused macroline-sarpagine type bisindole alkaloid.  
 
 
 
After discounting the signals due to the upper macroline-derived half, the 
monomeric unit corresponding to the lower half was deduced from NMR spectroscopic 
data to comprise an alkaloid of the sarpagine type, specifically, a 10-hydroxy- or 10-
methoxyalstoumerine (117). The 
1
H and 
13
C NMR data of lumutinine C (116) are 
summarized in Table 7.3, while the 
1
H NMR spectrum of 116 is shown in Figure 7.3. 
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Table 7.3. 
1
H and 
13
C NMR data () of lumutinine C (116)a 
Position C  Position C  
2 133.4  2' 139.3  
3 54.0 3.74 m 3' 48.7 3.82 m 
5 55.2 2.99 m 5' 56.4 2.87 m 
6 22.8 2.45 d (16) 6' 27.9 2.71 m 
6  3.28 m 6'  3.22 m 
7 107.0  7' 102.1  
8 126.4  8' 125.0  
9 118.1 7.50 d (7.5) 9' 111.4  
10 119.0 7.10 t (7.5) 10' 147.7  
11 120.9 7.17 t (7.5) 11' 112.6 6.71 d (9) 
12 108.9 7.25 d (7.5) 12' 107.7 7.01 d (9) 
13 136.9  13' 132.4  
14  26.7 1.18 m 14'   38.6 1.66 m 
14  2.35 td (13, 3) 14'  1.89 m 
15 30.4 1.87 m 15' 29.2 2.82 m 
16 43.5 2.00 m 16' 45.0 1.55 m 
17 62.3 3.67 dd (11.5, 4) 17' 64.5 3.42 m 
17  4.62 t (11.5) 17'  3.61 dd (12, 3)  
18 25.4 1.35 s 18' 22.5 1.34 d (6) 
19 99.0  19' 67.3 4.46 q (6) 
20 37.2 1.97 m 20' 149.3  
21 26.8 2.75 m 21' 136.1 6.44 s 
  3.25 m N1Me' 29.4 3.48 s 
N1Me 29.3 3.40 s    
N4Me 41.8 2.26 s    
aCDCl3, 400 and 100 MHz, respectively; assignments based on COSY, HMQC, and HMBC. 
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Figure 7.3. 
1
H NMR spectrum (CDCl3, 400 MHz) of lumutinine C (116). 
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Comparison of the NMR data with those reported for alstoumerine (118a)
106
 
showed a general agreement for the non-indole portion of the molecule, providing 
support for such a conclusion. Despite this, some inconsistencies were noted regarding 
the earlier structure elucidation of alstoumerine (118a). 
Alstoumerine (118), a sarpagine-type alkaloid, was first reported by Atta-ur-
Rahman and co-workers from the leaf extract of A. macrophylla collected in Sri 
Lanka.
106
 The structure of 118a was deduced based on NMR spectral data.  
The configuration of the hydroxy-substituted C-19 was previously determined 
using Horeau’s procedure107 and was assigned as 19R, while the configuration of C-16 
was assigned as 16S with the hydroxymethyl group pointing towards the indole moiety 
and H-16 pointing away from the indole moiety. This was despite the observation of the 
resonance due to H-16 at δH 1.63 and those for the C-17 oxymethylene hydrogens at δH 
3.46 and 3.64. The resonances of H-16 and H-17 are of diagnostic significance for the 
determination of C-16 configuration in the sarpagine type alkaloids.
108111
 The observed 
resonance for H-16 upfield at δH 1.63 is indicative of shielding due to it being located 
within the shielding zone of the aromatic moiety, which in turn requires H-16 to be 
oriented towards the indole moiety with the hydroxymethyl group directed away from 
the indole unit. The original assignment of the C-16 configuration of alstoumerine 
(118a), therefore, requires amendment to 16R (118b). In the case of lumutinine C (116), 
the resonance due to H-16 was observed at δH 1.55, while the resonance due to the C-
17 oxymethylene hydrogens were seen at δH 3.42 and 3.61. These values were similar 
to those in alstoumerine (118) and require H-16 to be directed towards the indole 
moiety (16R).  
Since we were in possession of authentic alstoumerine (118) from our past and 
ongoing work in alkaloid chemistry,
109
 a rigorous configurational assignment of 
alkaloid 118 was carried out. The 
1
H and 
13
C NMR data of alstoumerine (118) are 
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summarized in Table 7.4. The 
1
H NMR spectrum of 118 is shown in Figure 7.4. In 
addition to the chemical shift considerations mentioned above, the 16R configuration of 
alstoumerine (118b) was further confirmed by NOE experiments, which showed strong 
NOE between H-16 and H-6, requiring H-16 to be directed towards the indole moiety 
and hence proximate to H-6.  
 
Table 7.4. 
1
H and 
13
C NMR data () of alstoumerine (118)a 
Position C H 
2 139.5  
3 48.6 3.83 dd (10, 2) 
5 56.2 3.03 t (6) 
6 25.4 2.69 d (15) 
7 102.5 
8 127.3 
9 118.1 7.48 br d (8) 
10 118.9 7.10 td (8, 1) 
11 121.0 7.19 td (8, 1) 
12 108.7 7.28 br d (8) 
13 137.4  
14 38.8 1.61 m 
15 29.6 2.78 br s 
16 44.4 1.61 m 
17 64.7 3.46 dd (12, 5) 
  3.51 dd (12, 4) 
18 22.5 0.36 d (7) 
19 67.4 4.52 d (7) 
20 149.1  
21 136.4 6.54 d (1) 
NMe 29.3 3.58 s 
aCDCl3, 400 and 100 MHz, respectively; assignments are based on COSY, HMQC, and HMBC. 
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Figure 7.4. 
1
H NMR spectrum (CDCl3, 400 MHz) of alstoumerine (118).  
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The C-19 configuration was also reinvestigated, by repeating the determination 
using Horeau’s procedure.107 Alstoumerine (118) (1 equiv) was added to a solution of 
racemic 2-phenylbutyric anhydride (4 equiv) in anhydrous pyridine (1 ml). The 
resulting mixture was stirred for 20 h at rt. Water (3 ml) was then added and the mixture 
was allowed to stand for 30 min. The pH of the solution was adjusted to pH 9 by drop-
wise addition of NaOH (0.1 M), after which the solution was extracted with CH2Cl2. 
The aqueous layer was acidified to pH 3 using 1.0 M HCl and extracted with CH2Cl2. 
Evaporation of the solvent from the organic phase gave the unreacted 2-phenylbutyric 
acid: []25D 3.1 (c 1.66, C6H6); []
25
D 3 (c 1.66, CHCl3). The optical rotation of the 
unreacted 2-phenylbutyric acid was found to be negative (R), indicating the S 
configuration at C-19 in alstoumerine (118b). The determination was repeated several 
times to confirm that the correct result was obtained each time. 
The present determination therefore yielded a result (19S), which was opposite 
to that of the previous report (19R).
106
 In view of the two major discrepancies noted, an 
X-ray diffraction analysis was carried out (Figure 7.5), which confirmed the structure 
and absolute configuration of alstoumerine (118b). 
 
 
 
 Alstoumerine (118b) crystallized readily on standing in CHCl3 solution. The 
presence of heavy atoms (CHCl3) in the unit cell enabled measurement of the Flack
63
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parameter, which in turn permitted determination of the absolute configuration (Figure 
7.5).  
 
       
                                                Figure 7.5. X-ray crystal structure of 118b 
                                                                          [Flack parameter,
63
 x = 0.01(0.04);  
                                                                           Hooft parameter,
64
 y = 0.01(0.04)]. 
 
With the correct structure of alstoumerine (118b) unequivocally established, the 
structure of lumutinine C follows accordingly as shown in 116.  
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CHAPTER EIGHT 
Andransinine – An Example of Spontaneous Resolution  
of a Racemic Alkaloid Mixture 
 
8.1 Introduction 
 
8.1.1 Crystallization of racemates and enantiomers  
  
Chirality is a concept well known to all chemists concerned in any way with 
structure. It has numerous implications ranging from those affecting physical properties 
of matter to those related to biological mechanisms. The terminology of several 
concepts regarding chirality will be defined in following paragraphs.
112
  
The geometric property of a rigid object (or spatial arrangement of points or 
atoms) of being nonsuperposable on its mirror image is called chirality. A chiral object 
may exist in two enantiomorphic forms, which are mirror image of one another. Such 
forms lack inverse symmetry elements, that is, a center, a plane, and an improper mirror 
plane, a centre of inversion or a rotoinversion axis. Objects that possess one or more of 
these inverse symmetry elements are superposable on their mirror images; they are 
achiral. All objects necessarily belong to one of these categories; a hand, a spiral 
staircase, and a snail shell are all chiral, while a cube and a sphere are achiral.  
According to Lord Kelvin, “two equal and similar right hands are homochirally 
similar. Equal and similar right and left hands are heretochirally similar”.113 All of the 
foregoing definitions remain valid at the molecular level; there are achiral, as well as 
chiral molecules. The latter exist in two enantiomeric forms. The term enantiomer is 
used to designate either a single molecule, a homochiral collection of molecules, or 
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even a heterochiral collection that contains an excess of one enantiomer and whose 
composition is defined by its enantiomeric purity, or the enantiomeric excess, ee. 
The oldest known manifestation of molecular chirality is optical activity, or 
rotator power, the properties that are exhibited by the rotation of the plane of polarized 
light. Two enantiomers of a given compound have a rotator powers of equal absolute 
value, but of opposite sign, or sense. One is positive, or dextrorotatory, while the other 
is negative, or levorotatory. The absolute designations of sign are arbitrary inasmuch as 
they are wavelength, temperature, and solvent dependent, but the relative designations 
are always valid. That is, a given enantiomer may be () at one wavelength and () at 
another, while the other enantiomer will always have the opposite sign at the 
corresponding wavelength.  
The expression optically active substance may signify a pure enantiomer or a 
mixture containing an excess of one of the two. The composition of a mixture of two 
enantiomers may be characterized by its optical purity, which may in turn be determined 
from the ratio of the optical rotation of the mixture to that of the pure enantiomer. The 
optical purity (experimental value) is generally equal to the enantiomeric purity, which 
reflects the real composition. A pure enantiomer is often called optically pure.  
The absolute configuration is the spatial arrangement of the atoms of a 
physically identified chiral molecule entity (or group) and its stereochemical description 
(e.g., R or S, P or M, D or L, etc.), whereas the absolute structure is the spatial 
arrangement of the atoms of a physically identified non-centrosymmetric crystal and its 
description by way of unit-cell dimensions, space group and representative coordinates 
of all atoms. 
An equimolar mixture of two enantiomers whose physical state is unspecified or 
unknown is called racemate. It does not exhibit optical activity. The chemical name or 
formula of a racemate is distinguished from those of the enantiomers by the prefix (±). 
194 
 
The separation of the two enantiomers that constitute a racemate is called a 
resolution, or an optical resolution. When the separation is not complete, a mixture is 
obtained which is often called either a partially resolved racemate or a partially resolved 
enantiomer.  
Crystalline racemates may belong to one of three different classes. In the first, 
the crystalline racemate is a conglomerate, that is, a mechanical mixture of crystals of 
the two pure enantiomers (racemic conglomerate). The process of its formation on 
crystallization of a racemate is called spontaneous resolution, since pure or nearly pure 
enantiomers can often be obtained from the conglomerate by sorting. One of the most 
famous examples is the separation of a racemic conglomerate of sodium ammonium 
tartarate salt by Pasteur.
114
  
The second and most common type of crystalline racemate is that in which the 
two enantiomers are present in equal quantities in a well-defined arrangement within the 
crystal lattice. The resultant homogeneous solid phase corresponds to a true crystalline 
addition compound, which is called a racemic compound (also referred to as a ‘true 
racemate’).  
The third possibility corresponds to the formation of a solid solution between the 
two enantiomers, coexisting in an unordered manner in the crystal lattice. The term 
pseudoracemate (or racemic solid solution) is used to designate this case.  
 
8.1.2 Space groups 
 
A crystallographic space group is the set of geometrical symmetry operations 
that take a three-dimensional periodic object into itself. The space groups in three 
dimensions are made from combinations of the 32 crystallographic point groups with 
the 14 Bravais lattices, each of the latter belonging to one of 7 lattice systems.
112,115
 This 
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results in a space groups being some combination of the translational symmetry of a unit 
cell including lattice centering, the point group symmetry operations of reflections, 
rotation, and improper rotations (also called rota-inversion), and the screw axis and 
glide plane symmetry operations. The combination of all these symmetry operations 
results in a total of 230 unique space groups describing all possible crystal symmetries. 
All of the 230 space groups are collected in a book known as the International Tables 
for Crystallography. They are represented by the symmetry-elements diagram and 
general position diagram, notated with the Hermann-Mauguin symbols and other 
relevant information.
116
 
This results in a space groups being some combination of the translational 
symmetry of a unit cell including lattice centering, the point group symmetry operations 
of reflections, rotation, and improper rotations (also called rota-inversion), and 
the screw axis and glide plane symmetry operations. 
There are 230 ways of arranging objects repetitively in a three-dimensional 
network. These 230 space groups may be divided among the 32 crystal classes 
according to their symmetry. The 11 enantiomorphous crystal classes encompass 65 
space groups which are devoid of inverse symmetry elements. Thus, an enantiomer (or 
enantiomerically pure compounds) may only crystallize in one of these 65 groups (e.g., 
P21, P212121, C2, and P42).
112
  
While an enantiomer necessarily crystallizes in an enantiomorphous system, the 
inverse of this statement is not true. A racemate, in principle, may crystallize in any 
space groups, even in a chiral space groups; the optical activity of the crystal does not 
necessarily imply any optical activity of the molecules in the liquid state (a circular 
staircase may be built out of achiral blocks). In fact, in almost all cases, racemates 
crystallize in those space groups that possess elements of inverse symmetry (165 
possibilities, e.g., P  , P21/c, C2/c, and Pna21).
112
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The Tables shown below represents the division of the 32 crystal classes 
according to property (Table 8.1),
117,118
 and the relationship between the molecular 
properties, the nature of the solution, and the nature of possible crystals (Table 8.2).
117 
 
Table 8.1. Division of the 32 crystal classes according to property
117,118 
 Crystal characteristic 
 
Flack classification Crystal class 
1 Centrosymmetric Achiral 
CA 
(Centrosymmetric Achiral) 
  , 2/m, mmm, 4/m, 
4/mmm,   ,   m, 6/m, 
6/mmm, m  , m  m 
2 Non- centrosymmetric Achiral 
NA  
(Non-centrosymmetric Achiral) 
m, mm2,   , 4mm,   2m, 
3m,   , 6mm,   2m,   3m 
3 Non- centrosymmetric Chiral 
NC  
(Non-centrosymmetric Chiral) 
1, 2, 222, 4, 422, 3, 32, 6, 
622, 23, 432 
 
Table 8.2. Relationship between molecular properties, nature of the solution, and nature 
of possible crystals
117
 
Solution Chiral molecul Achiral Molecule 
 
Enantiopure  
chiral 
Enantiomeric mixture Homogeneous 
Molecular 
composition 
of the single 
crystal 
Enantiopure  
chiral 
Enantiopure 
chiral 
Enantiomeric mixture   
Crystal 
structure 
Achiral 
Non-centro-
symmetric 
chiral 
Conglomerate 
(collection of 
resolved 
crystals) 
Inversion 
twinned 
Non-
centrosymmetric 
achiral 
Racemic 
Disordered 
solid 
solution 
Non-
centro-
symmetric 
chiral 
Non-
centro-
symmetric 
achiral 
Centro-
symmetric 
achiral 
Flack 
classification 
 NC NC NC NA 
NA or 
CA 
    
Examples 
Not 
known 
in 
nature 
P212121 P61 and P65 
P21 
(twinned) 
Pc 
P21 or 
P21/c 
Any P3121 Pn P21/c 
 
8.1.3 X-ray radiation/source 
 
Copper (Cu K,  = 1.54184 Å) and molybdenum (Mo K,  = 0.71073 Å) are 
the two most common sources used for X-ray diffraction experiments.
115 
Copper X-ray tubes produce a higher flux of incident photons (for the same 
power settings) and these are diffracted more efficiently than molybdenum radiation. 
Hence, copper radiation is particularly useful for small or otherwise weakly diffracting 
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crystals, especially if the absorption effects are moderate. For crystals with long unit 
cell dimensions, reflections are further apart when the longer-wavelength copper 
radiation is used, and this can minimize reflection overlap. If absolute configuration 
determination is needed, but the crystals do not contain elements heavier than silicone, 
then copper radiation is essential. 
On the other hand, molybdenum radiation has less absorption effects, and this 
can be crucial if elements of a high atomic number are present. Molybdenum radiation 
allows the collection of data to a higher resolution, and is likely to cause fewer 
restrictions if low-temperature or other attachments are required.  
 
The following illustrative examples on when to use Cu or Mo X-ray source
115
: 
- a well-diffracting organic compound containing iodine: 
use Mo to minimize absorption 
- a poorly diffracting organic compound (CHNO): 
use Cu to maximize diffracted intensity 
- an organic compound (CHNO) with b > 50 Å: 
use Cu to minimize overlap 
- absolute configuration of C19H22N2O3 
feasible only with Cu 
- most metal complexes, etc. 
use Mo to minimize absorption 
- high-resolution studies 
use Mo 
 
The Chemistry Department, University of Malaya operates two X-ray 
diffractometers for small molecule crystallography studies. The first X-ray 
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diffractometer is the Bruker SMART APEX II, commissioned in December 2007, only 
has Mo K X-ray radiation. The second X-ray diffractometer, Agilent SuperNova Dual, 
comissioned more recently (April 2011) is a hybrid instrument with two different X-ray 
sources, Mo K and Cu K. The author has full access to the Bruker X-ray 
diffractometer, but only very limited access to the Agilent X-ray diffractometer. 
 
8.1.4 Glossary of terms 
 
Below is the glossary of terms which will be used in the subsequent chapter. 
Many of the definitions of terms given in this glossary are drawn from the IUPAC Basic 
Terminology of Stereochemistry,
118 
which have been summarized and reworded by 
Flack et al.
119
 
 
Absolute configuration: The spatial arrangement of the atoms of a physically identified 
chiral molecular entity (or group) and its stereochemical description (e.g., (R) or (S), (P) 
or (M), or D or L, etc.). 
 
Absolute structure: The spatial arrangement of the atoms of a physically identified non 
centrosymmetric crystal and its description by way of unit-cell dimensions, space group, 
and representative coordinates of all atoms. 
 
Chiral: Having the property of chirality. 
 
Chirality: The geometric property of a rigid object (or spatial arrangement of points or 
atoms) of being nonsuperposable by pure rotation and translation on its image formed 
by inversion through a point; the symmetry group of such an object contains no 
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symmetry operations of the second kind (inversion through a point,   ; reflection 
through a plane, m; roto-inversion,   ). When the object is superposable by pure rotation 
and translation on its inverted image, the object is described as being achiral; the 
symmetry group of such an object contains symmetry operations of the second kind. 
Barron
120
 provides a more general definition of chirality: ‘True chirality is exhibited by 
systems that exist in two distinct enantiomorphic states that are interconverted by space 
inversion but not by time reversal combined with any proper spatial rotation’.  
 
Chirality sense: The property that distinguishes enantiomorphs. The specification of two 
enantiomorphic forms by reference to an oriented space, e.g., of a screw, a right 
threaded one or a left threaded one. The expression opposite chirality is short for 
opposite chirality sense. 
 
Enantiomer: One of a pair of chiral molecular entities of opposite chirality sense. 
 
Enantiomerically pure/enantiopure: A sample in which all molecules have (within 
limits of detection) the same chirality sense. 
 
Enantiomorph: One of a pair of chiral objects or models that are non-superposable 
mirror images of each other.  
 
Flack parameter: The Flack parameter, x encodes the relative abundance of the 
‘strength’ and sign of the measured resonant scattering signal measured in units of f" 
(the imaginary component of the atomic scattering factor) in an inversion twin.
63
 In 
short, by determining x for all data (usually found between 0 and 1), if the value is near 
0 with a small standard uncertainty, the absolute structure given by the structure is 
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likely correct, and if the value is near 1, then the inverted structure is likely correct. If 
the value is near 0.5, the crystal may be racemic or twinned.  
 
Hooft parameter: A new probabilistic procedure introduced in 2008, based on Bijvoet-
pair intensity differences that can be used to establish the absolute structure.
64
 Hooft 
parameter, y behaves like the Flack parameter,
63
 in that it will have a value of 0 for the 
correct absolute structure model (with a small standard uncertainty), and 1 for the 
inverted model. 
 
Inversion twin: An inversion twin consists of centrosymmetrically related crystalline 
domains. The symmetry operation relating domain structures in an inversion twin is that 
of a centre of symmetry. In an inversion twin, the crystal lattice (i.e., the lattice 
translations after removing the atoms) is maintained throughout the whole volume of the 
sample, but the atoms and molecules take up either one spatial arrangement or the 
inverted one depending on the position within the crystal. A visual model of an 
inversion twin, applicable to chiral crystal structures, is to imagine the individual 
components of a racemic conglomerate being stuck together with their lattices being 
perfectly oriented. The inversion-twinned crystal is an oriented solid-state mixture of 
inverted structures. Inversion-twinned crystals do not form from an enantiopure sample 
of a substance. 
 
Racemate: An equimolar mixture of a pair of enantiomers. It does not exhibit optical 
activity in solution. The chemical name or formula of a racemate is distinguished from 
those of the enantiomers by the prefix (±) or rac or by the symbols (RS) or (SR).  
 
Racemic: Pertaining to a racemate. 
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Racemic compound: A crystalline racemate in which the two enantiomers are present in 
equal amounts in a well-defined arrangement within the lattice of a homogeneous 
crystalline addition compound. 
 
Racemic conglomerate: An equimolar mechanical mixture of crystals, each one of 
which contains only one of the two enantiomers present in a racemate. The process of 
its formation on crystallization of a racemate is called spontaneous resolution, since 
pure or nearly pure enantiomers can often be obtained from the conglomerate by 
sorting. 
 
Relative configuration: The configuration of any stereogenic centre with respect to any 
other stereogenic centre contained within the same molecular entity.  
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8.2 Andransinine  
 
Andransinine (119) is an andranginine (120)
121,122
 derivative recently isolated 
from the leaf extract of Alstonia angustiloba.
123
 
 
 
 
Compound 119 was isolated as a light yellowish oil. The UV spectrum was 
characteristic of an indole chromophore with absorption maxima at 223 and 284 nm, 
while the IR spectrum indicated the presence of NH (3387 cm
1
) and ester carbonyl 
(1732 cm
1
) functions. In addition, the presence of Wenkert-Bohlmann bands were 
noted at 2740 and 2885 cm
1
. The ESIMS of 119 showed an [M H] m/z 381 and 
HRESIMS measurements yielded the molecular formula C23H28N2O3 (DBE 11). The 
13
C NMR data (Table 8.3) showed 23 carbon resonances, comprising two methyl, seven 
methylene, six methine, and eight quaternary carbons. An ester carbonyl resonance was 
observed at C 171.8, while olefinic resonances due to a trisubstituted double bond were 
observed at C 126.0 and 134.0, in addition to the characteristic peaks due to the indole 
moiety. The 
1
H NMR data (Table 8.3) showed the presence of an unsubstituted indole 
moiety from the presence of four aromatic resonances (H 7.50, d, J = 8 Hz, H-9; 7.11, t, 
J = 8 Hz, H-10; 7.17, t, J = 8 Hz, H-11; 7.33, d, J = 8 Hz, H-12), an indolic NH as a 
broad singlet at H 8.17, a methoxy group associated with a methyl ester function as a 
singlet at H 3.63, a vinylic hydrogen at H 5.74, and an ethoxy group (H 3.19, m, 1H, 
CH3CHHO; 3.33, m, 1H, CH3CHHO; 1.11, t, J = 7 Hz, CH3CH2O). In addition, an 
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isolated aminomethine was observed as a singlet at H 3.79 (C 63.4). The 
1
H and 
13
C 
NMR data were similar to those of andranginine (120),
121
 the difference in the present 
alkaloid being replacement of the C-14, C-15 double bond by an ethoxy substituent at 
C-15.  
Andranginine (120) was previously isolated as an optically inactive alkaloid 
from Craspidospermum verticillatum,
121
 and the relative configuration was established 
by X-ray diffraction analysis.
122
 The observed NOE between H-21 and the hydrogens of 
the ethoxy group (H-22 and H-23) in 119 (Figure 8.1) indicated an -oriented H-15 and 
permitted the assignment of the relative configuration at C-15 as R. The observed H-
21/H-3, H-6 and H-15/H-19 NOEs (Figure 8.1) were also in accord with the relative 
configuration of andransinine as depicted in 119, as is the observed Wenkert-Bolmann 
bands in the IR spectrum, which is consistent with the trans disposition of H-21 and the 
N-4 lone pair.
29
  
 
 
Figure 8.1. Selected NOEs of 119. 
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Table 8.3.
 1
H and 
13
C NMR data () of andransinine (119)a 
Position C H 
2 137.9 
3 50.0 2.80 m 
3  3.08 m 
5a 57.0 3.17 m  
5b  3.31 m 
6 18.6 2.76 m 
6  3.12 m 
7 114.8 
8 127.6 
9 118.4 7.50 d (8) 
10 121.9 7.11 t (8) 
11 119.5 7.17 t (8) 
12 110.8 7.33 d (8) 
13 134.8 
14a 32.4 1.95 br dd (14, 3) 
14b  2.07 m 
15 78.0 3.78 m 
16 48.5 
17a 32.4 2.07 m 
17b  2.49 dd (13, 3) 
18 22.2 2.05 m 
18  2.20 m 
19 126.0 5.74 d (5) 
20 134.0 
21 63.4 3.79 s 
22 62.2 3.19 m 
  3.33 m 
23 15.4 1.11 t (7) 
CO2Me 52.4 3.63 s 
CO2Me 171.8 
NH  8.17 br s 
aCDCl3, 400 and 100 MHz, respectively; assignments based on COSY, HMQC, and HMBC. 
 
Since andransinine (119) crystallized readily from EtOAc to give good quality 
colorless block crystals (mp 212214 °C), an X-ray diffraction analysis was carried out 
(Mo K radiation) which confirmed all of the observations above (Figure 8.2). The 
crystal system is monoclinic, with a space group of P21 (a chiral space group). The 
crystal data and structure refinement parameters of 119 are summarized in Table 8.4. 
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                                                  Figure 8.2. X-ray crystal structure of andransinine (119). 
 
Table 8.4. Crystal data and structure refinement parameters of alkaloid 119 
Empirical formula C23H28N2O3 
Molecular formula C23H28N2O3 
Molecular weight, Mr 380.47 
Melting point 212214 °C 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Monoclinic 
Space group P21  
a 8.5064(2) Å 
b 9.1496(2) Å 
c 12.5255(2) Å 
α 90.00°  
β 96.0070(10)°  
γ 90.00° 
Volume, V 969.51(3) Å
3
 
No. of molecule per unit cell, Z 2 
Density (calcd) 1.303 mg/mm
3
 
F(000) 408.0 
Crystal size 0.44 × 0.21 × 0.17 mm 
2range for data collection 3.26 to 54.98° 
Index ranges 10 ≤ h ≤ 11, 11 ≤ k ≤ 11, 16 ≤ l ≤ 16  
Reflections collected 8915 
Independent reflections 2366[Rint = 0.0211] 
Data/restraints/parameters 2366/1/255  
Goodness-of-fit on F
2
 1.025  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0302, wR2 = 0.0759  
Final R indexes [all data] R1 = 0.0321, wR2 = 0.0774  
Largest diff. peak/hole / e Å
3
 0.22/0.18  
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From the crystal data shown above, it can be seen that compound 119 crystallized 
in a chiral space group (monoclinic, P21). Crystallization of 119 in a chiral space group 
was initially puzzling as it suggested the possibility that compound 119 is an 
enantiomerically pure compound. This is in contrast to the parent alkaloid, andranginine 
(120), which was obtained as an optically inactive racemate. The crystal system is 
monoclinic, with the observed space group of P2/c (centrosymmetric space group), 
which is consistent with a racemate.
112,115,117
   
Compound 119 initially isolated from A. angustiloba also gave inconsistent 
results for the specific rotation with values of []25D varying from +11 to 8 (the 
compound was re-purified each time before measurement) which contributed to the 
initial confusion. Compound 119 (and a minor amount of the methoxy derivative 121) 
was however, subsequently isolated as a racemate ([]25D = ) from the bark extract of 
Kopsia pauciflora, which indicated that the earlier inconsistent values obtained for 119 
from A. angustiloba, was likely a result of racemate contamination (which has been 
subsequently borne out by HPLC, vide infra). 
The 
1
H NMR spectrum of 119 obtained from A. angustiloba and K. pauciflora 
are shown in Figures 8.3 and 8.4, respectively.  
Recrystallization of 119 (from K. pauciflora) from EtOAc gave similar colorless 
block crystals with similar melting points as that obtained previously (mp 212214 °C). 
An X-ray diffraction analysis was carried out, and the results obtained indicated a 
similar crystal system (monoclinic, space group of P21) with the sample of 119 from A. 
angustiloba.  
 
 
 2
0
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Figure 8.3. 
1
H NMR spectrum (CDCl3, 400 MHz) of (±)-andransinine (119) obtained from A. angustiloba. 
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0
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Figure 8.4. 
1
H NMR spectrum (CDCl3, 400 MHz) of (±)-andransinine (119) obtained from K. pauciflora. 
 
 
 
 
 
209 
 
A non-enzymatic pathway (involving a Diels-Alder cycloaddition of a secodine-
type precursor as the key step) was presented to account for the isolation of racemic 
andranginine (120) from Craspidospermum verticillatum which was supported by the 
observation that thermolysis of the putative precursor, precondylocarpine acetate (121), 
at 100 
o
C in EtOAc solution, resulted in the formation of racemic 120, while carrying 
out the thermolysis in MeOH led to the formation of the methoxy derivative, 122 
(Scheme 8.1).
121
 It is therefore likely that both andransinine (119) and 122 are artifacts, 
formed by a similar pathway since the precursor alkaloid, precondylocarpine (121) or its 
acetate 123 was present among the alkaloids isolated and denatured ethanol was used in 
the extraction of the plant materials (K. pauciflora).
58
    
 
 
Scheme 8.1 
 
Examination of all the diffraction evidence, unit cell (Figures 8.5, 8.6, and 8.7), 
space group (Table 8.4), and structure determination, showed the presence of only one 
enantiomer. 
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Figure 8.5. Packing diagram of 119 viewing down the a-axis. 
 
 
Figure 8.6. Packing diagram of 119 viewing down the b-axis. 
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Figure 8.7. Packing diagram of 119 viewing down the c-axis. 
  
Compound 119 was also subjected to crystallization in different solvent systems, 
such as CH2Cl2/hexanes and MeOH. Physical examination of these crystals under the 
microscope did not yield any useful information. However, from the melting point 
determination, it can be seen that the crystals obtained from the EtOAc solution had a 
higher melting point, when compared with those of crystals obtained from 
CH2Cl2/hexanes and MeOH (Table 8.5). This suggested the formation of a racemic 
conglomerate.
112,124
 Crystals obtained from these solvents were then subjected to X-ray 
diffraction analyses. The physical data and X-ray diffraction analysis results are 
summarized in Table 8.5. 
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Table 8.5. Crystal data of andransinine (119) 
 
Crystals obtained from 
EtOAc solution 
Crystals obtained from 
CH2Cl2/hexanes solution 
Crystals obtained from 
MeOH solution 
Physical 
appearance 
Colorless block crystals 
(Figure 8.8) 
Colorless needles 
(Figure 8.9) 
Colorless lath crystals 
(Figure 8.10) 
Melting 
point 
212214 °C 186190 oC 204206 oC 
Crystal 
system 
Monoclinic Monoclinic Orthorhombic 
Unit cell 
dimension 
a = 8.4914(10) Å 
b = 9.1548(11) Å 
c = 12.4788(15) Å 
 
 =  = 90o,  = 95.838(3)o  
 
a = 39.082(4) Å 
b = 8.5880(11) Å 
c = 24.128(3) Å  
 
 =  = 90o,  = 
105.802(7)
o
 
 
a = 8.6828(2) Å 
b = 21.4082(4) Å 
c = 11.2277(2) Å  
 
 =  =  = 90o  
 
Space group 
P21 
(Non-centrosymmetric 
Chiral) 
C2/c 
(Centrosymmetric 
Achiral) 
Pna21 
(Non-centrosymmetric 
Achiral) 
Molecular 
composition 
of the single 
crystal 
Enantiopure chiral Enantiomeric mixture Enantiomeric mixture 
 
 
Figure 8.8. Andransinine (119) crystals obtained from EtOAc solution. 
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Figure 8.9. Andransinine (119) crystals obtained from CH2Cl2/hexanes solution. 
 
 
Figure 8.10. Andransinine (119) crystals obtained from MeOH solution. 
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From the X-ray data (Table 8.5), crystals obtained from EtOAc solution constitute 
a racemic conglomerate (an equimolar mechanical mixture of crystals, each one of 
which contains only one of the two enantiomers present in a racemate), while crystals 
from CH2Cl2/hexanes or MeOH solutions correspond to a racemic compound (or a 
crystalline racemate in which the two enantiomers are present in equal quantities in a 
well-defined arrangement within the crystal lattice). 
Thus, it can be seen that 119 isolated from A. angustiloba and K. pauciflora are 
racemates, which spontaneously resolved to form racemic conglomerate crystals in 
EtOAc (Table 8.5), but formed racemic compound crystals when recrystallized using 
different solvent systems such as CH2Cl2/hexanes or MeOH. This can be clearly seen in 
the partial unit cell for both crystals obtained from CH2Cl2/hexanes and MeOH 
solutions (Figure 8.11). 
Both batches of andransinine (119) were then subjected to chiral phase HPLC 
analysis,
125
 using a Chiralpack AD-H column (4.6 x 150 mm; 5 m; Daicel, Japan), 
with the solvent system of n-hexane/EtOH/diethylamine (DEA) (85:15:0.2) eluting in 
isocratic mode. 
The HPLC chromatogram showed that both batches of andransinine (119) 
showed two major peaks (Figure 8.12) at retention time of ca. 3 and 7 min, which 
correspond to a pair of enantiomers. However, the HPLC chromatogram of 119 
obtained from Alstonia angustiloba showed in addition to the presence of two major 
peaks, the presence of some minor peaks (Figure 8.12, Left). These minor peaks were 
not detected in the HPLC chromatogram of 119 obtained from K. pauciflora (Figure 
8.12, Right). Thus, the presence of optical activity of 119 obtained from A. angustiloba, 
was likely a result of racemate contamination. 
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Figure 8.11. Top: Partial unit cell for crystals of 119, obtained from CH2Cl2/hexanes 
solution. Bottom: Partial unit cell for crystals of 119, obtained from MeOH solution. It 
can be seen that (±)-andransinine are present in both of the unit cell.  
216 
 
 
Figure 8.12. Left: HPLC chromatogram of (±)-andransinine (119) obtained from A. 
angustiloba. Right: HPLC chromatogram of (±)-andransinine (119) obtained from K. 
pauciflora. (Daicel Chiralpak AD-H (5 μm, 4.6 x 150 mm); mobile phase, n-
hexane/EtOH/DEA = 85:15:0.2; ﬂow rate: 0.8 ml/min). 
 
Since (±)-andransinine (119) crystallized from EtOAc are racemic 
conglomerates, any of these crystals will yield an absolute configuration when the X-ray 
diffraction analysis is carried out using Cu K radiation. Accordingly, a suitably large 
crystal (ca. 0.43 x 0.35 x 0.28 mm) was picked from the EtOAc solution containing 
conglomerates of 119. It was then cut in half (ca. 0.20 x 0.35 x 0.28 mm). This half 
crystal was then subjected to X-ray diffraction analysis using Cu K radiation. The 
absolute configuration of this crystal was determined to be (15R,16S,21R)-andransinine 
(Scheme 8.2). 
The remaining half of the andransinine (119) crystal (ca. 0.23 x 0.35 x 0.28 mm) 
was dissolved in a minimum amount of EtOH and then subjected to chiral phase HPLC 
analysis (Scheme 8.2). 
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Scheme 8.2 
 
Racemic conglomerate 
crystals of 119 
One crystal was selected 
and cut into half 
Chiral phase 
HPLC analysis 
(Chiracel AD-H) 
X-ray diffraction 
analysis  
(Cu K radiation) 
 
 
X-ray crystal structure of (15R,16S,21R)- 
andransinine (119a) 
[Flack parameter,
63
 x = 0.15(0.12); 
 Hooft parameter,
64
 y = 0.03(0.04)]. 
 
 
HPLC chromatogram of  
(15R,16S,21R)-andransinine (119a). 
218 
 
It can be seen from the HPLC chromatogram that the retention time of the 
partially-dissolved crystal is ca. 3 min (Scheme 8.2), which corresponds to the first peak 
shown in the chromatogram in Figure 8.12. We can therefore conclude that the first 
peak in the HPLC chromatogram corresponds to (15R,16S,21R)-andransinine (119a), 
and the second peak (7 min) corresponds to (15S,16R,21S)-andransinine (119b) (Figure 
8.12). 
As attempts to obtain pure enantiomers from the conglomerate by mechanical 
sorting under the microscope was unsuccessful (lack of sufficient morphological 
differentiation), separation of both enantiomers was carried out using the same column 
and same solvent system as used previously in the analysis. Both enantiomers were 
successfully separated with >99% ee (Figure 8.13). 
 
  
Figure 8.13. Left: HPLC chromatogram of (15R,16S,21R)-andransinine/()-
andransinine (119a). Right: HPLC chromatogram of (15S,16R,21S)-andransinine/()-
andransinine (119b). (Daicel Chiralpak AD-H (5 μm, 4.6 x 150 mm); mobile phase, n-
hexane/EtOH/DEA = 85:15:0.2; ﬂow rate: 0.8 ml/min). 
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The optical rotation for both enantiomers was determined. The specific rotation 
for (15R,16S,21R)-andransinine (119a) was found to be []25D 85 (c 0.10, CHCl3), 
while that for (15S,16R,21S)-andransinine (119b) was found to be []25D 85 (c 0.07, 
CHCl3). Both enantiomers were recrystallized and the crystals obtained were subjected 
to an X-ray diffraction analysis, using Cu K radiation. The absolute configuration for 
both enantiomers are shown in Figure 8.14. 
 
                                                  
   
 
Figure 8.14. Left: X-ray crystal structure of (+)-andransinine (119a) [Flack parameter,
63
 
x = 0.10(0.12); Hooft parameter,
64
 y = 0.07(0.08)]. Right: X-ray crystal structure of ()-
andransinine (119b) [Flack parameter,
63
 x = 0.08(0.12); Hooft parameter,64 y = 
0.04(0.06)]. 
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8.3 Conclusion 
 
(±)-Andransinine (119), an artifact obtained during isolation of alkaloids from A. 
angustilaoba and K. pauciflora, was found to exhibit polymorphism in the solid state, 
forming crystals with different crystal systems and space groups in different solvent 
systems (Scheme 8.3). In addition, it undergoes spontaneous resolution when 
crystallized in EtOAc, forming racemic conglomerate crystals (Scheme 8.3). To the best 
of our knowledge this represents the first example encountered in alkaloids.  
 
 
Scheme 8.3 
 
Resolution of racemic (±)-andransinine (119) was carried out using chiral phase 
HPLC to afford the enantiomers, 119a and 119b, which were obtained with >99% ee. 
X-ray diffraction analysis yielded the absolute configuration of each enantiomer. 
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CHAPTER NINE 
X-Ray Diffraction of New Indole and Bisindole Alkaloids 
 
X-ray diffraction analyses were carried out on several new indole and bisindole 
alkaloids isolated from various plants in the family Apocynaceae. The author was 
responsible for crystallizing all of these alkaloids, carried out the diffraction 
experiments, and solved the structures. 
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9.1 Bisindole Alkaloids 
9.1.1 Leuconoline 
 
The new eburnane-sarpagine type bisindole alkaloid, leuconoline (124), was 
obtained from the stem-bark extract of Leuconotis griffithii.
126
 Suitable crystals of 124 
were obtained from the slow evaporation of 124 in EtOAc solution. The structure of 124 
is shown in Figure 9.1, while the crystal data and structure refinement parameters are 
summarized in Table 9.1. 
 
       
                                                                    Figure 9.1. X-ray crystal structure of 124. 
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Table 9.1. Crystal data and structure refinement parameters of leuconoline (124) 
Empirical formula C40H46N4O4  
Molecular formula C40H46N4O4 
Molecular weight, Mr 646.81  
Melting point 223224 C 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Orthorhombic  
Space group P212121  
a 7.0778(2) Å 
b 13.0650(4) Å 
c 37.7977(12) Å 
α 90.00°  
β 90.00°   
γ 90.00°   
Volume, V 3495.21(18) Å
3
 
No. of molecule per unit cell, Z 4  
Density (calcd) 1.229 mg/mm
3
 
F(000) 1384  
Crystal size 0.37 × 0.08 × 0.05 mm 
2range for data collection 4.32 to 49.5°  
Index ranges 8 ≤ h ≤ 8, 15 ≤ k ≤ 15, 44 ≤ l ≤ 42  
Reflections collected 26153  
Independent reflections 3428[Rint = 0.0728]  
Data/restraints/parameters 3428/0/439  
Goodness-of-fit on F
2
 1.168  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0644, wR2 = 0.1358  
Final R indexes [all data] R1 = 0.0716, wR2 = 0.1387  
Largest diff. peak/hole / e Å
3
 0.454/0.237  
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9.1.2 Lumusidines A and B  
 
Lumusidines A (125) and B (126) are new macroline-macroline type bisindole 
alkaloids isolated from the stem-bark extract of Alstonia macrophylla.
127
 The structures 
and relative configurations of both alkaloids were successfully determined via NMR 
spectroscopy, except for C-19 (in the case of 125 and 126) and C-20 (in the case of 
125).  
Attempts to obtain suitable crystals for both bisindole alkaloids were 
unsuccessful. Eventually, conversion of lumusidines A (125) and B (126) to their 
dimethyl diiodide salts 125a and 126a, via treatment with iodomethane, followed by 
crystallization from hot MeOH, furnished suitable crystals. X-ray diffraction analyses of 
these crystals yielded the absolute configuration of the salts, 125a and 126a, which in 
turn yielded the absolute configuration of lumusidines A (125) and B (126). The 
structures and absolute configuration of the dimethyl diiodide salts 125a and 126a are 
shown in Figures 9.2 and 9.3, respectively. 
The crystal data and structure refinement parameters of the dimethyl diiodide 
salt 125a are summarized in Table 9.2, while the crystal data and structure refinement 
parameters of the dimethyl diiodide salt 126a are summarized in Table 9.3. 
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Figure 9.2. X-ray crystal structure of 125a 
[Flack parameter:
63
 x = 0.01(0.03); Hooft parameter:
64
 y = 0.010(0.015)]. 
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Table 9.2. Crystal data and structure refinement parameters of compound 125a 
Empirical formula C45H62I2N4O7  
Molecular formula C45H56 N4O4

I2
2
.3H2O 
Molecular weight, Mr 1024.79  
Melting point > 198 °C dec 
Temperature during diffraction experiment, T 100 K  
X-ray source Mo K 
Crystal system Monoclinic  
Space group P21  
a 15.8916(2) Å 
b 8.92620(10) Å 
c 17.1572(3) Å 
α 90.00° 
β 112.2430(10)°   
γ 90.00°   
Volume, V 2252.67(5) Å
3
 
No. of molecule per unit cell, Z 2  
Density (calcd) 1.511 mg/mm
3
 
F(000) 1044.0  
Crystal size 0.18 × 0.12 × 0.10  
2range for data collection 2.56 to 50°  
Index ranges 18 ≤ h ≤ 18, 10 ≤ k ≤ 10, 20 ≤ l ≤ 20  
Reflections collected 17429  
Independent reflections 7729[Rint = 0.0469]  
Data/restraints/parameters 7729/10/550  
Goodness-of-fit on F
2
 1.030  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0505, wR2 = 0.1373  
Final R indexes [all data] R1 = 0.0592, wR2 = 0.1492  
Largest diff. peak/hole / e Å
3
 3.90/0.77  
Flack parameter 0.01(0.03) 
Hooft parameter 0.052(0.011) 
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Figure 9.3. X-ray crystal structure of 126a 
[Flack parameter:
63
 x = 0.01(0.03); Hooft parameter:
64
 y = 0.052(0.011)]. 
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Table 9.3. Crystal data and structure refinement parameters of compound 126a 
Empirical formula C45H64I2N4O8 
Molecular formula C45H58 N4O5

I2
2
.3H2O 
Molecular weight, Mr 1042.82 
Melting point 230−234 °C 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Monoclinic 
Space group C2 
a 28.5993(5) Å 
b 11.4265(2) Å 
c 18.3052(4) Å 
α 90.00°  
β 127.1400(10)°  
γ 90.00°  
Volume, V 4768.59(16) Å
3
 
No. of molecule per unit cell, Z 2  
Density (calcd) 0.404 mg/mm
3
 
F(000) 540.0  
Crystal size 0.42 × 0.21 × 0.07 mm 
2range for data collection 2.8 to 51°  
Index ranges 34 ≤ h ≤ 34, 13 ≤ k ≤ 13, 22 ≤ l ≤ 22  
Reflections collected 19239  
Independent reflections 8792[Rint = 0.0350]  
Data/restraints/parameters 8792/1/600  
Goodness-of-fit on F
2
 1.338  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0703, wR2 = 0.1874  
Final R indexes [all data] R1 = 0.0782, wR2 = 0.1938  
Largest diff. peak/hole / e Å
3
 1.82/0.69  
Flack parameter 0.05(0.03) 
Hooft parameter 0.052(0.011) 
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9.1.3 Lumusidine D 
 
Lumusidine D (127) was isolated from the stem-bark extract of Alstonia 
macrophylla.
127
 Suitable crystals of 127 were obtained from the slow evaporation of 
127 in CH2Cl2/hexanes solution. The structure and relative configuration of 127 are 
shown in Figure 9.4, while the crystal data and structure refinement parameters are 
summarized in Table 9.4. 
 
 
 
 
Figure 9.4. X-ray crystal structure of 127. 
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Table 9.4. Crystal data and structure refinement parameters of lumusidine D (127) 
Empirical formula  C43H50N4O4  
Molecular formula  C43H50N4O4 
Molecular weight, Mr 686.87  
Melting point > 270 
o
C dec 
Temperature during diffraction experiment, T   100 K 
X-ray radiation Mo K 
Crystal system  Orthorhombic  
Space group  P212121  
a  9.8540(5) Å 
b  14.1678(7) Å 
c  25.6785(12) Å  
α  90.00°  
β  90.00°  
γ 90.00°  
Volume, V 3585.0(3) Å
3
  
No. of molecule per unit cell, Z 4  
Density (calcd) 1.273 mg/mm
3
 
F(000)  1472.0  
Crystal size  0.23 × 0.05 × 0.04 mm 
2 range for data collection  3.18 to 52.88°  
Index ranges  12 ≤ h ≤ 12, 17 ≤ k ≤ 17, 32 ≤ l ≤ 32  
Reflections collected  31050  
Independent reflections  4140[Rint = 0.1502]  
Data/restraints/parameters  4140/0/467  
Goodness-of-fit on F
2
  1.069  
Final R indexes [I>=2σ (I)]  R1 = 0.0670, wR2 = 0.1375  
Final R indexes [all data]  R1 = 0.1211, wR2 = 0.1706  
Largest diff. peak/hole / e Å
3
  0.38/0.45  
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9.2 Indole Alkaloids 
 
9.2.1 Indole alkaloids from Tabernaemontana corymbosa 
 
9.2.1.1 Voatinggine and tabertinggine 
 
Voatinggine (128) and tabertinggine (129) are new alkaloids which possess an 
unprecedented pentacyclic skeleton. Voatinggine (128) is characterized by a 5-6-6 ring 
system for the monoterpenoid portion, while tabertinggine (129) possess a 6-5-6 ring 
system fused to the indolic portion.  
 
 
 
Suitable crystals of voatinggine (128) were obtained from the slow evaporation 
of 128 in CH2Cl2/MeOH solution. The structure and absolute configuration of 128 are 
shown in Figure 9.5, while the crystal data and structure refinement parameters are 
summarized in Table 9.5. 
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Figure 9.5. X-ray crystal structure of 128  
[Flack parameter:
63
 x = 0.17(0.19);  Hooft parameter:64 y = 0.10(0.15)]. 
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Table 9.5. Crystal data and structure refinement parameters of voatinggine (128) 
Empirical formula C19H22N2O2 
Molecular formula C19H22N2O2 
Molecular weight, Mr 310.39 
Melting point 186188 oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Cu K 
Crystal system Monoclinic 
Space group P21 
a 9.6564(3) Å 
b 8.3932(2) Å 
c 9.8414(3) Å 
α 90.00° 
β 102.188(3)° 
γ 90.00° 
Volume, V 779.65(4) Å
3
 
No. of molecule per unit cell, Z 2 
Density (calcd) 1.322 mg/mm
3
 
F(000) 332.0 
Crystal size 0.35 × 0.17 × 0.14 mm 
2range for data collection 9.2 to 148.44° 
Index ranges 11 ≤ h ≤ 10, 10 ≤ k ≤ 10, 12 ≤ l ≤ 10 
Reflections collected 5115 
Independent reflections 3066[Rint = 0.0160] 
Data/restraints/parameters 3066/1/214 
Goodness-of-fit on F
2
 1.098 
Final R indexes [I ≥ 2σ (I)] R1 = 0.0373, wR2 = 0.1061 
Final R indexes [all data] R1 = 0.0376, wR2 = 0.1064 
Largest diff. peak/hole / e Å
3
 0.32/0.20 
Flack parameter, x 0.17(0.19) 
Hooft parameter, y 0.10 (0.04) 
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Suitable crystals of tabertinggine (129) were obtained from the slow evaporation 
of 129 in CHCl3/hexanes solution. The crystals obtained were very unstable when 
removed from the mother liquor, as the crystals will transform from colorless block 
crystals to white amorphous in matter of minutes when exposed to air. Thus, the 
crystallization of 129 had to be carried out prior to mounting the crystal onto the X-ray 
diffractometer. The structure and absolute configuration of 129 are shown in Figure 9.6, 
while the crystal data and structure refinement parameters are summarized in Table 9.6. 
 
 
 
 
Figure 9.6. X-ray crystal structure of 129  
[Flack parameter:
63
 x = 0.17(0.19); Hooft parameter:64 y = 0.10(0.15)]. 
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Table 9.6. Crystal data and structure refinement parameters of tabertinggine (129) 
Empirical formula C20H23Cl3N2O2 
Molecular formula C19H20N2O. CHCl3. H2 O 
Molecular weight, Mr 429.75 
Melting point 186188oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Orthorhombic  
Space group P212121  
a 6.7462(2) Å 
b 9.3007(3) Å 
c 32.0517(9) Å 
α 90.00°  
β 90.00°  
γ 90.00°  
Volume, V 2011.06(10) Å
3
 
No. of molecule per unit cell, Z 4  
Density (calcd) 1.419 mg/mm
3
 
F(000) 896.0  
Crystal size 0.36 × 0.12 × 0.02 mm 
2range for data collection 4.56 to 54.98°  
Index ranges 8 ≤ h ≤ 8, 12 ≤ k ≤ 12, 41 ≤ l ≤ 41  
Reflections collected 18791  
Independent reflections 4605[Rint = 0.1101]  
Data/restraints/parameters 4605/0/257  
Goodness-of-fit on F
2
 0.951  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0588, wR2 = 0.1092  
Final R indexes [all data] R1 = 0.0945, wR2 = 0.1228  
Largest diff. peak/hole / e Å
3
 0.29/0.39  
Flack parameter, x 0.05(0.09) 
Hooft parameter, y 0.10(0.04) 
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9.2.1.2 Alkaloid 130 
 
Alkaloid 130 possesses a rare isoxazole in the ring system. Attempts to obtain 
suitable crystals for alkaloid 130 were unsuccessful. Eventually conversion of a small 
amount of alkaloid 130 (0.3 mg) to its methyl iodide salt 130a via treatment with 
iodomethane, furnished suitable crystals on recrystallization from hot MeOH. X-ray 
diffraction analysis on these crystals yielded the absolute configuration of compound 
130a, which in turn yielded the absolute configuration of alkaloid 130. The structure 
and absolute configuration of the methyl iodide salt 130a are shown in Figure 9.7, while 
the crystal data and structure refinement parameters are summarized in Table 9.7. 
 
 
 
 
Figure 9.7. X-ray crystal structure of 130a  
[Flack parameter:
63
 x = 0.00(0.03); Hooft parameter:64 y = 0.005(0.0016)]. 
 
 239 
 
 
Table 9.7. Crystal data and structure refinement parameters of compound 130a 
Empirical formula C19H22N2O4I 
Molecular formula C19H22N2O4

I

 
Molecular weight, Mr 469.29 
Melting point 214218oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Orthorhombic  
Space group P212121  
a 7.6879(8) Å  
b 13.0251(14) Å  
c 18.905(2) Å  
α 90.00°  
β 90.00°  
γ 90.00°  
Volume, V 1893.1(4) Å
3
 
No. of molecule per unit cell, Z 4  
Density (calcd) 1.647  mg/mm
3
 
F(000) 940.0 
Crystal size 0.20 × 0.20 × 0.02 mm 
2range for data collection 3.8 to 52.72° 
Index ranges 8 ≤ h ≤ 9, 8 ≤ k ≤ 16, 23 ≤ l ≤ 23 
Reflections collected 5892  
Independent reflections 3636[Rint = 0.0519]  
Data/restraints/parameters 3636/0/228  
Goodness-of-fit on F
2
 0.674  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0422, wR2 = 0.1050  
Final R indexes [all data] R1 = 0.0586, wR2 = 0.1160  
Largest diff. peak/hole / e Å
3
 1.02/0.93  
Flack parameter, x 0.00(0.03) 
Hooft parameter , y 0.005(0.0016) 
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9.2.1.3 Alkaloids 131 and 132 
 
Alkaloids 131 and its N-oxide derivative 132 are new iboga-type alkaloids. 
Alkaloid 131 is presumably the C-19 oxidation of the known alkaloid, (19S)-
hydroxyibogamine (133).
128 
Suitable crystals of 131 were obtained from the slow evaporation of 131 in 
CH2Cl2/hexanes solution. The structure of 131 is shown in Figure 9.8, while the crystal 
data and structure refinement parameters are summarized in Table 9.8. 
 
 
 
 
 
 
Figure 9.8. X-ray crystal structure of 131. 
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Table 9.8. Crystal data and structure refinement parameters of alkaloid 131 
Empirical formula C19H22N2O 
Molecular formula C19H22N2O 
Molecular weight, Mr 294.39 
Melting point 195199 oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Tetragonal  
Space group P41  
a 10.1845(18) Å  
b 10.1845(18) Å 
c 14.613(3) Å 
α 90.00°  
β 90.00°  
γ 90.00°  
Volume, V 1515.7(5) Å
3
 
No. of molecule per unit cell, Z 4  
Density (calcd) 1.290 mg/mm
3
 
F(000) 632.0  
Crystal size 0.52 × 0.13 × 0.02 mm 
2range for data collection 4 to 52.66°  
Index ranges 12 ≤ h ≤ 12, 12 ≤ k ≤ 12, 11 ≤ l ≤ 17  
Reflections collected 8061  
Independent reflections 1609[Rint = 0.0804]  
Data/restraints/parameters 1609/1/200  
Goodness-of-fit on F
2
 0.877  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0363, wR2 = 0.0623  
Final R indexes [all data] R1 = 0.0567, wR2 = 0.0672  
Largest diff. peak/hole / e Å
3
 0.16/0.17  
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Suitable crystals of 132 were obtained from the slow evaporation of 132 in 
MeOH solution. The structure of 132 is shown in Figure 9.9, while the crystal data and 
structure refinement parameters are summarized in Table 9.9. 
 
 
 
 
Figure 9.9. X-ray crystal structure of 132. 
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Table 9.9. Crystal data and structure refinement parameters of alkaloid 132 
Empirical formula C20H28N2O4 
Molecular formula C19H22N2O2.CH3OH.H2O 
Molecular weight, Mr 360.44 
Melting point > 188 
o
C dec 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Orthorhombic  
Space group P212121  
a 6.5750(4) Å  
b 14.2730(8) Å 
c 19.3071(10) Å 
α 90.00°  
β 90.00°  
γ 90.00°  
Volume, V 1811.87(18) Å
3
  
No. of molecule per unit cell, Z 4  
Density (calcd) 1.321 mg/mm
3
 
F(000) 776.0  
Crystal size 0.52 × 0.26 × 0.12 mm 
2range for data collection 3.54 to 52.82°  
Index ranges 8 ≤ h ≤ 8, 17 ≤ k ≤ 17, 23 ≤ l ≤ 24  
Reflections collected 13798  
Independent reflections 3710[Rint = 0.0759]  
Data/restraints/parameters 3710/0/250  
Goodness-of-fit on F
2
 1.018  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0498, wR2 = 0.1001  
Final R indexes [all data] R1 = 0.0784, wR2 = 0.1165  
Largest diff. peak/hole / e Å
3
 0.22/0.24  
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9.2.1.4 Alkaloid 134 
 
Alkaloid 134 is a new eburnane alkaloid which possesses an additional ring 
having an ether bridge between C-15 and C-18. Suitable crystals of 134 were obtained 
from the slow evaporation of 134 in CH2Cl2/hexanes solution. The structure and 
absolute configuration of 134 are shown in Figure 9.10, while the crystal data and 
structure refinement parameters are summarized in Table 9.10.
 
 
 
 
 
Figure 9.10. X-ray crystal structure of 134 
[Flack parameter:
63
 x = 0.08(0.18); Hooft parameter:64 y = 0.05(0.06)] 
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Table 9.10. Crystal data and structure refinement parameters of alkaloid 134 
Empirical formula C19H20N2O2 
Molecular formula C19H20N2O2  
Molecular weight, Mr 308.37  
Melting point > 252
 o
C dec 
Temperature during diffraction experiment, T 100 K 
X-ray source Cu K 
Crystal system Orthorhombic  
Space group P212121  
a 11.73280(10) Å 
b 13.07670(10) Å 
c 19.2454(2) Å  
α 90.00°  
β 90.00°  
γ 90.00°  
Volume, V 2952.75(5) Å
3
 
No. of molecule per unit cell, Z 8  
Density (calcd) 1.387 mg/mm
3
 
F(000) 1312.0  
Crystal size 0.48 × 0.23 × 0.23 mm 
2range for data collection 8.18 to 148.66°  
Index ranges 14 ≤ h ≤ 14, 15 ≤ k ≤ 16, 23 ≤ l ≤ 22  
Reflections collected 10671  
Independent reflections 5866[Rint = 0.0163]  
Data/restraints/parameters 5866/0/415  
Goodness-of-fit on F
2
 1.071  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0354, wR2 = 0.0902  
Final R indexes [all data] R1 = 0.0358, wR2 = 0.0906  
Largest diff. peak/hole / e Å
3
 0.30/0.18  
Flack parameter, x 0.08(0.18) 
Hooft parameter , y 0.05(0.06) 
 
 
 246 
 
 
9.2.2 Alkaloids from Kopsia grandifolia 
 
 
9.2.2.1 Grandilodines A and B  
 
 
The grandilodines A (135) and B (136) are new alkaloids isolated from the stem-
bark extract of Kopsia grandifolia.
129 
 
 
 
Crystals of grandilodine A (135) were obtained from the slow evaporation of 
135 in CH2Cl2/MeOH solution. The structure of 135 is shown in Figure 9.11, while the 
crystal data and structure refinement parameters are summarized in Table 9.11. 
 
 
 
 
Figure 9.11. X-ray crystal structure of 135. 
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Table 9.11. Crystal data and structure refinement parameters of grandilodine A (135) 
Empirical formula C24H30N2O6 
Molecular formula C24H30N2O6 
Molecular weight, Mr 442.50 
Melting point 120122 oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Orthorhombic  
Space group P212121  
a 8.0067(2) Å  
b 11.2455(3) Å  
c 24.1247(7) Å 
α 90.00°  
β 90.00°  
γ 90.00° 
Volume, V 2172.17(10) Å
3
 
No. of molecule per unit cell, Z 4  
Density (calcd) 1.353 mg/mm
3
 
F(000) 944.0  
Crystal size 0.61 × 0.20 × 0.15 mm 
2range for data collection 4 to 55°  
Index ranges 10 ≤ h ≤ 10, 14 ≤ k ≤ 14, 30 ≤ l ≤ 31  
Reflections collected 18782  
Independent reflections 2846[Rint = 0.0671]  
Data/restraints/parameters 2846/0/292  
Goodness-of-fit on F
2
 1.024  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0401, wR2 = 0.0910  
Final R indexes [all data] R1 = 0.0516, wR2 = 0.0969  
Largest diff. peak/hole / e Å
3
 0.27/0.27  
 
 248 
 
 
Crystals of grandilodine B (136) were obtained from the slow evaporation of 
135 in CH2Cl2/hexanes solution. The structure of 136 is shown in Figure 9.12, while the 
crystal data and structure refinement parameters are summarized in Table 9.12. 
 
 
 
 
 
Figure 9.12. X-ray crystal structure of 136. 
 
 
 
 249 
 
 
Table 9.12. Crystal data and structure refinement parameters of grandilodine B (136) 
Empirical formula C24H26N2O7 
Molecular formula C24H26N2O7 
Molecular weight, Mr 454.47 
Melting point 204206 oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Monoclinic  
Space group P21  
a 8.6505(2) Å 
b 8.0985(2) Å 
c 15.3926(4) Å 
α 90.00°  
β 90.057(2)°  
γ 90.00°  
Volume, V 1078.34(5) Å
3
 
No. of molecule per unit cell, Z 2  
Density (calcd) 1.400 mg/mm
3
 
F(000) 480.0  
Crystal size 0.47 × 0.28 × 0.08 mm 
2range for data collection 2.64 to 55°  
Index ranges 11 ≤ h ≤ 11, 10 ≤ k ≤ 10, 20 ≤ l ≤ 19  
Reflections collected 10203  
Independent reflections 2655[Rint = 0.0497]  
Data/restraints/parameters 2655/1/301  
Goodness-of-fit on F
2
 0.990  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0335, wR2 = 0.0759  
Final R indexes [all data] R1 = 0.0404, wR2 = 0.0790  
Largest diff. peak/hole / e Å
3
 0.21/0.20  
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9.2.2.2 Alkaloid 137 
 
 
Crystals of the new alkaloid 137 were obtained from the slow evaporation of 
137 in CH2Cl2/MeOH solution. The structure of 137 is shown in Figure 9.13, while the 
crystal data and structure refinement parameters are summarized in Table 9.13. From 
the crystal structure, an intramolecular hydrogen bond was observed between the C-
16OH and the amide carbonyl. 
 
 
 
 
 
 
 
Figure 9.13. X-ray crystal structure of 137. 
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Table 9.13. Crystal data and structure refinement parameters of alkaloid 137 
Empirical formula C23H24N2O7 
Molecular formula C23H24N2O7 
Molecular weight, Mr 440.44 
Melting point 206208 oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Monoclinic  
Space group P21  
a 9.9492(5) Å 
b 8.2037(4) Å 
c 13.0494(7) Å 
α 90.00° 
β 109.845(3)° 
γ 90.00°  
Volume, V 1001.84(9) Å
3
 
No. of molecule per unit cell, Z 2  
Density (calcd) 1.460 mg/mm
3
 
F(000) 464.0  
Crystal size 0.58 × 0.15 × 0.06  
2range for data collection 3.32 to 55°  
Index ranges 12 ≤ h ≤ 12, 10 ≤ k ≤ 10, 16 ≤ l ≤ 16  
Reflections collected 9224  
Independent reflections 2462[Rint = 0.0536]  
Data/restraints/parameters 2462/1/291  
Goodness-of-fit on F
2
 1.142  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0504, wR2 = 0.1186  
Final R indexes [all data] R1 = 0.0588, wR2 = 0.1220  
Largest diff. peak/hole / e Å
3
 0.35/0.32  
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9.2.2.3 Alkaloid 138 
 
 
Alkaloid 138 is the first example of an aspidofractinine-type alkaloid which has 
lost one carbon in the piperidine ring D, resulting in five-membered lactam ring D. 
Crystals of 138 were obtained from the slow evaporation of 138 in 
CH2Cl2/MeOH solution. It can be seen that 138 co-crystallized with the solvent used 
during crystallization (MeOH). The structure of 138 is shown in Figure 9.14, while the 
crystal data and structure refinement parameters are summarized in Table 9.14. 
 
 
 
 
Figure 9.14. X-ray crystal structure of 138. 
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Table 9.14. Crystal data and structure refinement parameters of alkaloid 138 
Empirical formula C21H26N2O4 
Molecular formula C20H22N2O3.CH3OH 
Molecular weight, Mr 370.44 
Melting point 180182 oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Orthorhombic  
Space group P212121  
a 6.7581(2) Å 
b 11.4548(3) Å 
c 23.3157(6) Å 
 90.00°  
 90.00°  
 90.00°  
Volume, V 1804.93(9) Å
3
 
No. of molecule per unit cell, Z 4  
Density (calcd) 1.363 mg/mm
3
 
F(000) 792.0  
Crystal size 0.58 × 0.25 × 0.13 mm 
2range for data collection 3.5 to 54.96°  
Index ranges 8 ≤ h ≤ 8, 14 ≤ k ≤ 14, 30 ≤ l ≤ 30  
Reflections collected 16954  
Independent reflections 2385[Rint = 0.0513]  
Data/restraints/parameters 2385/0/251  
Goodness-of-fit on F
2
 1.113  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0332, wR2 = 0.0856  
Final R indexes [all data] R1 = 0.0399, wR2 = 0.0993  
Largest diff. peak/hole / e Å
3
 0.25/0.25  
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9.2.2.4 Alkaloid 139 
 
 
Alkaloid 139 is notable for having incorporated an additional five-membered 
ring fused to the piperidine ring D of an aspidofractinine carbon skeleton. Crystals of 
139 were obtained from the slow evaporation of 139 in CH2Cl2/hexanes solution. It can 
also be seen that 139 co-crystallized with the solvent used during crystallization 
(CH2Cl2). The absolute structure of 139 is shown in Figure 9.15, while the crystal data 
and structure refinement parameters are summarized in Table 9.15. 
 
 
Figure 9.15. X-ray crystal structure of 139 
[Flack parameter:
63
 x = 0.02(0.12);  Hooft parameter:64 y = 0.00(0.07)]. 
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Table 9.15. Crystal data and structure refinement parameters of alkaloid 139 
Empirical formula C25H28Cl2N2O3 
Molecular formula C24H26N2O3.CH2Cl2 
Molecular weight, Mr 475.39 
Melting point 268270 oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Orthorhombic  
Space group P212121  
a 6.6620(4) Å 
b 9.8110(5) Å 
c 34.4440(18) Å  
 90.00° 
 90.00° 
 90.00° 
Volume, V 2251.3(2) Å
3
 
No. of molecule per unit cell, Z 4  
Density (calcd) 1.403 mg/mm
3
 
F(000) 1000.0  
Crystal size 0.42 × 0.04 × 0.02 mm 
2range for data collection 2.36 to 52.76°  
Index ranges 8 ≤ h ≤ 8, 12 ≤ k ≤ 12, 42 ≤ l ≤ 42  
Reflections collected 19611  
Independent reflections 4609[Rint = 0.1662]  
Data/restraints/parameters 4609/0/294  
Goodness-of-fit on F
2
 0.853  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0600, wR2 = 0.1277  
Final R indexes [all data] R1 = 0.1258, wR2 = 0.1664  
Largest diff. peak/hole / e Å
3
 0.35/0.35  
Flack parameter 0.02(0.12) 
Hooft parameter 0.00(0.07) 
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9.2.2.5 Alkaloid 140 
 
 
Alkaloid 140 is a new alkaloid isolated from the stem-bark extract of Kopsia 
grandifolia. Suitable crystals of 140 were obtained from the slow evaporation of 140 in 
CH2Cl2/MeOH solution. The structure of 140 is shown in Figure 9.16, while the crystal 
data and structure refinement parameters, are summarized in Table 9.16. 
 
 
 
 
 
 
 
 
 
Figure 9.16. X-ray crystal structure of 140. 
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Table 9.16. Crystal data and structure refinement parameters of alkaloid 140 
Empirical formula C19H22N2O2 
Molecular formula C19H22N2O2 
Molecular weight, Mr 310.39 
Melting point 190192 oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Monoclinic  
Space group P21  
a 14.2796(4) Å 
b 7.9986(2) Å 
c 15.7780(5) Å 
 90.00°  
 116.781(2)°  
 90.00°  
Volume, V 1608.81(8) Å
3
 
No. of molecule per unit cell, Z 4  
Density (calcd) 1.281 mg/mm
3
 
F(000) 664.0  
Crystal size 0.72 × 0.22 × 0.10 mm 
2range for data collection 2.9 to 54.98°  
Index ranges 18 ≤ h ≤ 18, 10 ≤ k ≤ 10, 20 ≤ l ≤ 20  
Reflections collected 15425  
Independent reflections 3962[Rint = 0.0983]  
Data/restraints/parameters 3962/1/417  
Goodness-of-fit on F
2
 0.957  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0409, wR2 = 0.0877  
Final R indexes [all data] R1 = 0.0526, wR2 = 0.0915  
Largest diff. peak/hole / e Å
3
 0.25/0.23  
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9.2.2.6  (19R)-Hydroxyeburnamenine 
 
 
(19R)-Hydroxyeburnamenine (141) is a new eburnane alkaloid. Crystals of 141 
were obtained from the slow evaporation of 141 in CH2Cl2/MeOH solution. The 
structure of 141 is shown in Figure 9.17, while the crystal data and structure refinement 
parameters are summarized in Table 9.17. 
 
          
 
  
Figure 9.17. X-ray crystal structure of 141. 
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Table 9.17. Crystal data and structure refinement parameters of (19R)-
hydroxyeburnamenine (141) 
Empirical formula C19H22N2O 
Molecular formula C19H22N2O 
Molecular weight, Mr 294.39 
Melting point 162164 oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Monoclinic  
Space group P21  
a 8.63910(10) Å 
b 7.92600(10) Å 
c 11.5438(2) Å 
 90.00°  
 98.4100(10)°  
 90.00°  
Volume, V 781.945(19) Å
3
 
No. of molecule per unit cell, Z 2  
Density (calcd) 1.250 mg/mm
3
 
F(000) 316.0  
Crystal size 0.34 × 0.16 × 0.15 mm 
2range for data collection 3.56 to 55°  
Index ranges 11 ≤ h ≤ 11, 10 ≤ k ≤ 10, 14 ≤ l ≤ 14  
Reflections collected 6701  
Independent reflections 1920[Rint = 0.0384]  
Data/restraints/parameters 1920/1/201  
Goodness-of-fit on F
2
 1.095  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0373, wR2 = 0.0852  
Final R indexes [all data] R1 = 0.0451, wR2 = 0.1035  
Largest diff. peak/hole / e Å
3
 0.26/0.20  
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9.2.2.7 Alkaloid 142 
 
 
Alkaloid 142 may be an artifact of the alkaloid 141, in view of the presence of 
an ethoxy group in the structure, and the use of EtOH during extraction.
130
 Crystals of 
142 were obtained from the slow evaporation of 142 in CH2Cl2/MeOH solution. The 
structure of 142 is shown in Figure 9.18, while the crystal data and structure refinement 
parameters are summarized in Table 9.18. 
 
 
 
 
Figure 9.18. X-ray crystal structure of 142. 
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Table 9.18. Crystal data and structure refinement parameters of alkaloid 142 
Empirical formula C21H28N2O2 
Molecular formula C21H28N2O2 
Molecular weight, Mr 340.45 
Melting point 150152 oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Orthorhombic  
Space group P212121  
a 8.4666(3) Å  
b 12.1895(4) Å  
c 16.9938(6) Å  
 90.00°  
 90.00°  
 90.00°  
Volume, V 1753.82(10) Å
3
  
No. of molecule per unit cell, Z 4  
Density (calcd) 1.289 mg/mm
3
 
F(000) 736.0  
Crystal size 0.41 × 0.09 × 0.06 mm 
2range for data collection 4.12 to 52.72°  
Index ranges 10 ≤ h ≤ 10, 15 ≤ k ≤ 15, 21 ≤ l ≤ 21  
Reflections collected 15258  
Independent reflections 2060[Rint = 0.1237]  
Data/restraints/parameters 2060/0/229  
Goodness-of-fit on F
2
 1.038  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0516, wR2 = 0.0938  
Final R indexes [all data] R1 = 0.0846, wR2 = 0.1050  
Largest diff. peak/hole / e Å
3
 0.20/0.25  
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9.2.3  Alkaloids from Alstonia angustifolia 
 
9.2.3.1  (7S)-N(1)-Demethylalstonoxine B (143) 
 
 
(7S)-N(1)-Demethylalstonoxine B (143) is a new ring-opened macroline 
oxindole alkaloid isolated from the leaf extract of Alstonia angustifolia. The structure 
and relative configuration were established by 2D NMR techniques. The NMR data 
however, were insufficient to establish the stereochemistry of C-19 and for this purpose, 
an X-ray diffraction analysis was carried out. Suitable crystals of 143 were obtained 
from the slow evaporation of 143 in CH2Cl2/hexanes solution.  From the crystal 
structure, it can be seen that alkaloid 143 co-crystallized with the solvent (CHCl3). It 
can also be seen that an intramolecular hydrogen bond was formed between C-17OH 
and N-4 lone pair (Figure 9.19). The crystal data and structure refinement parameters 
are summarized in Table 9.19. 
 
                                                             
                                                            Figure 9.19. X-ray crystal structure of 143. 
                                                             [Flack parameter:
63
 x = 0.07(0.08);  
                                                               Hooft parameter:
64
 y = 0.06(0.06)]. 
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Table 9.19. Crystal data and structure refinement parameters of (7S)-N(1)- 
demethylalstonoxine B (143) 
Empirical formula C19H25N2O3Cl3 
Molecular formula C18H24N2O3.CHCl3 
Molecular weight, Mr 340.45 
Melting point 110112 oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Orthorhombic  
Space group P212121  
a 9.7811(7) Å 
b 12.2584(8) Å  
c 17.0772(13) Å 
 90.00°  
 90.00°  
 90.00°  
Volume, V 2047.6(3) Å
3
  
No. of molecule per unit cell, Z 4  
Density (calcd) 1.414 mg/mm
3
 
F(000) 912.0  
Crystal size 0.36 × 0.26 × 0.16 mm 
2range for data collection 4.1 to 52.88°  
Index ranges 12 ≤ h ≤ 12, 15 ≤ k ≤ 15, 21 ≤ l ≤ 21  
Reflections collected 17212  
Independent reflections 4207[Rint = 0.0998]  
Data/restraints/parameters 4207/0/251  
Goodness-of-fit on F
2
 1.038  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0487, wR2 = 0.1142  
Final R indexes [all data] R1 = 0.0672, wR2 = 0.1253  
Largest diff. peak/hole / e Å
3
 0.32/0.40  
Flack parameter, x 0.07(0.08) 
Hooft parameter, y 0.06(0.06) 
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9.2.3.2  (7S)-Alstoumerine oxindole 
 
(7S)-Alstoumerine oxindole (144) is a new oxindole of the sarpagine type 
alkaloid isolated from stem-bark extract of Alstonia angustifolia. As with alkaloid 143, 
the NMR experimental results were insufficient to establish the relative stereochemistry 
of C-19. Since alkaloid 144 readily crystallized from CH2Cl2/hexanes solution, an X-ray 
diffraction analysis was carried out which reveals the structure and relative 
configuration of alkaloid 144. From the crystal structure, it can be seen that a water 
molecule had been incorporated into the crystal lattice, and the water molecule formed 
hydrogen bond with the N-4 lone pair. The structure of 144 is shown in Figure 9.20, 
while the crystal data and structure refinement parameters are summarized in Table 
9.20. 
                                                                       
 
          Figure 9.20. X-ray crystal structure of 144. 
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Table 9.20. Crystal data and structure refinement parameters of (7S)-alstoumerine 
oxindole (144) 
Empirical formula C20H26N2O4 
Molecular formula C20H24N2O3.H2O 
Molecular weight, Mr 358.43 
Melting point > 160 °C dec 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Orthorhombic  
Space group P21212 
a 11.5360(2) Å 
b 19.2745(3) Å 
c 8.11190(10) Å 
 90.00
o
  
 90.00
o
 
 90.00
o
 
Volume, V 1803.69(5) Å
3 
No. of molecule per unit cell, Z 4  
Density (calcd) 1.320 mg/mm
3
 
F(000) 768.0  
Crystal size 0.22 × 0.16 × 0.05 mm 
2range for data collection 4.12 to 52.78°  
Index ranges 14 ≤ h ≤ 14, 23 ≤ k ≤ 24, 10 ≤ l ≤ 10  
Reflections collected 13706  
Independent reflections 3699[Rint = 0.0618]  
Data/restraints/parameters 3699/0/247  
Goodness-of-fit on F
2
 0.993  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0444, wR2 = 0.0815  
Final R indexes [all data] R1 = 0.0670, wR2 = 0.0912  
Largest diff. peak/hole / e Å
3
 0.19/0.19 
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9.2.4  Alkaloids from Leuconotis griffithii 
 
9.2.4.1 Leuconodines B and E 
 
 
The alkaloids leuconodines B (68) and E (71) are new leuconoxine-type 
alkaloids isolated from the stem-bark extract of L.griffithii.  
 
 
 
Crystals of 68 were obtained from the slow evaporation of 68 in CH2Cl2/MeOH 
solution. From the crystal structure, it can be seen that a MeOH molecule has been 
incorporated into the crystal lattice. The structure of 68 is shown in Figure 9.21, while 
the crystal data and structure refinement parameters are summarized in Table 9.21. 
 
 
Figure 9.21. X-ray crystal structure of 68. 
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Table 9.21. Crystal data and structure refinement parameters of leuconodine B (68) 
Empirical formula C20H26N2O4   
Molecular formula C19H22N2O3.CH3OH 
Molecular weight, Mr 358.43 
Melting point 198200 °C 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Orthorhombic  
Space group P212121  
a 8.0382(5) Å 
b 14.5281(9) Å 
c 15.2187(8) Å 
 90.00°  
 90.00°  
 90.00°  
Volume, V 1777.24(18) Å
3
 
No. of molecule per unit cell, Z 4  
Density (calcd) 1.340 mg/mm
3
 
F(000) 768.0  
Crystal size 0.17 × 0.15 × 0.04 mm 
2range for data collection 3.88 to 52.88°  
Index ranges 10 ≤ h ≤ 10, 18 ≤ k ≤ 18, 18 ≤ l ≤ 18  
Reflections collected 12249  
Independent reflections 2090[Rint = 0.1043]  
Data/restraints/parameters 2090/0/240  
Goodness-of-fit on F
2
 1.008  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0491, wR2 = 0.0988  
Final R indexes [all data] R1 = 0.0801, wR2 = 0.1091  
Largest diff. peak/hole / e Å
3
 0.290.23  
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Crystals of 71 were obtained from the slow evaporation of 71 in CH2Cl2/MeOH 
solution. The structure of 71 is shown in Figure 9.22, while the crystal data and 
structure refinement parameters are summarized in Table 9.22. 
 
 
 
 
Figure 9.22. X-ray crystal structure of 71. 
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Table 9.22. Crystal data and and structure refinement parameters of leuconodine E (71) 
Empirical formula C19H24N2O2  
Molecular formula C19H24N2O2  
Molecular weight, Mr 312.40  
Melting point > 230 °C dec 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Orthorhombic  
Space group P212121  
a 8.1326(7) Å  
b 10.6116(9) Å  
c 18.2366(17) Å  
α 90.00  
β 90.00  
γ 90.00  
Volume, V 1573.8(2) Å
3 
No. of molecule per unit cell, Z 4  
Density (calcd) 1.318 mg/mm
3
 
F(000) 672.0  
Crystal size 0.801 × 0.169 × 0.03  
2range for data collection 4.44 to 46.72°  
Index ranges 9 ≤ h ≤ 8, 11 ≤ k ≤ 11,20 ≤ l ≤ 20  
Reflections collected 9956  
Independent reflections 1332[Rint = 0.0872]  
Data/restraints/parameters 1332/0/210  
Goodness-of-fit on F
2
 1.082  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0403, wR2 = 0.0858  
Final R indexes [all data] R1 = 0.0654, wR2 = 0.0966  
Largest diff. peak/hole / e Å
3
 0.17/0.25  
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9.2.4.2 nor-Rhazinicine 
 
 
nor-Rhazinicine (73) is a new alkaloid isolated from the stem-bark extract of 
Leuconotis griffithii. Suitable crystals of 73 were obtained from the slow evaporation of 
73 in CH2Cl2/MeOH solution. The structure of 73 is shown in Figure 9.23, while the 
crystal data and structure refinement parameters are summarized in Table 9.23. 
 
 
 
 
 
 
 
Figure 9.23. X-ray crystal structure of 73. 
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Table 9.23. Crystal data and structure refinement parameters of nor-rhazinicine (73) 
Empirical formula C18H18N2O2  
Molecular formula C18H18N2O2 
Molecular weight, Mr 294.34 
Melting point 190192 °C 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Monoclinic  
Space group P21  
a 13.646(3) Å 
b 8.3619(17) Å 
c 14.658(3) Å 
 90.00°  
 115.775(11)°  
 90.00°  
Volume, V 1506.2(5) Å
3
 
No. of molecule per unit cell, Z 4  
Density (calcd) 1.298 mg/mm
3
 
F(000) 624.0  
Crystal size 0.52 × 0.32 × 0.05  
2range for data collection 3.08 to 60.26°  
Index ranges 18 ≤ h ≤ 18, 11 ≤ k ≤ 7, 20 ≤ l ≤ 20  
Reflections collected 7175  
Independent reflections 4095[Rint = 0.1347]  
Data/restraints/parameters 4095/1/399  
Goodness-of-fit on F
2
 1.107  
Final R indexes [I ≥ 2σ (I)] R1 = 0.1262, wR2 = 0.3258  
Final R indexes [all data] R1 = 0.1574, wR2 = 0.3522  
Largest diff. peak/hole / e Å
3
 0.84/0.74  
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CHAPTER TEN 
Experimental 
 
10.1 General 
 
Melting points were determined on a Mel-Temp melting point apparatus and 
were uncorrected. Optical rotations were determined on a JASCO P-1020 digital 
polarimeter. IR spectra were recorded on a Perkin-Elmer Spectrum 400 
spectrophotometer or on a Perkin-Elmer 1600 Series FT-IR spectrophotometer. UV 
spectra were obtained on a Shimadzu UV-3101PC. ESIMS and HRESIMS were 
obtained on an Agilent 6530 Q-TOF mass spectrometer. EIMS and HRLSIMS were 
obtained at Organic Mass Spectrometry, Central Science Laboratory, University of 
Tasmania, Tasmania, Australia. GC-EIMS was obtained on a Shimadzu GCMS-
QP2010 Plus mass spectrometer. All air/moisture-sensitive reactions were carried out 
under N2 in oven-dried glassware. THF was freshly distilled from Na/benzophenone 
under nitrogen while, CH2Cl2 and pyridine were distilled from CaH2 under nitrogen. All 
other reagents were used without further purification. 
 
10.2 NMR Spectroscopy 
 
1
H, 
13
C, and 2D NMR spectra were recorded at 
1
H resonance frequency of either 
400 MHz (JEOL JNM-LA 400, JNM-ECA 400, or Bruker Avance III 400 
spectrometers) or 600 MHz (Bruker Avance III 600 spectrometer). The deuterium 
signals from CDCl3, CD2Cl2, or THF-d8 were used for the field frequency lock. All 
experiments were performed at room temperature (ca. 22 
o
C) unless otherwise stated. 
The chemical shifts were expressed in (ppm) downfield from TMS and all J values 
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were given in Hz. The multiplicity of each signal was denoted as follows: s - singlet, d - 
doublet, t - triplet, q - quartet, m - multiplet, br - broad. 
 
10.3 Single Crystal X-ray Diffraction 
 
X-ray diffraction analyses were carried out on a Bruker SMART APEX II CCD 
area detector system equipped with a graphite monochromator and a Mo K fine-focus 
sealed tube (= 0.71073 Å), or on an Agilent Technologies SuperNova Dual CCD area 
detector system equipped with mirror monochromator and a SuperNova (Cu K) X-ray 
source (= 1.50352 Å).  
Suitable crystals were obtained mainly from slow evaporation in various solvent 
systems. The crystals were observed under a microscope with a polarizer attached. A 
single crystal was chosen based on the shape (does not contain deformity), size (more 
than 0.1 x 0.1 x 0.1 mm in dimension), and the ability to transmit and extinguish 
polarized light completely. The crystal was then fixed with an adhesive 
(perfluoropolyether oil) onto a glass fibre that is in turn glued into a ‘copper pip’ that 
fits into the well at the top of the goniometer head.  
The goniometer head was then attached to the  circle of the diffractometer. The 
crystal was optically adjusted so that its center does not move when it was rotated. A 
stream of N2 gas cooled to  was used for low temperature diffraction experiments. 
The diffraction experiment was carried out with full-sphere data collection ( scan).  
The structures were solved by direct methods (SHELXS-97) and refined with 
full-matrix least-squares on F
2
 (SHELXL-97). All non-hydrogen atoms were refined 
anisotropically and all hydrogen atoms were placed in idealized positions and refined as 
riding atoms with the relative isotropic parameters. The absolute structures were 
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determined by refinement of the Flack parameter
63
 and computation of the Hooft 
parameter.
64
 
 
10.4 Chromatographic Methods 
 
10.4.1 Normal phase chromatography 
 
 Thin layer chromatography was carried out using precoated 5 x 10 cm aluminium 
plates, 0.25 mm thickness, silica gel 60 F254 (Merck 5554). Column chromatography 
was performed using silica gel (Merck 9385, 230-400 Mesh ASTM). The ratio of silica 
gel to sample was approximately 30:1 for crude samples, and 100:1 for semi-pure 
fractions. The gel was made into a slurry with chloroform before it was packed onto a 
column and allowed to equilibrate for at least an hour before use. Centrifugal 
preparative TLC was carried out using a chromatotron (Harrison Research) with 1 mm 
thick plates 24 cm diameter of silica gel PF 254 (Merck 7749). The plate was prepared 
as follows. A long piece of cellophane tape was secured around the edge of the plate to 
form a mould. Silica gel (50 g) was added to about 100 ml of cold water and the slurry 
formed was poured onto the circular glass plate. The circular glass plate was rotated 
while the gel was being poured to obtain an even setting. The plate was then left to air 
dry for about an hour before being dried in an oven at 80 
o
C for about 12 hours. The 
sample was dissolved in a minimum volume of suitable solvent and loaded at the center 
of the plate while the plate was rotating to form a thin band. Elution was then carried out 
with the appropriate solvent system.  
Some of the solvent systems used were Et2O, Et2O:hexanes, Et2O:MeOH, 
CH2Cl2, CH2Cl2:MeOH, CH2Cl2:hexanes, CH2Cl2:MeOH, CHCl3, CHCl3:hexanes, 
275 
 
CHCl3:MeOH, EtOAc:hexanes. In many instances, the solvents were saturated with 
NH3 prior to use.  
 
10.4.2 Gel permeation chromatography 
 
Gel permeation chromatography was carried out using Sephadex G-75 (Aldrich). 
The gel was equilibrated (swelled) in excess MeOH at rt for 3 hours. It was then made 
into a slurry via stirring, poured into a column (100 x 3 cm), and allowed to equilibrate 
for at least a day. Samples were dissolved in a minimum amount of MeOH, filtered with 
nylon membrane (0.42 m) prior to loading into the column. After the chromatography 
the column was regenerated by eluting with MeOH (three times the column volume).  
 
10.4.3 Chiral phase high performance liquid chromatography 
 
Chiral phase HPLC analysis and separation were performed using a system 
comprising a Waters 600 controller, a Waters 600 pump, and a Waters 2489 variable-
wavelength absorbance detector. The column used was a Chiralpak AD-H (4.6 x 150 
mm), Daicel, Japan, packed with amylose tris (3,5-dimethylphenylcarbamate) coated on 
5 μm silica gel. The mobile phase used for the analysis and separation, was n-
hexane/EtOH/diethylamine (DEA, 85:15:0.2), with a ﬂow rate of 0.8 ml/min. 
 
 
 
 
 
 
276 
 
10.5  Dragendorff’s Reagent 
 
 Solution A: 0.85 g of bismuth nitrate was dissolved in a mixture of 10 ml glacial 
acetic acid and 40 ml of distilled water. 
 
Solution B: 8 g of potassium iodide was dissolved into 20 ml of distilled water.  
 
 A stock solution was prepared by mixing equal volumes of solutions A and B. 
Dragendorff’s reagent was prepared by mixing 1 ml of stock solution with 2 ml of 
glacial acetic acid and 10 ml of distilled water. Orange spots on the developed TLC 
plates indicated the presence of alkaloids.  
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10.6 Chapter 2 
 
10.6.1 Isolation and compound data of mersiphyllines A (37) and B (38) 
 
The fractions containing alkaloids 37 and 38 obtained from the initial normal phase 
chromatography of the basic fraction from the leaf extract of K. singapurensis
 
were 
pooled.
28
 This pooled fraction was then further purified by repeated gel permeation 
chromatography (Sephadex G-75, MeOH as mobile phase), to give mersiphylline A (37) 
and mersiphylline B (38). 
 
Mersiphylline A (37): colorless oil and subsequently as colorless block crystals from 
EtOH; mp 184186 C; []25D 59 (c 0.43, CHCl3); UV (EtOH) max (log ) 219 (4.21), 
245 (3.79), and 287 (3.16) nm; IR (dry film) max 3463, 1746, and 1717 cm
1
; For 
1
H 
and 
13
C NMR data, see Table 2.1; EIMS m/z (rel. int.) 486 [M]

 (43), 442 (100), 441 
(88), 427 (37), 409 (29), 381 (48), 355 (22), 327 (20), 295 (15), 260 (10), 204 (26), and 
158 (42); HREIMS m/z [M]
 
486.1629 (calcd for C24H26N2O9, 486.1638). 
 
Crystallographic data of mersiphylline A (37): crystal data and structure refinement 
parameters of 37 are summarized in Table 10.1. 
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Table 10.1. Crystal data and structure refinement parameters of mersiphylline A (37) 
Empirical formula C26H32N2O10 
Molecular formula C24H26N2O9.C2H5OH 
Molecular weight, Mr 532.54 
Melting point 184186 oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Orthorhombic 
Space group P212121 
a 10.8951(5) Å 
b 14.6956(7) Å 
c 15.0936(7) Å 
α 90.00° 
β 90.00° 
γ 90.00° 
Volume, V 2416.6(2) Å
3
 
No. of molecule per unit cell, Z 4 
Density (calcd) 1.464 mg/mm
3
 
F(000) 1128 
Crystal size 0.30 × 0.15 × 0.10 mm 
2range for data collection 3.86 to 61° 
Index ranges 15 ≤ h ≤ 5, 20 ≤ k ≤ 19, 20 ≤ l ≤ 19 
Reflections collected 13836 
Independent reflections 3969[Rint = 0.0446] 
Data/restraints/parameters 3969/0/348 
Goodness-of-fit on F
2
 1.026 
Final R indexes [I ≥ 2σ (I)] R1 = 0.0426, wR2 = 0.0931 
Final R indexes [all data] R1 = 0.0556, wR2 = 0.0988 
Largest diff. peak/hole / e Å
3
 0.347/0.262 
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Mersiphylline B (38): colorless oil; []25D –58 (c 0.04, CHCl3); UV (EtOH) max (log 
) 212 (3.84), 245 (3.22), and 287 (2.90) nm; IR (dry film) max 3427, 1744, and 1711 
cm
–1
; For 
1
H and 
13
C NMR data, see Table 2.1; EIMS m/z (rel. int.) 472 [M]
+
 (73), 441 
(18), 428 [M – CO2]

 (100), 427 [M – CO2H]
+
 (91), 413 (98), 395 (18), 381 (59), 367 
(55), 351 (13), 335 (23), and 299 (21); HREIMS m/z 472.1836 [M]
 
(calcd for 
C24H28N2O8, 472.1846). 
 
10.6.2 Esterification of mersiphylline A (38) 
 
To a solution of 38 (11 mg, 0.023 mmol) in anhydrous benzene (4 ml) was added 113 l 
of TMS-diazomethane (0.22 mmol, 2 M in hexanes). The solution was stirred at rt for 
12 h and concentrated in vacuo. The crude mixture was purified via passage through a 
short pad of silica gel. The 
1
H NMR spectrum of the crude product showed the absence 
of the characteristic deshielded COOH peak at ca. H 16 ppm, indicating that the 
esterification reaction was complete.  
 
10.6.3 Formation of the alkaloid-borane complex 40 
 
BH3-THF (28 l, 1 M in THF) was added to 40 (7 mg, 0.0014 mmol) in THF at 0 

C 
and the mixture was stirred for 5 h, after which a further 28 l (1 M in THF) BH3.THF 
solution was added, and the mixture stirred for another 1 h at 0 

C. Removal of the 
solvent in vacuo, followed by centrifugal preparative TLC (SiO2, 5% MeOH:Et2O) gave 
40 (6 mg, 84%; direct workup without H2O or MeOH quenching gave the best yield of 
40) as a colorless oil: []25D –58 (c 0.04, CHCl3); UV (EtOH) max (log ) 219 (4.78), 
243 (4.24), and 289 (3.67) nm; IR (dry film) max 3480 (OH), 2432, 2376, and 2285 
(BH2), 1748 (C=O,  ester), 1704 (C=O, carbamate), and 1694 (C=O, borane ester) cm
–1
; 
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For 
1
H and 
13
C NMR data, see Table 2.1; EIMS m/z (rel. int.) 498 [M]
+
 (35), 496 (16), 
441 (100), 409 (33), 381 (49), 323 (25), 204 (18), 158 (26), and 44 (63); HREIMS m/z 
498.1780 [M]
+
 (calcd for C24H27N2O9
11
B, 498.1804), m/z 496.1754 [M  H] (calcd for 
C24H26N2O9
10
B, 496.1762). 
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10.7 Chapter 3 
 
10.7.1 Compound data of lirofolines A (44) and B (45) 
 
Lirofoline A (44): colorless oil; []25D 41 (c 1.36, CHCl3); UV (EtOH) max (log ) 
216 (4.29), 258 (4.08), 280 (3.94), and 309 (3.96) nm; IR (dry film) max 1651 (C=O) 
cm
1
; For 
1
H and 
13
C NMR data, see Table 3.1; EIMS m/z (rel int) 324 [M]

 (100), 295 
[M CHO or M  CH2CH3]

 (20), 280 (56), 267 (10), 253 (20), 248 (19), 224 (9), 135 
(37), and 122 (13); HREIMS found m/z 324.1837 [M]

 (calcd for C20H24N2O2, 
324.1838). 
 
Lirofoline B (45): colorless oil; []25D 17 (c 0.08, CHCl3); UV (EtOH) max (log ) 
218 (4.31), 256 (4.09), 278 (3.92), and 308 (3.95) nm; IR (dry film) max 3407 (OH) and 
1651 (C=O) cm
1
; For
 1
H and 
13
C NMR data, see Table 3.1; FABMS m/z 355 [M  H]; 
HRFABMS found m/z 355.2018 [M  H] (calcd for C21H26N2O3  H, 355.2022). 
 
10.7.2 Compound data of ibogaine (46) 
  
The starting material for the transformation, ibogaine (46) was obtained from T. 
corymbosa and T. divaricata from previous alkaloid studies.
39,42 
 
Ibogaine (46): light yellowish oil; []25D 53 (c 0.10, CHCl3); UV (EtOH) max (log ) 
229 (4.48), 287 (4.24), and 296 (4.26) nm; IR (dry film) max 3402 cm
1
; For 
1
H NMR 
and 
13
C NMR data, see Table 3.2; ESIMS m/z 311 [M H] (C20H26N2O  H). 
 
 
282 
 
10.7.3 Oxidation of ibogaine (46) to ibogaine N-oxide (50) 
 
To a solution of 46 (50 mg, 0.18 mmol) in CH2Cl2 (10 ml) was added m-CPBA (37 mg, 
0.22 mmol), and the mixture was stirred for 30 min at 0 
o
C. The mixture was quenched 
with 1 M Na2CO3 (10 ml), extracted with CH2Cl2 (3 x 20 ml), and the combined CH2Cl2 
extracts were then washed with water, dried (Na2SO4), the solvent evaporated, and the 
residue purified by centrifugal preparative TLC (SiO2, 25% MeOH:CHCl3, NH3-
saturated) to give ibogaine N-oxide (50) (44 mg, 83%) as light yellowish oil; []25D  
(c 0.16, CHCl3); UV (EtOH) max (log ) 210 (4.00), 224 (3.98), 280 (3.58),  297 (3.50), 
and 307 (3.32) nm; IR (dry film) max 3149 cm
1
, For 
1
H and 
13
C NMR data, see Table 
3.2; ESIMS m/z 327 [M  H]; HRESIMS m/z 327.2080 [M  H] (calcd for 
C20H26N2O2  H, 327.2073). 
 
10.7.4 Formation of alcohol 51 via Polonovski transformation 
 
To a stirred solution of 50 (12 mg, 0.037 mmol) in 50 ml of CH2Cl2, was added acetic 
anhydride at 10 oC. After stirring for 15 min, the mixture was quenched with 10% 
NaOH (15 ml) and extracted with CH2Cl2 (3 x 20 ml). The combined organic phase was 
dried (Na2SO4), the solvent evaporated, and the residue was purified with a short pad of 
silica gel, eluting with CH2Cl2 to give alcohol 51 (8.2 mg, 70%). Only 
1
H NMR and 
ESIMS were carried out on the alcohol, due to instability of 51. Alcohol 51: light 
yellowish oil; 
1
H NMR (400 MHz, CDCl3) 7.10 (1H, d, J = 8.9 Hz), 7.09 (1H, d, J = 
2.3 Hz), 6.80 (1H, dd, J = 8.9, 2.3 Hz), 4.88 (1H, d, J = 11.4), 4.78 (1H, d, J = 11.4 Hz), 
3.86 (3H, s), 3.94 (2H, s), 3.19 (1H, dt, J = 10, 3 Hz), 3.15 (1H, br dt, J = 12, 2.2 Hz), 
2.79 (1H, dt, J = 10, 2 Hz), 2.74 (1H, br s), 2.07 (1H, br t, J = 12 Hz), 1.86 (1H, m), 
1.76 (1H, m), 1.69 (1H, m), 1.58 (2H, m), 1.56 (1H, m), 1.52 (1H, m), 0.94 (3H, t, J = 
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7.3 Hz). ESIMS m/z 327 [M  H]; HRESIMS m/z [M  H] 327.2077 (calcd for 
C20H26N2O2  H, 327.2067). 
 
10.7.5 Attempted oxidation of alcohol 51 to lirofoline A (44) via Dess-Martin 
periodinane (DMP) oxidation 
 
A solution of the alcohol 51 (5 mg, 0.015 mmol) in CH2Cl2 (4 ml) was treated with 
DMP reagent (50 l, 0.3 M in CH2Cl2) at rt. TLC of the reaction mixture showed no 
definitive products, although the starting material had been consumed.  
 
10.7.6 Oxidation of alcohol 51 to lirofoline A via Ley oxidation 
 
To a stirred suspension of the alcohol 51 (7 mg, 2.65 mmol), 4-methylmorpholine-N-
oxide (542 mg, 46.3 mmol), and 4 Å molecular sieves (1.54 g, 500 mg/mmol) in 
CH2Cl2:MeCN 1:1 (5 ml) was added tetrapropylammonium perruthenate (TPAP, 54 
mg, 0.154 mmol). The mixture was stirred for 20 h at rt, filtered through a pad of Celite, 
the solvent removed in vacuo, and the residue was purified by centrifugal preparative 
TLC (SiO2, Et2O, NH3-saturated) to give lirofoline A (44) (2.1 mg, 30% yield). The 
spectroscopic (
1
H and 
13
C NMR, IR, UV) and other data ([D and Rf of TLC in 
different solvent systems) of semisynthetic lirofoline A (44) were indistinguishable 
from those of the natural lirofoline A (44).
39 
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10.8 Chapter 4 
 
10.8.1 Isolation and compound data of leuconolam (54) 
 
The fractions containing leuconolam (54), obtained from initial normal phase 
chromatography of the basic fraction from the stem-bark extract of L. griffithii, were 
pooled. This pooled fraction was then further purified by repeated normal phase 
chromatography, to give leuconolam (54). 
 
Leuconolam (54): colorless block crystals from MeOH; mp 178180 oC [lit49 263264 
o
C]; []25D 303 (c 0.75, CHCl3) [lit
49
 []D  28.3 (c 0.7 CHCl3)]; UV (EtOH) max (log 
) 205 (4.00), 220 (3.22), and 292 (3.96) nm; IR (dry film) max 3263, 1683, and 1650 
cm
1
; For 
1
H and 
13
C NMR data, see Tables 4.4 and 4.5, respectively; ESIMS m/z 327 
[M  H] (C19H22N2O3  H). 
 
Crystallographic data of alkaloid 54: crystal data and structure refinement parameters of 
54 are summarized in Table 10.2. 
 
 
 
 
 
 
 
 
 
285 
 
Table 10.2. Crystal data and structure refinement parameters of leuconolam (54) 
Empirical formula C20H26N2O4  
Molecular formula C19H22N2O3.CH3OH 
Molecular weight, Mr 358.43 
Melting point 178180 oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Orthorhombic 
Space group P212121 
a 8.1821(6) Å 
b 10.9066(8) Å 
c 19.9093(15) Å 
α 90.00°  
β 90.00°  
γ 90.00° 
Volume, V 1776.7(2) Å
3
 
No. of molecule per unit cell, Z 4  
Density (calcd) 1.340 mg/mm
3
 
Crystal size 0.43 × 0.32 × 0.25 mm 
2range for data collection 4.1 to 61.78°  
Index ranges 7 ≤ h ≤ 11, 11 ≤ k ≤ 12, 27 ≤ l ≤ 27  
Reflections collected 4213  
Independent reflections 2363[Rint = 0.0529]  
Data/restraints/parameters 2363/0/243  
Goodness-of-fit on F
2
 1.001  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0389, wR2 = 0.0961  
Final R indexes [all data] R1 = 0.0433, wR2 = 0.0991  
Largest diff. peak/hole / e Å
3
 0.29/0.24  
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10.8.2 Reaction of leuconolam (54) with NaHMDS 
 
 
To a stirred solution of 54 (11.1 mg, 0.034 mmol) in THF (5 ml) was added dropwise 
NaHMDS (34 l, 1 M) and the mixture was stirred at 0 oC. TLC analysis of the mixture 
over a period of 15 h showed only the presence of starting material. 
 
10.8.3 Reaction of leuconolam (54) with NaOMe 
 
To a solution of 54 (18 mg, 0.055 mmol) in MeOH (3 ml) was added a freshly prepared 
solution of Na (2.8 mg, 0.121 mmol) in 1 ml MeOH at 0 

C. TLC of the reaction 
mixture (in a period of 16 h) showed only the presence of 54. 
 
10.8.4 Reaction of leuconolam (54) with KOH/MeOH/EtOH 
 
 
Leuconolam (54) (50 mg, 0.15 mmol) was dissolved in methanolic ethanol (9:1, 50 ml). 
Two pellets of KOH were then added and the solution was stirred at rt for 6 h, quenched 
with 5% HCl (20 ml), and basified with 10% NaHCO3 (30 ml). The mixture was then 
extracted with CH2Cl2 (4 x 100 ml), washed with water, dried (Na2SO4), concentrated in 
vacuo, and the residue purified by centrifugal preparative TLC (SiO2, 10% MeOHEt2O, 
NH3-saturated) to give 74 (6 mg, 12%) and 76 (1.5 mg, 3%) and recovered 54 (10 mg, 
20%).  
 
Compound 74: colorless oil and subsequently as colorless block crystals from 
CCl4/MeOH; mp 266268 
o
C [lit
49
 175177 
o
C]; []25D 198 (c 0.06, CHCl3) [lit
49
 []D 
14.3 (c 0.35, CHCl3)]; UV (EtOH) max (log ) 210  (4.50), 253 (4.01), and 287 (3.38) 
nm; IR (dry film) max 3226 and 1667 cm
1
; For 
1
H and 
13
C NMR data, see Table  4.1; 
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ESIMS m/z 327 [M  H]; HRESIMS m/z 327.1712 [M  H] (calcd for C19H22N2O3  
H, 327.1703). 
 
Crystallographic data of compound 74: crystal data and structure refinement parameters 
of 74 are summarized in Table 10.3.  
 
Table 10.3. Crystal data and structure refinement parameters of compound 74 
Empirical formula C19H22N2O3 
Molecular formula C19H22N2O3 
Molecular weight, Mr 326.39 
Melting point 266 oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Triclinic  
Space group P1  
a 10.1848(2) Å  
b 10.3617(2) Å  
c 10.3845(2) Å  
α 71.7420(10)°  
β 67.3790(10)°  
γ 60.6480(10)°  
Volume, V 871.06(3) Å
3 
No. of molecule per unit cell, Z 2  
Density (calcd) 1.244 mg/mm
3
 
F(000) 348.0  
Crystal size 0.62 × 0.21 × 0.10 mm 
2range for data collection 4.3 to 55°  
Index ranges 13 ≤ h ≤ 13, 13 ≤ k ≤ 13, 13 ≤ l ≤ 13  
Reflections collected 8035  
Independent reflections 3993[Rint = 0.0509]  
Data/restraints/parameters 3993/3/488  
Goodness-of-fit on F
2
 1.020  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0486, wR2 = 0.1257  
Final R indexes [all data] R1 = 0.0531, wR2 = 0.1287  
Largest diff. peak/hole / e Å
3
 1.27/0.27  
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Compound 76: colorless oil and subsequently as colorless block crystals from MeOH: 
mp 250252 oC; []25D = 150 (c 0.01, CHCl3); UV (EtOH) max (log ) 210  (4.46), 
251 (4.22), and 306 (3.00) nm; IR (dry film) max 3322, 1712, and 1681 cm
1
; For 
1
H 
and 
13
C NMR data, see Table 4.1; ESIMS m/z 327 [M  H]; HRESIMS m/z 327.1710 
[M  H] (calcd for C19H22N2O3
  H, 327.1703). 
 
Crystallographic data of 76: crystal data and structure refinement parameters of 76 are 
summarized in Table 10.4. 
 
Table 10.4. Crystal data and structure refinement parameters of compound 76 
Empirical formula C19H22N2O3 
Molecular formula C19H22N2O3 
Molecular weight, Mr 326.39 
Melting point 250 oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Orthorhombic  
Space group P212121  
a 9.6652(5) Å 
b 16.1799(9) Å  
c 21.1959(11) Å  
 90.00°  
 90.00°  
 90.00°  
Volume, V 3314.7(3) Å
3 
No. of molecule per unit cell, Z 8  
Density (calcd) 1.308 mg/mm
3
 
F(000) 1392.0  
Crystal size 0.31 × 0.27 × 0.15 mm 
2range for data collection 3.16 to 61.26°  
Index ranges 13 ≤ h ≤ 13, 23 ≤ k ≤ 22, 29 ≤ l ≤ 30  
Reflections collected 36904  
Independent reflections 5465[Rint = 0.0352]  
Data/restraints/parameters 5465/0/445  
Goodness-of-fit on F
2
 1.013  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0356, wR2 = 0.0877  
Final R indexes [all data] R1 = 0.0409, wR2 = 0.0905  
Largest diff. peak/hole / e Å
3
 0.33/0.20  
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10.8.5 Reaction of leuconolam (54) with 5% HCl  
  
To a stirred solution of 5% HCl (5 ml) was added 54 (11 mg, 0.034 mmol). The mixture 
was stirred for 12 h at rt. The mixture was quenched with 10% Na2CO3 (10 ml), 
extracted with CH2Cl2 (3 x 10 ml), washed with water (3 x 20 ml), dried (Na2SO4), and 
concentrated in vacuo. TLC of the residue showed only the presence of 54 (8.9 mg, 81% 
recovery).    
 
10.8.6 Reaction of leuconolam (54) with 5% HCl/CH2Cl2 in the presence of 
tetraethylammonium chloride (TEACl) 
 
Leuconolam (54) (14.5 mg, 0.044 mmol) was added into a two-phase system 
comprising 5% HCl (5 ml), CH2Cl2 (5 ml), and TEACl (7 mg, 0.044 mmol). The 
mixture was stirred for 12 h at rt, quenched with 10% Na2CO3 (10 ml), and extracted 
with CH2Cl2 (3 x 5 ml). The combined organic extract was then washed with water (3 x 
20 ml), dried (Na2SO4), concentrated in vacuo, and the residue purified by centrifugal 
preparative TLC (SiO2, 5% MeOHEt2O, NH3-saturated) to give 6,7-
dehydroleuconoxine (63) (6.5 mg, 47%), amino lactam-lactone 78 (0.2 mg, 1.4%) and 
recovered 54 (5.1 mg, 35%). 
 
6,7-Dehydroleuconoxine (63): colorless block crystals from CH2Cl2/hexanes; mp 
164168 oC; []25D  271 (c 0.11, CHCl3); UV (EtOH) max (log ) 203 (4.32), 252 
(4.33), and 350 (3.70) nm; IR (dry film) max 1691, 1649, and 1595 cm
1
; For 
1
H and 
13
C NMR data, see Tables 4.4 and 4.5, respectively; ESIMS m/z 309 [M  H]; 
HRESIMS m/z 309.1590 [M  H] (calcd for C19H20N2O2  H, 309.1598); GC-EIMS 
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m/z (rel int) 308 [M]

 (74), 279 [M  CH2CH3]

 (100), 251 (58), 237 (20), 223 (28), 209 
(15), 184 (10), 171 (18), 156 (32), 142 (8), and 129 (18). 
 
Crystallographic data of 63: crystal data and structure refinement parameters of 63 are 
summarized in Table 10.5. 
 
Table 10.5. Crystal data and structure refinement parameters of 6,7-
dehydroleuconoxine (63) 
Empirical formula C19H20N2O2 
Molecular formula C19H20N2O2 
Molecular weight, Mr 308.38 
Melting point 164168 oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Orthorhombic  
Space group P212121  
a 8.8855(4) Å 
b 11.3940(5) Å 
c 14.8635(7) Å 
 90°  
 90°  
 90° 
Volume, V 1504.80(12) Å
3
  
No. of molecule per unit cell, Z 4  
Density (calcd) 1.3611 mg/mm
3
 
F(000) 656.3  
Crystal size 0.48 × 0.34 × 0.26 mm 
2range for data collection 4.5 to 61.2°  
Index ranges 0 ≤ h ≤ 12, 0 ≤ k ≤ 15, 0 ≤ l ≤ 21  
Reflections collected 2554  
Independent reflections 2554[Rint = 0.0000]  
Data/restraints/parameters 2554/0/208  
Goodness-of-fit on F
2
 1.042  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0374, wR2 = 0.0929  
Final R indexes [all data] R1 = 0.0433, wR2 = 0.0968  
Largest diff. peak/hole / e Å
3
 0.29/0.26  
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Amino lactam-lactone 78: yellowish oil and subsequently as yellowish block crystals 
from CH2Cl2/hexanes; mp 179182 
o
C; []25D 116 (c 0.52, CHCl3); UV (EtOH) max 
(log ) 212 (4.87), 240 (4.83), and 342 (4.01) nm; IR (dry film) max 3483, 3397, 1743, 
and 1709 cm
1
; For 
1
H and 
13
C NMR data, see Table 4.6; EIMS m/z (rel. int.) 326 [M]

 
(100), 299 (5), 280 (10), 267 (12), 239 (20), 225 (5), 209 (7), and 185 (8); HREIMS m/z 
[M]
 
 326.1629 (calcd for C19H22N2O3, 326.1630). 
 
Crystallographic data of 78: crystal data and structure refinement parameters of 78 are 
summarized in Table 10.6. 
 
Table 10.6. Crystal data and structure refinement parameters of compound 78 
Empirical formula C39H46N4O6Cl2 
Molecular formula 2C19H22N2O3.CH2Cl2 
Molecular weight, Mr 737.70 
Melting point 179182  oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Monoclinic  
Space group P21  
a 8.00860(10) Å 
b 14.9302(3) Å 
c 15.3044(3) Å 
α 90.00°  
β 94.6480(10)°  
γ 90.00°  
Volume, V 1823.93(6) Å
3
 
No. of molecule per unit cell, Z 2  
Density (calcd) 1.447 mg/mm
3
 
Crystal size 0.63 × 0.17 × 0.04 mm  
2range for data collection 3.64 to 61.02°  
Index ranges 11 ≤ h ≤ 10, 20 ≤ k ≤ 21, 21 ≤ l ≤ 22  
Reflections collected 19605 
Independent reflections 10151[Rint = 0.0318]  
Data/restraints/parameters 10151/0/462 
Goodness-of-fit on F
2
 0.958  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0460, wR2 = 0.0998 
Final R indexes [all data] R1 = 0.0724, wR2 = 0.1134 
Largest diff. peak/hole / e Å
3
 0.37/0.41  
Flack parameter, x 0.06(0.06) 
Hooft parameter, y 0.02(0.03) 
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10.8.7 Reaction of leuconolam (54) with concentrated HCl in MeOH 
 
Leuconolam (54) (12.9 mg, 0.040 mmol) was dissolved in a minimal amount of MeOH 
(ca. 0.1 ml). Concentrated HCl was then added dropwise (2 drops). The mixture was 
stirred for 16 h at rt, quenched with 10% Na2CO3 (10 ml), and extracted with CH2Cl2 (3 
x 5 ml). The combined organic extract was then washed with water (3 x 20 ml), dried 
(Na2SO4), concentrated in vacuo, and the residue purified by centrifugal preparative 
TLC (SiO2, 5% MeOHEt2O, NH3-saturated) to give O-methylleuconolam (77) (8.6 mg, 
63%) and recovered 73 (0.5 mg, 4%).   
 
O-Methylleuconolam (77): colorless oil and subsequently as colorless block crystals 
from MeOH; mp 214218 oC [lit49 155156 oC]; []25D 240 (c 0.6, CHCl3); UV 
(EtOH) max (log ) 238 (3.99) and 348 (3.03) nm; IR (dry film) max 3477 and 1693 
cm
1
; For 
1
H and 
13
C NMR data, see Table 4.3; ESIMS m/z 341 [M  H] (C20H24N2O3 
 H). 
 
10.8.8 Reaction of leuconolam (54) with 10-camphorsulfonic acid (CSA) in 
anhydrous CH2Cl2 
 
To a stirred solution of CSA (15 mg, 0.066 mmol) and CH2Cl2 (5 ml) was added 
leuconolam (54) (14.3 mg, 0.044 mmol). The mixture was stirred for 12 h at rt, 
quenched with 10% K2CO3 (10 ml), and extracted with CH2Cl2 (3 x 5 ml). The 
combined organic extract was then washed with water (3 x 10 ml), dried (Na2SO4), 
concentrated in vacuo, and the residue purified by centrifugal preparative TLC (SiO2, 
5% MeOHEt2O, NH3-saturated) to give 6,7-dehydroleuconoxine (63) (8.2 mg, 62%), 
amino lactam-lactone 78 (0.1 mg, 2%) and recovered 54 (1.4 mg, 10%). 
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10.8.9 Reaction of leuconolam (54) with CSA in anhydrous CH2Cl2/MeOH 
 
To a stirred solution of CSA (13.2 mg, 0.057 mmol) and CH2Cl2 (5 ml) was added 
leuconolam (54) (11.8 mg, 0.038 mmol). The mixture was stirred for 30 min and MeOH 
(6 l, 0.152 mmol) then was added. The mixture was stirred for another 11 h at rt, 
quenched with 10% K2CO3 (10 ml), and extracted with CH2Cl2 (5 x 10 ml). The 
combined organic extract was then washed with water (3 x 10 ml), dried (Na2SO4), 
concentrated in vacuo, and the residue purified by centrifugal preparative TLC (SiO2, 
5% MeOHEt2O, NH3-saturated) to give O-methylleuconolam (77) (6.6 mg, 54%) and 
6,7-dehydroleuconoxine (63) (2.2 mg, 19%). 
 
10.8.10 Reaction of leuconolam (54) with CSA in anhydrous MeOH 
 
To a stirred solution of CSA (11.8 mg, 0.051 mmol) and MeOH (5 ml) was added 
leuconolam (54) (11 mg, 0.034 mmol). The mixture was stirred for 12 h at rt, quenched 
with 10% K2CO3 (10 ml), and extracted with CH2Cl2 (5 x 10 ml). The combined 
organic extract was then washed with water (3 x 10 ml), dried (Na2SO4), concentrated in 
vacuo, and the residue purified by centrifugal preparative TLC (SiO2, 5% MeOHEt2O, 
NH3-saturated) to give O-methylleuconolam (77) (10.9 mg, 94%), amino lactam-lactone 
78 (0.1 mg, 2%) and recovered 54 (0.4 mg, 4%). 
 
10.8.11 Reaction of leuconolam (54) with p-toluenesulfonic acid (PTSA) in 
anhydrous MeOH 
 
To a stirred solultion of PTSA (9.5 mg, 0.056 mmol) and MeOH (5 ml) was added 
leuconolam (54) (12 mg, 0.037 mmol). The mixture was stirred for 12 h at rt, quenched 
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with 10% K2CO3 (10 ml) and extracted with CH2Cl2 (5 x 10 ml). The combined organic 
extract was then washed with water (3 x 10 ml), dried (Na2SO4), concentrated in vacuo, 
and the residue purified by centrifugal preparative TLC (SiO2, 5% MeOHEt2O, NH3-
saturated) to give O-methylleuconolam (77) (11.8 mg, 94%), amino lactam-lactone 78 
(0.1 mg, 0.8%), and recovered 54 (0.4 mg, 4%). 
 
10.8.12 Reaction of leuconolam (54) with PTSA in anhydrous CH2Cl2 
 
To a stirred solution of PTSA (8.6 mg, 0.05 mmol) and CH2Cl2 (5 ml) was added 
leuconolam (54) (11.7 mg, 0.036 mmol). The mixture was stirred for 15 h at rt, 
quenched with 10% Na2CO3 (10 ml), and extracted with CH2Cl2 (3 x 5 ml). The 
combined organic extract was then washed with water (3 x 10 ml), dried (Na2SO4), 
concentrated in vacuo, and the residue purified by centrifugal preparative TLC (SiO2, 
Et2O, NH3-saturated) to give 6,7-dehydroleuconoxine (63) (0.6 mg, 5%), amino lactam-
lactone 78 (5 mg, 42%) and recovered 54 (0.4 mg, 3%). 
 
10.8.13 Reaction of 6,7-dehydroleuconoxine (63) with 5% HCl/CH2Cl2 in the 
presence of TEACl 
 
6,7-Dehydroleuconoxine (63) (19.5 mg, 0.063 mmol) was added into a two-phase 
system comprising 5% HCl (5 ml), CH2Cl2 (5 ml), and TEACl (10 mg, 0.063 mmol). 
The mixture was stirred for 12 h at rt, quenched with 10% Na2CO3 (10 ml), and 
extracted with CH2Cl2 (3 x 5 ml). The combined organic extract was then washed with 
water (3 x 20 ml), dried (Na2SO4), concentrated in vacuo, and the residue purified by 
centrifugal preparative TLC (SiO2, 5% MeOHEt2O, NH3-saturated) to give leuconolam 
(54) (2.9 mg, 15%) and recovered 6,7-dehydroleuconoxine (63) (16.3 mg, 84%). 
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10.8.14 Reaction of 6,7-dehydroleuconoxine (63) with CSA in anhydrous CH2Cl2 
 
To a stirred solution of CSA (11.8 mg, 0.051 mmol) and CH2Cl2 (5 ml) was added 6,7-
dehydroleuconoxine (63) (11 mg, 0.034 mmol). TLC of the reaction mixture after 15 h 
showed traces of leuconolam (54) and amino lactam-lactone 78, in addition to the 
starting material 63. 
 
10.8.15 Reaction of 6,7-dehydroleuconoxine (63) with PTSA in anhydrous CH2Cl2 
 
To a stirred solution of PTSA (9.2 mg, 0.054 mmol) and CH2Cl2 (5 ml) was added 6,7-
dehydroleuconoxine (63) (10.3 mg, 0.036 mmol). The mixture was stirred for 10 h at rt, 
quenched with 10% Na2CO3 (10 ml), and extracted with CH2Cl2 (3 x 5 ml). The 
combined organic extract was then washed with water (3 x 10 ml), dried (Na2SO4), 
concentrated in vacuo, and the residue purified by centrifugal preparative TLC (SiO2, 
Et2O, NH3-saturated) to give amino lactam-lactone 78 (7.1 mg, 70%) and recovered 63 
(0.3 mg, 1%). 
 
10.8.16 Reaction of O-methylleuconolam (77) with PTSA in anhydrous CH2Cl2 
 
To a stirred solution of PTSA (8 mg, 0.044 mmol) and CH2Cl2 (5 ml) was added O-
methylleuconolam (77) (10 mg, 0.029 mmol). TLC of the mixture after 10 h showed 
traces of leuconolam (54) and amino lactam-lactone (78), in addition to the starting 
material 77. 
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10.8.17 Hydrogenation of 6,7-dehydroleuconoxine (63) 
 
6,7-Dehydroleuconoxine (63) (20 mg, 0.061 mmol) was dissolved in CH2Cl2 (5 ml) and 
then stirred over 10% Pd/C (12.4 mg) under a hydrogen atmosphere (hydrogen balloon) 
at rt for 1 h. The catalyst was removed by filtration over Celite. Evaporation of the 
solvent in vacuo, followed by chromatography of the resulting residue (SiO2, 5% 
MeOHEt2O, NH3-saturated) gave leuconoxine (56) (18.1 mg, 90%) as a colorless oil 
and subsequently as colorless block crystals from MeOH; mp 210215 oC (lit50 238242 
o
C); []25D 86 (c 0.68, CHCl3) [lit
50
 []
25
D 88 (c 1.2, MeOH)]; UV (EtOH) max (log 
) 202 (4.42), 240 (3.82), and 270 (3.16) nm; IR (dry film) max 1743 and 1709 cm
1
; 
For 
1
H and 
13
C NMR data, see Table 4.8; ESIMS m/z 311 [M  H](C19H22N2O2  H). 
 
10.8.18 Bromination of leuconolam (54) 
 
Leuconolam (54) (11 mg, 0.034 mmol) was dissolved in CHCl3 (4 ml), and Br2 (2.6 l, 
0.051 mmol) was added dropwise at rt. After being stirred for 14 h, the mixture was 
quenched with 10% Na2CO3 (10 ml), extracted with CHCl3 (3 x 5 ml), washed with 
water, dried (Na2SO4), the solvent removed in vacuo, and the residue purified by 
centrifugal preparative TLC (SiO2, 5% MeOH:CHCl3, NH3-saturated) to give 6,7-
dibromoleuconoxine (82) (13.7 mg, 86%) as white amorphous; mp 98102 oC (lit49 mp 
109110 oC); []25D 38 (c 0.62, CHCl3) [lit
49
 []
25
D 32 (c 0.5, CHCl3)]; UV (EtOH) 
max (log ) 208 (4.32), 227 (4.22), and 292 (3.35) nm; IR (dry film) max 1709 and 1691 
cm
1
; For 
1
H and 
13
C NMR data, see Table 4.9; ESIMS m/z 467 [M  H]; HRESIMS 
m/z 466.9965 [M  H] (calcd for C19H20N2O2
79
Br2  H, 466.9964). 
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10.8.19 Bromination of 6,7-dehydroleuconoxine (63) 
 
6,7-Dehydroleuconoxine (63)  (7 mg, 0.021 mmol) was dissolved in CHCl3 (4 ml), and 
Br2 (1.2 l, 0.032 mmol) was added dropwise at rt, and the mixture stirred for 13 h. The 
mixture was quenched with 10% Na2CO3 (10 ml), extracted with CHCl3 (3 x 5 ml), 
washed with water, dried (Na2SO4), the solvent removed in vacuo, and the residue 
purified by centrifugal preparative TLC (SiO2, 5% MeOH:CHCl3, NH3-saturated) to 
give 6,7-dibromoleuconoxine (82) (9.6 mg, 96%). 
 
10.8.20 Debromination of 6,7-dibromoleuconoxine (82) 
 
To a solution of 6,7-dibromoleuconoxine (82) (13 mg, 0.028 mmol) in AcOH (5 ml) 
was added freshly activated zinc (91 mg, 0.139 mmol). The mixture was stirred for 2 h, 
after which the mixture was poured into saturated Na2CO3 (30 ml), extracted with 
CH2Cl2 (3 x 20 ml), washed with water (3 x 20 ml), dried (Na2SO4), the solvent 
removed in vacuo, and the residue purified by centrifugal preparative TLC (SiO2, 5% 
MeOH:CHCl3, NH3-saturated) to give 6,7-dehydroleuconoxine (63) (3.7 mg, 41%). 
 
 
10.8.21 Reaction of 6,7-dehydroleuconoxine (63) with BH3.SMe2 
 
BH3.SMe2 (75 l, 1 M in THF) was added to 6,7-dehydroleuconoxine (63)  (16 mg, 
0.051 mmol) in THF (5 ml) and the mixture was stirred for 24 h at rt. The progress of 
the reaction was monitored by TLC and the reaction was quenched with NH4Cl solution 
when >95% of the starting material had been consumed. The mixture was extracted 
with CH2Cl2 (3 x 10 ml), washed with water (3 x 20 ml), dried over Na2SO4, filtered, 
the solvent removed in vacuo, and the residue purified by centrifugal preparative TLC 
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(SiO2, 5% MeOH:CHCl3, NH3-saturated) to give compounds 86 (5.6 mg, 37%) and 87 
(1 mg, 6%). 
 
Compound 86: yellowish oil and subsequently as yellowish needles from MeOH; mp 
128132 oC; []25D = +584 (c 0.35, CHCl3); UV (EtOH) max (log ) 209 (3.65), 246 
(3.86), and 388 (3.02) nm; IR (dry film) max 1682 and 1641 cm
1
; For 
1
H and 
13
C NMR 
data, see Table 4.10; ESIMS m/z 295 [M  H]; HRESIMS m/z [M  H] 295.1792 
(calcd for C19H22N2O  H, 295.1805). 
 
Crystallographic data of compound 86: crystal data and structure refinement parameters 
of 86 are summarized in Table 10.7. 
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Table 10.7. Crystal data and structure refinement parameters of compound 86 
Empirical formula C19H22N2O 
Molecular formula C19H22N2O 
Molecular weight, Mr 294.39 
Melting point 128132 oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Orthorhombic 
Space group P212121 
a 11.2107(6) Å 
b 11.5443(6) Å  
c 12.1199(7) Å 
α 90.00°  
β 90.00°  
γ 90.00°  
Volume, V 1568.55(15) Å
3
  
No. of molecule per unit cell, Z 4  
Density (calcd) 1.247 mg/mm
3
 
F(000) 632.0  
Crystal size 0.90 × 0.60 × 0.02 mm 
2range for data collection 4.88 to 55°  
Index ranges 14 ≤ h ≤ 14, 15 ≤ k ≤ 15, 15 ≤ l ≤ 14  
Reflections collected 14949  
Independent reflections 2057[Rint = 0.0271]  
Data/restraints/parameters 2057/0/200  
Goodness-of-fit on F
2
 1.029  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0379, wR2 = 0.0921  
Final R indexes [all data] R1 = 0.0478, wR2 = 0.0985  
Largest diff. peak/hole / e Å
3
 0.14/0.11  
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Compound 87: fluorescent yellowish oil and subsequently as fluorescent yellowish 
rods from CH2Cl2/hexanes; mp 198200 
o
C; []25D = 667 (c  0.33, CHCl3); UV 
(EtOH) max (log ) 209 (4.14), 245 (4.42), and 394 (3.64) nm; IR (dry film) max 3343, 
1666, and 1644 cm
1
; For 
1
H and 
13
C NMR data, see Table 4.10; ESIMS m/z 311 [M 
H]; HRESIMS m/z [M H] 311.1750 (calcd for C19H22N2O2  H, 311.1754). 
 
Crystallographic data of compound 87: crystal data and structure refinement parameters 
of compound 87 are summarized in Table 10.8. 
 
Table 10.8. Crystal data and structure refinement parameters of compound 87 
Empirical formula C19H24N2O2 
Molecular formula C19H24N2O2 
Molecular weight, Mr 312.40 
Melting point 128132 oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Trigonal  
Space group P31  
a 11.4602(2) Å 
b 11.4602(2) Å 
c 10.0616(2) Å 
α 90.00°  
β 90.00°  
γ 120.00°  
Volume, V 1144.41(4) Å
3
 
No. of molecule per unit cell, Z 3  
Density (calcd) 1.360 mg/mm
3
 
F(000) 504.0  
Crystal size 0.7 × 0.2 × 0.2 mm 
2range for data collection 4.1 to 54.9°  
Index ranges 14 ≤ h ≤ 14, 14 ≤ k ≤ 14, 13 ≤ l ≤ 13  
Reflections collected 8827  
Independent reflections 3344[Rint = 0.0480]  
Data/restraints/parameters 3344/1/210  
Goodness-of-fit on F
2
 1.211  
Final R indexes [I ≥ 2σ (I)] R1 = 0.1315, wR2 = 0.3662  
Final R indexes [all data] R1 = 0.1326, wR2 = 0.3669  
Largest diff. peak/hole / e Å
3
 0.72/0.72  
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10.8.22 Attempted enolate-mediated C-6 oxidation of leuconoxine (56) 
 
A solution of 56 (11 mg, 0.035 mmol) in THF (5 ml) was added to a solution of lithium 
diisopropylamide (LDA, 27 l, 2 M in THF) in THF (10 ml) at 0 C and the resulting 
mixture was stirred for 30 min. Dry O2 was then bubbled into the solution for 10 min. 
Na2SO3 solution (1 M, 2 ml) was added and the mixture extracted with CH2Cl2 (3 x 10 
ml), dried (Na2SO4), and then concentrated in vacuo. The resulting residue was purified 
by centrifugal preparative TLC (SiO2, 5% MeOHEt2O, NH3-saturated) to afford 
compound 90 (2.4 mg, 21%) and recovered 56 (7.6 mg, 69%).   
 
Compound 90: colorless oil, and subsequently as colorless needles from 
CH2Cl2/hexanes; mp 184186 
o
C; []25D = 29 (c 0.16, CHCl3); UV (EtOH) max (log 
) 210  (4.10), 241 (3.88), and 274 (3.23) nm; IR (dry film) max 3417 and 1675 cm
1
; 
For 
1
H and 
13
C NMR data, see Table 4.11; ESIMS m/z 327 [M  H]; HRESIMS m/z 
[M  H] 327.1710 (calcd for C19H22N2O3  H, 327.1703). 
 
Crystallographic data of compound 90: crystal data and structure refinement parameters 
of compound 90 are summarized in Table 10.9. 
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Table 10.9. Crystal data and structure refinement parameters of compound 90 
Empirical formula C19H22N2O3 
Molecular formula C19H22N2O3 
Molecular weight, Mr 326.39 
Melting point 184186 oC 
Temperature during diffraction experiment, T 298 K 
X-ray source Mo K 
Crystal system Orthorhombic  
Space group P212121  
a 7.1721(4) Å 
b 26.1619(13) Å  
c 27.9882(15) Å 
α 90.00°  
β 90.00°  
γ 90.00°  
Volume, V 5251.6(5) Å
3
 
No. of molecule per unit cell, Z 12  
Density (calcd) 1.238 mg/mm
3
 
F(000) 2088.0  
Crystal size 0.68 × 0.08 × 0.02 mm 
2range for data collection 4.26 to 41.8°  
Index ranges 0 ≤ h ≤ 7, 0 ≤ k ≤ 26, 0 ≤ l ≤ 28  
Reflections collected 3171  
Independent reflections 3171[Rint = 0.0000]  
Data/restraints/parameters 3171/0/656  
Goodness-of-fit on F
2
 0.920  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0508, wR2 = 0.1153  
Final R indexes [all data] R1 = 0.0769, wR2 = 0.1242  
Largest diff. peak/hole / e Å
3
 0.38/0.21  
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10.8.23 Reaction of leuconolam (54) with trifluoroacetic acid 
 
To a stirred solution of 54 (11 mg, 0.034 mmol) and CH2Cl2 (5 ml) was added TFA (9.5 
l, 0.068 mmol). The mixture was stirred for 13 h at rt, quenched with 10% Na2CO3 (10 
ml), and extracted with CH2Cl2 (3 x 5 ml). The combined organic extract was then 
washed with water (3 x 10 ml), dried (Na2SO4), concentrated in vacuo, and the residue 
purified by centrifugal preparative TLC (SiO2, 5% MeOHEt2O, NH3-saturated) to give 
6,7-dehydroleuconoxine (63) (4.1 mg, 37%) and recovered leuconolam (54) (5.8 mg, 
53%).  
 
10.8.24 Reaction of leuconolam (54) with excess trifluoroacetic acid 
 
To a stirred solution of 54 (13 mg, 0.04 mmol) and CH2Cl2 (5 ml) was added TFA (60 
l, 0.8 mmol). The mixture was stirred for 12 h at rt, quenched with 10% Na2CO3 (10 
ml), and extracted with CH2Cl2 (3 x 5 ml). The combined organic extract was then 
washed with water (3 x 10 ml), dried (Na2SO4), concentrated in vacuo, and the residue 
purified by centrifugal preparative TLC (SiO2, 5% MeOHEt2O, NH3-saturated) to 6,7-
dehydroleuconoxine (63) (3.9 mg, 30%), leuconodine A (67) (3.3 mg, 25%) and 
recovered 54 (1.2 mg, 9%).  
 
Leuconodine A (67): colorless oil and subsequently as colorless block crystals from 
EtOH; mp 13436 oC; []25D = 19 (c 0.03, CHCl3); UV (EtOH) max (log ) 209 
(4.16), 241 (3.89), and 277 (3.29) nm; IR (dry film) max 3357 and 1676 cm
1
; For 
1
H 
and 
13
C NMR data, see Table 4.12; EIMS m/z (rel. int.) 326 [M]

 (100), 309 (8), 298 
(48), 283 (35), 252 (18), 237 (8), and 212 (17); HREIMS m/z 326.1633  [M]

 (calcd for 
C19H22N2O3, 326.1630).  
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Crystallographic data of alkaloid 67: crystal data and structure refinement parameters of 
alkaloid 67 are summarized in Table 10.10. 
 
Table 10.10. Crystal data and structure refinement parameters of leuconodine A (67) 
Empirical formula C21H28N2O4 
Molecular formula C19H22N2O3.C2H5OH 
Molecular weight, Mr 372.45 
Melting point 134137 oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Orthorhombic 
Space group P212121 
a 7.3486(4) Å 
b 15.0738(7) Å 
c 16.6740(8) Å 
α 90.00°  
β 90.00°  
γ 90.00°  
Volume, V 1847.00(16) Å
3
  
No. of molecule per unit cell, Z 4  
Density (calcd) 1.339 mg/mm
3
 
F(000) 1128 
Crystal size 0.63 × 0.17 × 0.04 mm  
2range for data collection 3.64 to 61.02°  
Index ranges 10 ≤ h ≤ 10, 21 ≤ k ≤ 21, 22 ≤ l ≤ 22  
Reflections collected 19671  
Independent reflections 3065[Rint = 0.1165]  
Data/restraints/parameters 3065/0/248  
Goodness-of-fit on F
2
 1.066  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0512, wR2 = 0.1044  
Final R indexes [all data] R1 = 0.1133, wR2 = 0.1263  
Largest diff. peak/hole / e Å
3
 0.26/0.28  
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10.8.25 Oxidation of leuconodine A (67) 
 
A solution of 67 (7 mg, 0.021 mmol) in CH2Cl2 (5 ml) was treated with the Dess-Martin 
periodinane reagent (82 l, 0.3 M in CH2Cl2) and the mixture was stirred at rt for 30 
min. Et2O (25 ml) and NaOH (10 ml, 1.3 M) were then added and the mixture was 
stirred for another 15 minutes. The aqueous layer was removed and the organic layer 
was washed with 1.3 M NaOH (2 x 10 ml), dried with Na2SO4, the solvent removed in 
vacuo, and the residue purified by centrifugal preparative TLC (SiO2, 5% MeOH:Et2O, 
NH3-saturated) to give leuconodine F (72) (5.3 mg, 76%) as colorless oil, and 
subsequently as colorless block crystals from MeOH: mp 246250 oC; []25D = 94 (c 
0.05, CHCl3); UV (EtOH) max (log ) 202 (4.42), 234 (4.12), 251 (4.02) and 349 (3.10) 
nm; IR (dry film) max 1715 and 1689 cm
1
; For 
1
H and 
13
C NMR data, see Table 4.12; 
ESIMS m/z [M  H]+ 325; HRESIMS m/z 325.1453 [M  H]+ (calcd for C19H20N2O3, 
325.1547).  
 
Crystallographic data of alkaloid 72: crystal data and structure refinement parameters of 
alkaloid 72 are summarized in Table 10.11. 
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Table 10.11. Crystal data and structure refinement parameters of leuconodine F (72) 
Empirical formula C19H20N2O3  
Molecular formula C19H20N2O3  
Molecular weight, Mr 324.37 
Melting point 246250 oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Monoclinic  
Space group P21  
a 9.7373(4) Å  
b 7.3976(3) Å  
c 11.4361(5) Å  
α 90.00°  
β 107.522(2)°  
γ 90.00°  
Volume, V 785.55(6) Å
3 
No. of molecule per unit cell, Z 2  
Density (calcd) 1.371 mg/mm
3
 
F(000) 344.0  
Crystal size 0.64 × 0.09 × 0.03  
2range for data collection 3.74 to 52.82°  
Index ranges 12 ≤ h ≤ 12, 9 ≤ k ≤ 9, 14 ≤ l ≤ 14  
Reflections collected 5507  
Independent reflections 1735[Rint = 0.0332]  
Data/restraints/parameters 1735/1/218  
Goodness-of-fit on F
2
 1.048  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0333, wR2 = 0.0718  
Final R indexes [all data] R1 = 0.0461, wR2 = 0.0761  
Largest diff. peak/hole / e Å
3
 0.20/0.17  
 
 
307 
 
10.9      Chapter 5 
 
10.9.1     Partial synthesis of alstolucine A (91) 
 
10.9.1.1 Compound data of alstolucines A (91) and B (94) 
 
Alstolucines A (91) and B (94) were isolated from the leaf extract of Alstonia 
spatulata.
74
 
 
Alstolucine A (91): light yellowish oil; []25D 438 (c 0.12, CHCl3); UV (EtOH) max 
(log ) 230 (3.32), 298 (3.26), and 328 (3.46) nm; IR (dry film) max 3378, 1742, and 
1683 cm
1
; For 
1
H and 
13
C NMR data, see Table 5.1; ESIMS m/z 413 [M  H]; 
HRESIMS m/z 413.2074 [M  H] (calcd for C23H28N2O5  H, 413.2071). 
 
Alstolucine B (94): colorless block crystals from CHCl3; mp >160 

C dec; []25D 515 
(c 1.28, CHCl3); UV (EtOH) max (log ) 232 (3.85), 295 (3.75), and 326 (3.91) nm; IR 
(dry film) max 3361, 1704, and 1678 cm
1
; For 
1
H and 
13
C NMR data, see Table 5.1; 
ESIMS m/z 339 [M  H]; HRESIMS m/z 339.1714 [M  H] (calcd for C20H22N2O3  
H, 339.1703).  
 
Crystallographic data of alkaloid 94: crystal data and structure refinement parameters of 
alkaloid 94 are summarized in Table 10.12. 
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Table 10.12. Crystal data and structure refinement parameters of alstolucine B (94) 
Empirical formula  C20H22N2O3  
Molecular formula C20H22N2O3 
Molecular weight, Mr  338.40  
Melting point  >160 
o
C dec 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system  Orthorhombic  
Space group  P212121  
a 7.80370(10) Å 
b 11.7086(2) Å 
c 18.3534(3) Å  
α 90.00°  
β 90.00° 
γ 90.00° 
Volume, V 1676.96(5) Å
3
 
No. of molecule per unit cell, Z  4  
Density (calcd) 1.340 mg/mm
3
  
F(000)  720.0  
Crystal size 0.55 × 0.26 × 0.14 mm 
2  range for data collection  4.12 to 54.98°  
Index ranges 10 ≤ h ≤ 10, 15 ≤ k ≤ 15, 23 ≤ l ≤ 23  
Reflections collected 15918  
Independent reflections 2204 [Rint = 0.0365]  
Data/restraints/parameters  2204/0/228  
Goodness-of-fit on F
2
  1.073  
Final R indexes [I ≥ 2σ (I)]  R1 = 0.0350, wR2 = 0.0917  
Final R indexes [all data]  R1 = 0.0384, wR2 = 0.0941  
Largest diff. peak/hole / e Å
3
  0.30/0.34  
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10.9.1.2 Epimerization of ()-alstolucine B (94) to compound 95  
 
To a solution of the ketone 94 (12 mg, 0.035 mmol) in 1 ml of MeOH was added a 
freshly prepared solution of Na (1.2 mg, 0.053 mmol) in 1 ml MeOH at 0 

C. The 
mixture was allowed to stir at rt for 3 h. The solvent was evaporated in vacuo, and water 
(5 ml) was added. The product was extracted with CH2Cl2 (3 x 10 ml). The combined 
organic extract was dried (Na2SO4), filtered, and concentrated in vacuo, and the residue 
was purified by centrifugal preparative TLC (SiO2, 5% MeOHCHCl3, NH3-saturated) 
to afford the isomerized ketone 95 (4.2 mg, 35%), and recovered 94 (7.6 mg, 63%).  
 
Compound 95: light yellowish oil; []25D 371 (c 0.35, CHCl3); UV (EtOH) max (log 
) 229 (3.32), 297 (3.21), and 328 (3.38) nm; IR (dry film) max 3364, 1704, and 1678 
cm
1
; For 
1
H and 
13
C NMR data, see Table 5.2; ESIMS m/z 339 [M  H];  HRESIMS 
m/z 339.1710 [M  H] (calcd for C20H22N2O3  H, 339.1703).  
 
10.9.1.3 NaBH4 reduction of compound 95 
 
To a mixture of compound 95 (8 mg, 0.024 mmol) in 2 ml of MeOH at 0 
o
C was added 
NaBH4 (1.6 mg, 0.041 mmol). The solution was stirred at rt for 1 h. Saturated NaHCO3 
(5 ml) solution was added, and the product was extracted with CH2Cl2 (3 x 10 ml). The 
combined organic extract was dried (Na2SO4), filtered, and concentrated in vacuo, and 
the residue was purified by centrifugal preparative TLC (SiO2, 10% MeOHEt2O, NH3-
saturated) to afford N(4)-demethylalstogustine (92, 6.8 mg, 85%) and compound 93 (0.8 
mg, 10%).  
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N(4)-Demethylalstogustine (92): light yellowish oil; []25D 399 (c 0.33, CHCl3) [lit
76 
[]D 442 (c 0.55, EtOH)]; UV (EtOH) max (log ) 228 (3.88), 298 (3.82), and 329 
(3.98) nm; IR (dry film) max 3373 and 1670 cm
1
; For 
1
H and 
13
C NMR data, see Table 
5.2; ESIMS m/z 341 [M  H]; HRESIMS m/z 341.1866 [M  H] (calcd for 
C20H24N2O3  H, 341.1860).  
 
Compound 93: light yellowish oil; []25D 361 (c 0.18, CHCl3); UV (EtOH) max (log 
) 226 (3.82), 298 (3.77), and 329 (3.94) nm; IR (dry film) max 3370 and 1672 cm
1
; 
For 
1
H and 
13
C NMR data, see Table 5.2; ESIMS m/z 341 [M  H]; HRESIMS m/z 
341.1867 [M  H] (calcd for C20H24N2O3  H, 341.1860). 
 
10.9.1.4 O-Acylation of N(4)-demethylalstogustine (92) 
 
To a stirred solution of 92 (6.5 mg, 0.019 mmol), CH2Cl2 (5 ml), and triethylamine (13 
l, 0.095 mmol), was added dropwise ethyl chloroformate (9 l, 0.095 mmol), and the 
mixture was stirred for 30 min at rt. The mixture was quenched with saturated NH4Cl 
(10 ml) and extracted with CH2Cl2 (3 x 10 ml). The combined organic extract was dried 
(Na2SO4), the solvent evaporated in vacuo, and the residue purified by centrifugal 
preparative TLC (SiO2, 2% MeOHCHCl3, NH3-saturated) to give the O-carboethoxy 
derivative, alstolucine A (91) (5.4 mg, 69%) as a light yellowish oil. The spectroscopic 
(
1
H and 
13
C NMR, IR, and UV) and other data ([D and Rf of TLC in different solvent 
systems) of semisynthetic alstolucine A (91) were indistinguishable from those of the 
natural alstolucine A (91).
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10.9.2    Partial synthesis of ()-eburnamaline (96) 
 
10.9.2.1 Compound data of ()-eburnamaline (96) and ()-eburnamonine (98) 
 
The alkaloid ()-eburnamaline (96) was obtained the stem-bark extract of from L. 
griffithii.
81 
 
()-Eburnamaline (96): light yellowish oil; []25D  (c 0.21, CHCl3); UV (EtOH) 
max (log ) 230 (3.76) and 280 (3.16) nm; IR (dry film) max 3370 cm
1
; For 
1
H and 
13
C 
NMR data, see Table 5.3; EIMS m/z (rel. int.) m/z 312 [M]

 (100), 294 (23), 283 (20), 
265 (76), 242 (26), 224 (38), 208 (18), 196 (12), 180 (8), and 144 (5); HREIMS m/z 
312.1827 (calcd for C19H24N2O2, 312.1838); ESIMS m/z 313 [M H]

; HRESIMS m/z 
313.1926 [M H] (calcd for C19H24N2O2  H, 313.1911). 
 
The starting material for the partial synthesis of ()-eburnamaline (96), (+)-
eburnamonine (98) was obtained from the stem extract of Kopsia larutensis.
87
  
 
()-Eburnamonine (98): colorless block crystals; mp 175177 oC; []25D 108 (c 0.24, 
CHCl3); UV (EtOH) λmax  (log ) 207 (4.40), 246 (4.46), 270 (4.18), and 302 (3.91) nm; 
IR (dry film) max 1716 (C=O, lactam) cm
1
; For 
1
H and 
13
C NMR data, see Table 5.3; 
ESIMS m/z  [M H] 295 (C19H22N2O  H). 
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10.9.2.2 Oxidation of ()-eburnamonine (98) 
 
Method A. A solution of ()-eburnamonine (98) (100 mg, 0.34 mmol) in THF (5 ml) 
was added to a solution of lithium diisopropylamide (LDA, 0.42 ml, 2 M in THF) in 
THF (10 mL) at 0 

C and the resulting mixture was stirred for 30 min. Dry O2 was then 
bubbled into the solution for 10 min. Na2SO3 solution (1 M, 5 ml) was added and the 
mixture extracted with EtOAc (3 x 15 ml), dried (Na2SO4), and then concentrated in 
vacuo. The resulting residue was purified by centrifugal preparative TLC (SiO2, 2% 
MeOHCHCl3, NH3-saturated) to afford ()-17-hydroxyeburnamonine (99) (27.5 mg, 
26%). 
 
Method B. A solution of ()-eburnamonine (98) (46 mg, 0.16 mmol) in THF (2 ml) was 
added to a solution of lithium diisopropylamide (LDA, 0.2 ml, 2 M in THF) in THF (2 
ml) at 0 

C and the resulting mixture stirred for 30 min. A solution of (1S)-()-(10-
camphorsulfonyl)oxaziridine (90 mg, 0.4 mmol) in THF (1 ml) was then added, and the 
mixture stirred for another 20 min. The reaction was quenched by addition of a saturated 
solution of NH4Cl (2 ml), and the mixture poured into brine (10 ml) and extracted with 
CH2Cl2 (3 x 10 ml). The combined organic extracts were dried (Na2SO4), filtered, 
concentrated in vacuo, and the resulting residue was then purified by centrifugal 
preparative TLC (SiO2, 2% MeOHCHCl3, NH3-saturated) to afford ()-17-
hydroxyeburnamonine (99) (40 mg, 83%).  
 
()-17-Hydroxyeburnamonine (99): light yellowish oil; []25D 126 (c 0.62, CHCl3); 
UV (EtOH) max (log ) 229 (4.15) and 282 (3.56) nm; IR (dry film) max 3382 and 1703 
cm
1
; For 
1
H and 
13
C NMR data, see Table 5.4; ESIMS m/z 311 [M  H]; HRESIMS 
m/z [M  H]311.1760 (calcd for C19H23N2O2, 311.1760). 
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10.9.2.3 Reduction of ()-17-hydroxyeburnamonine (99) 
 
To a solution of 99 (72 mg, 0.23 mmol) in THF (10 ml) at 0 

C was added LiAlH4 (23 
mg, 0.6 mmol) and the mixture was refluxed for 2 h. The mixture was cooled to 0 

C, 
following which, water (0.1 ml), then NaOH (3 M, 0.1 ml), and finally water (0.3 ml) 
was added. The mixture was stirred for 3 h at rt and then filtered through a pad of 
Celite. The filtrate was concentrated in vacuo and the resulting residue was purified by 
centrifugal preparative TLC (SiO2, 5% MeOHCH2Cl2, NH3-saturated) to afford 
compounds 96 (39 mg, 54%) and 100 (28 mg, 39%). The spectroscopic (
1
H and 
13
C 
NMR, IR, and UV) and other data ([D and Rf of TLC in different solvent systems) of 
semisynthetic ()-eburnamaline (96) were indistinguishable from those of the natural 
()-eburnamaline (96).80  
 
Compound 100: white amorphous solid and subsequently as colorless crystals from 
CH2Cl2; mp 190193 

C; []25D 44 (c 0.62, MeOH); UV (EtOH) max (log ) 229 
(4.41) and 281 (3.82) nm; IR (dry film) max 3448 cm
1
; For 
1
H and 
13
C NMR data, see 
Table 5.4; ESIMS m/z 313 [M  H]; HRESIMS m/z 313.1915 [M  H](calcd for 
C19H24N2O2  H, 313.1916).  
 
Crystallographic data of compound 100: crystal data and structure refinement 
parameters of compound 100 are summarized in Table 10.13. 
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Table 10.13. Crystal data and structure refinement parameters of compound 100 
Empirical formula  C41H54Cl6N4O4  
Molecular formula 2C19H24N2O2 .3CH2Cl2 
Molecular weight , Mr 879.58  
Melting point 190193 C 
Temperature during diffraction experiment, T   100 K  
X-ray source Mo K 
Crystal system  Hexagonal  
Space group  P65  
a 20.6890(4) Å 
b 20.6890(4) Å 
c 17.1028(3) Å 
α 90.00° 
β 90.00° 
γ 120.00°   
Volume, V 6339.8(2) Å
3
 
No of molecule per unit cell, Z  15  
Density (calcd) 2.051 mg/mm
3
 
F(000)  6930.0  
Crystal size  0.38 × 0.08 × 0.07 mm  
2 range for data collection  2.28 to 52.78°  
Index ranges  25 ≤ h ≤ 25, 24 ≤ k ≤ 25, 21 ≤ l ≤ 21  
Reflections collected  55539  
Independent reflections  8656[Rint = 0.0947]  
Data/restraints/parameters  8656/1/502  
Goodness-of-fit on F
2
  1.083  
Final R indexes [I ≥ 2σ (I)]  R1 = 0.0526, wR2 = 0.1224 
Final R indexes [all data]  R1 = 0.0735, wR2 = 0.1369 
Largest diff. peak/hole / e Å
3
  0.71/0.34  
Flack parameter, x 0.07(0.06) 
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10.10   Chapter 6 
 
10.10.1 Compound data of perhentidines AC (101103), perhentinine (104), and 
macralstonine (105) 
 
The alkaloids perhentidines AC (101103), perhentinine (104) and macralstonine 
(105) were isolated from the stem-bark extracts of Alstonia macrophylla and Alstonia 
angustifoia.
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Perhentidine A (101): light yellowish oil; []25D 77 (c 0.40, CHCl3); UV (EtOH) max 
(log ) 231 (4.69) and 286 (3.69) nm; IR (dry film) max 3400, 1702, 1648, and 1617 
cm
1
; For 
1
H and 
13
C NMR data, see Tables 6.1 and 6.2, respectively; ESIMS m/z 705 
[M ]; HRESIMS m/z 705.4010 [M  H] (calcd for C43H52N4O5  H, 705.4013). 
 
Perhentidine B (102):  light yellowish oil; []25D –38 (c 0.52, CHCl3); UV (EtOH) λmax 
(log ) 234 (4.49) and 286 (3.81) nm; IR (dry film) max 3392, 1707, 1653, and 1618 
cm
−1
; For 
1
H and 
13
C NMR data, see Tables 6.1 and 6.2, respectively; ESIMS m/z 705 
[M H];  HRLSIMS m/z 705.3993 [M  H] (calcd for C43H52N4O5  H, 705.4013). 
 
Perhentidine C (103): light yellowish oil; []25D 73 (c 0.50, CHCl3); UV (EtOH) max 
(log ) 230 (4.53) and 285 (3.93) nm; IR (dry film) max 3387, 1703, 1651, and 1615 
cm
1
; For 
1
H and 
13
C NMR data, see Tables 6.1 and 6.2, respectively; EIMS m/z (rel. 
int.) 686 [M H2O]

 (100), 616 (6), 547 (5), 486 (42), 379 (27), 343 (12), 307 (15), 277 
(5), 251 (19), 197 (99), 170 (21), and 70 (8); HRLSIMS m/z 705.4029 [M H] (calcd 
for C43H52N4O5  H, 705.4013). 
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Perhentinine (104): light yellowish oil; []25D 61 (c 0.12, CHCl3); UV (EtOH) max 
(log ) 231 (4.25) and 298 (3.45) nm; IR (dry film) max 3400, 1701, 1651, and 1616 
cm
1
; For
 1
H and 
13
C NMR data, see Tables 6.3 and 6.4, respectively; ESIMS m/z 705 
[M H]; HRESIMS m/z 705.4019 [M H] (calcd for C43H52N4O5  H, 705.4013). 
 
Macralstonine (105): colorless rectangular rod crystals from CH2Cl2/MeOH; mp 
260263 oC [lit92 279280 oC]; []25D 23 (c 0.5, CHCl3) [lit
92
 22 (c 2.0, CHCl3)]; UV 
(EtOH) max (log ) 229 (4.47), 259 (2.94) and 294 (2.85) nm; IR (dry film) max 3402, 
1701, 1651, and 1616 cm
1
; (nujol) 3393, 1643, and 1619 cm
1
; (CHCl3) max 3683, 
1706, 1649, and 1618 cm
1
; For 
1
H and 
13
C NMR data, see Tables 6.5 and 6.6, 
respectively; ESIMS m/z 705 [M  H]. 
 
Crystallographic data of alkaloid 105: crystal data and structure refinement parameters 
of alkaloid 105 are summarized in Table 10.14. 
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Table 10.14. Crystal data and structure refinement parameters of mactalstonine (105) 
Empirical formula C43H52N4O5  
Molecular formula C43H52N4O5  
Molecular weight, Mr 704.89  
Melting point 260263 oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Cu K 
Crystal system Monoclinic  
Space group C2  
a 30.173(4) Å 
b 6.7184(6) Å 
c 18.895(2) Å 
α 90.00°  
β 108.475(14)°  
γ 90.00° 
Volume, V 3632.9(7) Å
3
 
No. of molecule per unit cell, Z 4  
Density (calcd) 1.289 mg/mm
3
 
F(000) 1512.0  
Crystal size 0.20 x 0.10 x 0.02 mm 
2range for data collection 6.18 to 134.94°  
Index ranges 36 ≤ h ≤ 34, 8 ≤ k ≤ 7, 22 ≤ l ≤ 22  
Reflections collected 16346  
Independent reflections 6280[Rint = 0.0528]  
Data/restraints/parameters 6280/1/477  
Goodness-of-fit on F
2
 1.051  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0720, wR2 = 0.1869  
Final R indexes [all data] R1 = 0.0947, wR2 = 0.2054  
Largest diff. peak/hole / e Å
3
 0.26/0.27  
Flack parameter 0.1(0.4) 
Hooft parameter 0.30(0.14) 
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10.10.2 General procedure for the acetylation of alkaloids 101106 
 
To a solution of the appropriate alkaloid (1.0 mmol), pyridine (3 equiv), and CH2Cl2, 
was added acetic anhydride (1.5 equiv), and the mixture was stirred at rt. The progress 
of the reaction was monitored by TLC. When the TLC showed ca. 95% completion, the 
reaction was quenched with 5% Na2CO3. The organic layer was washed with water, 
dried with Na2SO4, concentrated in vacuo, and the residue was purified by centrifugal 
preparative TLC (SiO2, 25% MeOH:CHCl3, NH3-saturated) to give the corresponding 
O-acetyl derivatives.  
 
O-Acetylperhentidine A (101a). Reaction of 101 (18.3 mg, 0.026 mmol) with acetic 
anhydride (3.7 l, 0.039 mmol) in pyridine (6.3 l, 0.079 mmol) and CH2Cl2 (2 ml) 
gave 101a (9.1 mg, 47%): light yellowish oil; []25D 111 (c 0.45, CHCl3,); UV (EtOH) 
max (log ) 210 (4.73), 230 (4.99), and 285 (4.30) nm; IR (neat) max 1732, 1703, 1652, 
and 1620 cm
1
; For
 1
H and 
13
C NMR data, see Tables 6.7 and 6.8, respectively; ESIMS 
m/z 747 [M  H]; HRESIMS m/z 747.4122 [M  H] (calcd for C45H54N4O6  H, 
747.4116). 
 
O-Acetylperhentidine B (102a). Reaction of 102 (18.8 mg, 0.027 mmol) with acetic 
anhydride (3.9 l, 0.04 mmol) in pyridine (6.4 l, 0.081) and CH2Cl2 (2 ml) gave 102a 
(8.5 mg, 43%): light yellowish oil; []25D 42.3 (c 0.43, CHCl3,); UV (EtOH) max (log 
) 210 (4.76), 230 (5.01), and 288 (4.32) nm; IR (neat) max 1734, 1709, 1654, and 1619 
cm
1
;
 
For
 1
H and 
13
C NMR data, see Tables 6.7 and 6.8, respectively; ESIMS m/z 747 
[M H]; HRESIMS m/z 747.4109 [M H] (calcd for C45H54N4O6  H, 747.4116). 
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O-Acetylperhentidine C (103a). Reaction of 103 (2.8 mg, 0.004 mmol) with acetic 
anhydride (0.6 l, 0.006 mmol) in pyridine (1 l, 0.012) and CH2Cl2 (1 ml) gave 103a 
(2.2 mg, 74%): colorless oil; []D 105 (c 0.11, CHCl3); UV (EtOH) max (log ) 230 
(4.70) and 285 (4.07) nm; IR (dry film) max 1737, 1706, 1650, and 1618 cm
1
; For 
1
H 
and 
13
C NMR data, see Tables 6.7 and 6.8, respectively; ESIMS m/z 747 [M  H]; 
HRESIMS m/z 747.4118 [ ] (calcd for C45H54N4O6  H, 747.4116). 
 
O-Acetylperhentinine acetate (104a). Reaction of 104 (15.1 mg, 0.021 mmol) with 
acetic anhydride (3 l, 0.032 mmol) in pyridine (5 l, 0.063 mmol) and CH2Cl2 (2 ml) 
gave 104a (8.2 mg, 52%): light yellowish oil; []25D 103 (c 0.35, CHCl3,); UV (EtOH) 
max (log ) 210 (4.90), 230 (5.15), and 295 (4.41) nm; IR (neat) max 1736, 1706, 1651, 
and 1618 cm
1
; For
 1
H and 
13
C NMR data, see Tables 6.3 and 6.4, respectively; ESIMS 
m/z 747 [M  H]; HRESIMS m/z 747.4123 [M  H] (calcd for C45H54N4O6  H, 
747.4116). 
 
O-Acetyl-E-secomacralstonine (106a). Reaction of 106 (16.8 mg, 0.024 mmol) with 
acetic anhydride (3.4 l, 0.036 mmol) in pyridine (5.8 l, 0.071 mmol) and CH2Cl2 (2 
ml) gave 106a (11 mg, 62%): light yellowish oil; []25D 34 (c 1.1, CHCl3,); UV 
(EtOH) max (log ) 211 (4.72), 230 (5.00), and 297 (4.21) nm; IR (neat) max 1732, 
1715, 1651, and 1614  cm
1
; For
 1
H and 
13
C NMR data, see Tables 6.5 and 6.6, 
respectively; ESIMS m/z 747 [M  H]; HRESIMS m/z 747.4119 [M  H] (calcd for 
C45H54N4O6 H, 747.4116). 
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10.10.3 Conversion of perhentinine (104) to its dimethyl diiodide salt 104b  
 
Iodomethane (0.5 ml, 8 mmol) was added to perhentinine (104) (16 mg, 0.02 mmol) and 
allowed to stand for 24 h at rt. Excess iodomethane was then removed under reduced 
pressure to furnish a yellowish residue which on recrystallization from hot MeOH, gave 
the corresponding dimethyl diiodide salt 104b (14 mg, 62%): light yellowish block 
crystals; mp 228230 oC; []25D 55 (c 0.05, MeOH); UV (EtOH) max (log ) 221 
(5.83) and 295 (4.97) nm; ESIMS m/z 367 [M]
2
; HRESIMS m/z 367.2207 [M]
2
 (calcd 
for C45H58N4O5, 734.4396). 
 
Crystallographic data of compound 104b: crystal data and structure refinement 
parameters of compound 104b are summarized in Table 10.15. 
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Table 10.14. Crystal data and structure refinement parameters of compound 104b 
Empirical formula C42H54N4O5I2  
Molecular formula C42H54N4O5 
2
I2
2 
Molecular weight, Mr 948.69  
Melting point 228230 oC 
Temperature during diffraction experiment, T 100 K  
X-ray source Mo K 
Crystal system Orthorhombic  
Space group P212121  
a 14.5059(2) Å 
b 14.8002(2) Å 
c 22.4594(3) Å 
α 90.00°  
β 90.00°  
γ 90.00°  
Volume, V 4821.81(11) Å
3
 
No. of molecule per unit cell, Z 4  
Density (calcd) 1.307 mg/mm
3
 
F(000) 1920.0  
Crystal size 0.21 x 0.19 x 0.16 mm 
2range for data collection 3.3 to 50°  
Index ranges 17 ≤ h ≤ 17, 17 ≤ k ≤ 17, 26 ≤ l ≤ 26  
Reflections collected 37534  
Independent reflections 8480[Rint = 0.0340]  
Data/restraints/parameters 8480/0/585  
Goodness-of-fit on F
2
 1.590  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0634, wR2 = 0.1922  
Final R indexes [all data] R1 = 0.0695, wR2 = 0.1988  
Largest diff. peak/hole / e Å
3
 3.10/0.90  
Flack parameter 0.04(0.03) 
Hooft parameter 0.022(0.07) 
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10.11 Chapter 7 
 
10.11.1  Compound data of scolaricine (114), lumutinine C (116), and alstoumerine 
(118) 
 
The alkaloid scholaricine (114) was obtained from the leaf extract of Alstonia 
angustiloba.
104
 Lumutinine C (116) was obtained from the bark extract of Alstonia 
macrophylla,
105
 while alstoumerine (118) was obtained from the stem-bark extract of 
Alstonia angustifolia.
74 
 
Scholaricine (114): light yellowish oil and subsequently as colorless needles from 
CHCl3; mp 176180 
o
C [lit
102
 >180 
o
C dec]; []25D 577 (c 0.56, CHCl3) [lit
102 200 
(CHCl3)]; UV (EtOH) max (log ) 213 (4.19), 237 (3.97), 286 (3.60), and 341 (3.94) 
nm; For 
1
H and 
13
C NMR data, see Table 7.2; ESIMS m/z 357 [M  H]. 
 
Crystallographic data of alkaloid 114: crystal data and structure refinement parameters 
of alkaloid 114 are summarized in Table 10.16. 
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Table 10.16. Crystal data and structure refinement parameters of scholaricine (114)  
Empirical formula  C44H58N4O11  
Molecular formula 2C20H24N2O4.C4H8O2.H2O 
Molecular weight, Mr 818.94  
Melting point 176180 oC 
Temperature during diffraction experiment, T 100 K  
X-ray source Mo K 
Crystal system  Orthorhombic  
Space group  P212121  
a 10.4901(3) Å 
b 18.5736(5) Å 
c 21.1075(5) Å 
α 90.00°  
β 90.00°  
γ 90.00°  
Volume, V 4112.56(19) Å
3
 
No. of molecule per unit cell, Z 4  
Density (calcd)  1.326 mg/mm
3
 
F(000)  1760  
Crystal size/mm
3
  0.301 × 0.282 × 0.096  
2 range for data collection  2.92 to 50°  
Index ranges  12 ≤ h ≤ 12, 22 ≤ k ≤ 22, 25 ≤ l ≤ 25  
Reflections collected  31934  
Independent reflections  4055[Rint = 0.1005]  
Data/restraints/parameters  4055/3/545  
Goodness-of-fit on F
2
  1.071  
Final R indexes [I ≥ 2σ (I)]  R1 = 0.0592, wR2 = 0.1509  
Final R indexes [all data]  R1 = 0.0839, wR2 = 0.1641  
Largest diff. peak/hole / e Å
3
  0.296/0.634  
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Lumutinine C (116): light yellowish oil; []25D +84 (c 0.3, CHCl3); UV (EtOH) max 
(log ε) 208 (5.31), 228 (5.33), and 284 (4.78) nm; IR(dry film) νmax 3360 cm
−1
; For 
1
H 
and 
13
C NMR data, see Table 7.3; ESIMS m/z 661 [M + H]
+
; HRESIMS m/z 661.3749 
[M  H] (calcd for C41H48N4O4+ H, 661.3748). 
 
Alstoumerine (118): colorless block crystals from CHCl3; mp 174176 

C [lit
106
 170 
o
C]; []25D 30 (c 0.09, CHCl3) [lit
106
 5.5 (c 2.0, CHCl3)]; UV (EtOH) max (log ) 219 
(3.89), 234 (3.93), 274 (3.73), 284 (3.77), and 293 (3.71) nm; For 
1
H NMR and 
13
C 
NMR data, see Table 7.4; ESIMS m/z 325 [M H].  
 
Crystallographic data of alkaloid 118: crystal data and structure refinement parameters 
of alkaloid 118 are summarized in Table 10.17.  
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Table 10.17. Crystal data and structure refinement parameters of alstoumerine (118) 
Empirical formula C22H26Cl6N2O2  
Molecular formula C20H24N2O2.2CHCl3 
Molecular weight, Mr 563.15  
Melting point 174–176 ˚C 
Temperature during diffraction experiment, T 100(2)  
X-ray source Mo K 
Crystal system Orthorhombic  
Space group P212121  
a 10.3890(2) Å 
b 10.4473(2) Å 
c 23.0709(4) Å 
α 90.00°  
β 90.00°  
γ 90.00°  
Volume, V 2504.05(8) Å
3
 
No. of molecule per unit cell, Z 4  
Density (calcd) 1.494 mg/mm
3
 
F(000) 1160  
Crystal size 0.69 × 0.18 × 0.16  
2range for data collection 4.28 to 60.96°  
Index ranges 14 ≤ h ≤ 14, 14 ≤ k ≤ 14, 32 ≤ l ≤ 31  
Reflections collected 27532  
Independent reflections 7322[Rint = 0.0389]  
Data/restraints/parameters 7322/22/321  
Goodness-of-fit on F
2
 1.024  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0397, wR2 = 0.0827  
Final R indexes [all data] R1 = 0.0493, wR2 = 0.0867  
Largest diff. peak/hole / e Å
3
 0.436/0.326  
Flack Parameter  0.01(0.04)  
Hooft Parameter  0.01(0.04)  
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10.11.2 Determination of the C-19 configuration of alstoumerine (118) by Horeau’s 
method 
 
Alstoumerine (118) (45 mg, 0.145 mmol) was added to a solution of racemic 2-
phenylbutyric anhydride (168 l, 0.145 mmol) in anhydrous pyridine (1 ml). The 
resulting mixture was stirred for 20 h at rt. Water (3 ml) was then added and the mixture 
was allowed to stand for 30 min. The pH of the solution was adjusted to pH 9 by drop-
wise addition of NaOH (0.1 M), after which the solution was extracted with CH2Cl2 (3 x 
20 ml). The aqueous layer was acidified to pH 3 using 1.0 M HCl and extracted with 
CH2Cl2 (3 x 10 ml). Evaporation of the solvent from the organic phase gave the 
unreacted 2-phenylbutyric acid: []25D 3.1 (c 1.66, C6H6); []
25
D 3 (c 1.66, CHCl3). 
The optical rotation of the unreacted 2-phenylbutyric acid was found to be negative (R), 
indicating the S configuration at C-19 in alstoumerine (118b). The determination was 
repeated several times to confirm that the correct result was obtained 
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10.12 Chapter 8 
 
10.12.1  Compound data of andransinine (119) 
 
(±)-Andransinine (119) was isolated first isolated from the leaf extract of Alstonia 
angustiloba,
123
 and subsequently from the leaf extract of Kopsia pauciflora.
58 
 
(±)-Andransinine (119) from A. angustiloba: light orange block crystals from EtOAc, 
mp 212214 °C; colorless needles from CH2Cl2/hexanes, mp 186190 
o
C; colorless lath 
crystals from MeOH, mp 204206 oC; []25D 8 (c 0.13, CHCl3); UV (EtOH) max (log 
) 223 (3.70) and 284 (3.08) nm; IR (dry film) max 3378, 2885, 2840, and 1732 cm
1
; 
For 
1
H and 
13
C NMR data, see Table 8.3; ESIMS m/z 381 [M + H]

; HRESIMS m/z 
381.2178 [M + H]

 (calcd for C23H28N2O3  H, 381.2173). 
 
(±)-Andransinine (119) from K. pauciflora: []25D 0 (c 0.18, CHCl3); The melting 
points of crystals obtained from various solvent systems, UV, IR, 
1
H and 
13
C NMR, and 
HRESIMS data were similar to those of (±)-andransinine (119) obtained from A. 
angustiloba. 
 
10.12.2 X-ray crystallographic analysis of (±)-andransinine (119) 
 
Racemic conglomerate crystals of (±)-andransinine (119) were obtained from EtOAc 
solution. The crystal data and structure refinement parameters of 119 are shown in 
Table 8.4.  
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Racemic compound crystals of (±)-andransinine (119) were obtained from 
CH2Cl2/hexanes solution. The crystal data and structure refinement parameters are 
summarized in Table 10.18.  
 
Table 10.18. Crystal data and structure refinement parameters of alkaloid 119 obtained 
from CH2Cl2/hexanes solution 
Empirical formula C23H28N2O3 
Molecular formula C23H28N2O3 
Molecular weight, Mr 380.47 
Melting point 186190 oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Monoclinic  
Space group C2/c  
a 39.082(4) Å 
b 8.5880(11) Å  
c 24.128(3) Å  
α 90.00°  
β 105.802(7)°  
γ 90.00° 
Volume, V 7792.2(16) Å
3
 
No. of molecule per unit cell, Z 16  
Density (calcd) 1.297 mg/mm
3
 
F(000) 3264.0  
Crystal size 0.54 × 0.25 × 0.03 mm  
2range for data collection 3.5 to 50°  
Index ranges 46 ≤ h ≤ 46, 10 ≤ k ≤ 10, 27 ≤ l ≤ 28  
Reflections collected 29475  
Independent reflections 6868[Rint = 0.2374]  
Data/restraints/parameters 6868/0/509  
Goodness-of-fit on F
2
 0.766  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0573, wR2 = 0.0949  
Final R indexes [all data] R1 = 0.1933, wR2 = 0.1292  
Largest diff. peak/hole / e Å
3
 0.24/0.25  
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Racemic compound crystals of (±)-andransinine (119) were obtained from MeOH 
solution. The crystal data and structure refinement parameters are summarized in Table 
10.19.  
 
Table 10.19. Crystal data and structure refinement parameters of alkaloid 119 obtained 
from MeOH solution. 
Empirical formula C24H32N2O4 
Molecular formula C23H28N2O3.CH3OH 
Molecular weight, Mr 412.52 
Melting point 204206 oC 
Temperature during diffraction experiment, T 100 K 
X-ray source Mo K 
Crystal system Orthorhombic  
Space group Pna21  
a 8.6828(2) Å 
b 21.4082(4) Å 
c 11.2277(2) Å 
α 90.00°  
β 90.00°  
γ 90.00°  
Volume, V 2087.04(7) Å
3
 
No. of molecule per unit cell, Z 4  
Density (calcd) 1.313 mg/mm
3
 
F(000) 888.0  
Crystal size 0.84 × 0.36 × 0.24 mm 
2range for data collection 3.8 to 55°  
Index ranges 11 ≤ h ≤ 11, 27 ≤ k ≤ 27, 14 ≤ l ≤ 14  
Reflections collected 18902  
Independent reflections 4796[Rint = 0.0263]  
Data/restraints/parameters 4796/1/275  
Goodness-of-fit on F
2
 1.028  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0352, wR2 = 0.0908  
Final R indexes [all data] R1 = 0.0372, wR2 = 0.0923  
Largest diff. peak/hole / e Å
3
 0.49/0.34  
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10.12.3 X-ray diffraction and chiral phase HPLC analyses of a single crystal of 
andransinine (119) selected from the racemic conglomerate 
 
 
Racemic conglomerate crystals of (±)-andransinine (119) were obtained from EtOAc 
solution. A crystal with substantial size (ca. 0.43 x 0.35 x 0.28 mm) was selected from 
the conglomerate. It was then cut into half (ca. 0.20 x 0.35 x 0.28 mm). This half crystal 
was subjected to an X-ray diffraction analysis, using Cu K radiation. The crystal data 
and structure refinement parameters are summarized in Table 10.20. 
 
The remaining half of the andransinine (119) crystal (ca. 0.23 x 0.35 x 0.28 mm) was 
dissolved in a minimum amount of EtOH and subjected to chiral phase HPLC analysis, 
using a chiral column (Chiralpak AD-H, 4.6 mm x 150 mm, Daicel, Japan) with n-
hexane/EtOH/DEA (85:15:0.2, flow rate 0.8 ml/min) as eluting solvent. A single peak 
was observed, corresponding to a retention time of 3 min 47 sec. 
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Table 10.20. Crystal data and structure refinement parameters of alkaloid 119 (half 
crystal) 
Empirical formula C23H28N2O3 
Molecular formula C23H28N2O3 
Molecular weight, Mr 380.47 
Melting point 212214 °C 
Temperature during diffraction experiment, T 100 K 
X-ray source Cu K 
Crystal system Monoclinic 
Space group P21  
a 8.50960(10) Å  
b 9.15380(10) Å 
c 12.53330(10) Å 
α 90.00°  
β 96.0300(10)°  
γ 90.00°  
Volume, V 970.882(17) Å
3
 
No. of molecule per unit cell, Z 2  
Density (calcd) 1.301 mg/mm
3
 
F(000) 408.0  
Crystal size 0.20 × 0.15 × 0.10  
2range for data collection 7.1 to 148.34°  
Index ranges 10 ≤ h ≤ 10, 11 ≤ k ≤ 10, 15 ≤ l ≤ 15  
Reflections collected 7322  
Independent reflections 3769[Rint = 0.0191]  
Data/restraints/parameters 3769/1/255  
Goodness-of-fit on F
2
 1.047  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0347, wR2 = 0.0904  
Final R indexes [all data] R1 = 0.0349, wR2 = 0.0907  
Largest diff. peak/hole / e Å
3
 0.21/0.19  
Flack parameter, x 0.06(0.15) 
Hooft parameter, y 0.03(0.04) 
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10.12.4  Resolution of (±)-andransinine (119) by chiral phase HPLC followed by X-
ray diffraction analyses of the resolved enantiomers  
 
(±)-Andransinine (119) (9.1 mg) was dissolved in EtOH (1 ml) and resolved by means 
of chiral phase HPLC (100 injections, 10 l each) using a chiral column (Chiralpak AD-
H, 4.6 mm x 150 mm, Daicel, Japan) and eluting with n-hexane/EtOH/DEA (85:15:0.2, 
flow rate 0.8 ml/min) to yield two fractions: Fraction 1 (retention time 3 min 51 sec, 2.2 
mg) and Fraction 2 (retention time 7 min 52 sec, 1.3 mg). 
 
()-Andransinine (119a) from Fraction 1, colorless block crystal from EtOAc (ee > 
99%); mp 212214 °C; []25D  (c 0.10, CHCl3); The UV, IR, 
1
H and 
13
C NMR data 
were identical to racemic 119. The crystal data and structure refinement parameters, 
bond lengths, and bond angles are summarized in Table 10.21.  
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Table 10.21. Crystal data and structure refinement parameters of ()-andransinine 
(119a) 
Empirical formula C23H28N2O3 
Molecular formula C23H28N2O3 
Molecular weight, Mr 380.47 
Melting point 212214 °C 
Temperature during diffraction experiment, T 100 K 
X-ray source Cu K 
Crystal system Monoclinic 
Space group P21  
a 8.5069(2) Å  
b 9.1472(2) Å 
c 12.5299(3) Å 
α 90.00°  
β 96.035(2)°  
γ 90.00°  
Volume, V 969.60(4) Å
3
 
No. of molecule per unit cell, Z 2  
Density (calcd) 1.3032 mg/mm
3
 
F(000) 409.3  
Crystal size 0.20 × 0.15 × 0.10  
2range for data collection 7.1 to 150.58°  
Index ranges 9 ≤ h ≤ 10, 11 ≤ k ≤ 10, 15 ≤ l ≤ 10  
Reflections collected 9097  
Independent reflections 3624[Rint = 0.0222]  
Data/restraints/parameters 3624/0/254  
Goodness-of-fit on F
2
 1.023  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0297, wR2 = 0.0783 
Final R indexes [all data] R1 = 0.0309, wR2 = 0.0784 
Largest diff. peak/hole / e Å
3
 0.17/0.16  
Flack parameter, x 0.10(0.12) 
Hooft parameter, y 0.07(0.08) 
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()-Andransinine (119b) from Fraction 2, colorless block crystals from EtOAc (ee > 
99%); mp 212214 °C []25D  (c 0.07, CHCl3); The UV, IR, 
1
H and 
13
C NMR data 
were identical to racemic 119. The crystal data and structure refinement parameters are 
summarized in Table 10.22.  
 
Table 10.22. Crystal data and structure refinement parameters of ()-andransinine 
(119b) 
Empirical formula C23H28N2O3 
Molecular formula C23H28N2O3 
Molecular weight, Mr 380.47 
Melting point 212214 °C 
Temperature during diffraction experiment, T 100 K 
X-ray source Cu K 
Crystal system Monoclinic 
Space group P21  
a 8.5089(2) Å  
b 9.1505(2) Å 
c 12.5241(2) Å 
α 90.00°  
β 96.049(2)°  
γ 90.00°  
Volume, V 969.71(4) Å
3
 
No. of molecule per unit cell, Z 2  
Density (calcd) 1.3030 mg/mm
3
 
F(000) 409.3  
Crystal size 0.20 × 0.15 × 0.10  
2range for data collection 7.1 to 153.14°  
Index ranges 10 ≤ h ≤ 10, 11 ≤ k ≤ 11, 15 ≤ l ≤ 15  
Reflections collected 9877 
Independent reflections 3991[Rint = 0.0198]  
Data/restraints/parameters 3624/0/254  
Goodness-of-fit on F
2
 1.023  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0301, wR2 = 0.0803 
Final R indexes [all data] R1 = 0.0310, wR2 = 0.0803 
Largest diff. peak/hole / e Å
3
 0.21/0.17  
Flack parameter, x 0.08(0.12) 
Hooft parameter, y 0.04(0.06) 
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10.13  Chapter 9 
 
10.13.1 Conversion of lumusidine A (125) to its dimethyl diiodide salt 125a 
 
Iodomethane (0.5 ml) was added to lumusidine A (125) (4.2 mg, 0.006 mmol) and 
allowed to stand for 24 h at rt. Excess iodomethane was then removed under reduced 
pressure to furnish a yellowish residue that, on recrystallization from hot MeOH, gave 
the corresponding dimethyl diiodide salt 125a (2.8 mg, 48%): light yellowish block 
crystals; mp >198
 o
C dec; ESIMS m/z 358 [M]
2
; HRESIMS m/z 358.2157 [M]
2
 (calcd 
for C45H56N4O4, 716.4302). 
 
10.13.2 Conversion of lumusidine B (126) to its dimethyl diiodide salt 126a 
 
Iodomethane (0.5 ml) was added to lumusidine A (126) (5.4 mg, 0.008 mmol) and 
allowed to stand for 24 h at rt. Excess iodomethane was then removed under reduced 
pressure to furnish a yellowish residue that, on recrystallization from MeOH, gave the 
corresponding dimethyl diiodide salt 126a (3.2 mg, 40%): light yellowish block 
crystals; mp 230−234 °C; ESIMS m/z 367 [M]2+; HRESIMS m/z 367.2207 [M]2+ (calcd 
for C45H58N4O5, 734.4407). 
 
10.13.3 Conversion of alkaloid 130 to its methyl iodide salt 130a 
 
Iodomethane (0.5 ml) was added to alkaloid 130 (0.3 mg, 0.001 mmol) and allowed to 
stand for 24 h at rt. Excess iodomethane was then removed under reduced pressure to 
furnish a yellowish residue that, on recrystallization from MeOH, gave the 
corresponding dimethyl diiodide salt 130a (0.1 mg, 23%): light yellowish block 
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crystals; mp 214218 °C; ESIMS m/z 323 [M]+; HRESIMS m/z 323.1758 [M]+ (calcd 
for C19H20N2O2, 323.1760). 
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